Clinical trial NCT03423186
Conditions: Sanfilippo Syndrome Type A (MPS IIIA)
Sponsor: Swedish Orphan Biovitrum
Start date: 2018-06-19; Completion date: 2019-10-25
Enrollment: 6 participants; Allocation: NON_RANDOMIZED; Intervention model: PARALLEL

Brief summary:
MPS IIIA, also known as Sanfilippo A, is an inherited lysosomal storage disease (LSD). MPS IIIA is caused by a deficiency in sulfamidase, one of the enzymes involved in the lysosomal degradation of the glycosaminoglycan (GAG) heparan sulfate (HS). The natural course of MPS IIIA is characterized by devastating neurodegeneration with initially mild somatic involvement. The aims of the present study is to assess the dose related safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SOBI003, a chemically modified recombinant human (rh) Sulfamidase developed as an enzyme replacement therapy (ERT).

Detailed description:
This is an open-label, non-controlled, parallel, sequential ascending multiple-dose, multicenter study to assess the dose related safety, tolerability, PK and PD of SOBI003 in pediatric MPS IIIA patients. Patients between 1 and 6 years of age who have not received previous treatment for MPS IIIA with an ERT, gene- or stem cell therapy will be eligible to participate in the study. The study is planned to consist of 3 dose cohorts, each comprising 3 patients. Treatment initiations will be staggered within each cohort in order to be able to observe, interpret and treat possible adverse reactions. SOBI003 is administered as weekly i.v. infusions over a period of 24 weeks. Upon completion of the 24-week treatment period with satisfactory tolerability, the patient is offered to receive continued SOBI003 treatment by participation in an extension study.

Arms: arm 1: SOBI003 dose 3 mg/kg once weekly for 24 weeks arm 2: SOBI003 dose 10 mg/kg once weekly for 24 weeks
Interventions: intervention 1: SOBI003
Intervention descriptions: intervention 1: Weekly i.v.infusion

Protocol documents:
Prot_000.pdf: 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 1 of 88 
Version 2.0 Final Date 06 Jul 2018 
An open, non-controlled, parallel, ascending multiple-dose, 
multicenter study to assess the safety, tolerability, pharmacokinetics 
and pharmacodynamics of SOBI003 in pediatric MPS IIIA patients 
Version 2.0, Amended Protocol of the Study 
Including Amendment 1 
SOBI003-001 
IND no. 128889 
Type of Study: Phase I/II, Human Pharmacology, Therapeutic Exploratory 
Sponsor’s Medical Director 
Principal Coordinating Investigator 
Anders Bröijersén, MD, PhD 
Medical Director Clinical Development 
Swedish Orphan Biovitrum AB (publ) 
 
 
Paul Harmatz, MD 
Associate Director in Gastroenterology 
UCSF Benioff Children's Hospital Oakland 
 
  
 
Signature 
Date 
Signature 
Date 
Sponsor’s Study Manager 
Sponsor’s Statistician 
 
 
 
 
Signature 
Date 
Signature 
Date 
Confidential 
This protocol contains confidential information belonging to Swedish Orphan Biovitrum. Except as may be 
otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such information in 
confidence and not to disclose it to others (except where required by applicable law) nor use it for unauthorized 
purposes. In the event of actual or suspected breach of this obligation, Swedish Orphan Biovitrum should be 
promptly notified. 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 2 of 88 
Version 2.0 Final Date 06 Jul 2018 
Investigator statement 
I have read the amended protocol entitled “An open, non-controlled, parallel, ascending 
multiple-dose, multicenter study to assess the safety, tolerability, pharmacokinetics and 
pharmacodynamics of SOBI003 in pediatric MPS IIIA patients” and the accompanying current 
investigator’s brochure. I agree to conduct the clinical investigation in compliance with the Final 
Protocol, Version 2.0, 06 Jul 2018, the International Council on Harmonisation (ICH) 
harmonised tripartite guideline E6(R2): Guideline for Good Clinical Practice, applicable 
regulatory/government regulations, and in accordance with the latest revision of the Ethical 
Principles for Medical Research Involving Human Subjects (the Declaration of Helsinki). I will 
not implement any changes to study procedures or conduct without prior approval from the 
sponsor and, when applicable, the Independent Ethics Committee/Institutional Review Board 
and Regulatory Authority. 
I agree to maintain the confidentiality of this study protocol, as described on the title page. 
Further, I will not publish results of the study without authorization from Swedish Orphan 
Biovitrum AB (publ). 
 
 
 
 
Signature of Principal Investigator 
 
Date 
 
 
 
 
 
 
Printed Name of Principal Investigator 
 
 
 
 
 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 3 of 88 
Version 2.0 Final Date 06 Jul 2018 
Table of contents 
Protocol Amendment History and Reasons for Amendment .......................................................... 7 
1 
Synopsis ............................................................................................................................ 8 
2 
Abbreviations and definition of terms............................................................................. 15 
3 
Ethics ............................................................................................................................... 17 
3.1 
Independent ethics committee .................................................................................... 17 
3.2 
Ethical conduct of the study ....................................................................................... 17 
3.3 
Patient information and consent ................................................................................. 18 
4 
Study administrative structure ........................................................................................ 18 
4.1 
Sponsor ....................................................................................................................... 18 
4.2 
Clinical research organizations .................................................................................. 18 
4.2.1 
Study management................................................................................................. 18 
4.2.2 
Neurodevelopment assessments ............................................................................ 19 
4.3 
Central laboratories .................................................................................................... 19 
4.4 
Central MRI reading ................................................................................................... 20 
4.5 
Data monitoring committee ........................................................................................ 20 
4.6 
Safety review committee ............................................................................................ 20 
5 
Introduction ..................................................................................................................... 20 
5.1 
Background ................................................................................................................ 21 
5.1.1 
MPS IIIA ............................................................................................................... 21 
5.1.2 
SOBI003 ................................................................................................................ 21 
5.1.3 
SOBI003 nonclinical development ........................................................................ 22 
5.1.4 
SOBI003 immune mediated reactions ................................................................... 23 
5.2 
Study rationale ............................................................................................................ 24 
5.3 
Potential risks and benefits ......................................................................................... 24 
6 
Study objectives and endpoints ....................................................................................... 26 
6.1 
Primary objective ....................................................................................................... 26 
6.1.1 
Primary endpoint ................................................................................................... 26 
6.1.2 
Secondary endpoints related to the primary objective ........................................... 26 
6.2 
Secondary objectives .................................................................................................. 26 
6.2.1 
Secondary endpoints .............................................................................................. 27 
6.3 
Exploratory objectives ................................................................................................ 27 
6.3.1 
Exploratory endpoints ............................................................................................ 28 
7 
Investigational plan ......................................................................................................... 29 
7.1 
Overall study design and plan .................................................................................... 29 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 4 of 88 
Version 2.0 Final Date 06 Jul 2018 
7.2 
Discussion of study design ......................................................................................... 32 
7.3 
Selection of study population ..................................................................................... 33 
7.3.1 
Inclusion criteria .................................................................................................... 33 
7.3.2 
Exclusion criteria ................................................................................................... 34 
7.3.3 
Withdrawal of patients from treatment or study .................................................... 34 
7.3.3.1 Withdrawal from treatment ............................................................................... 34 
7.3.3.2 Withdrawal from study ..................................................................................... 35 
7.3.4 
Replacement of withdrawn patients....................................................................... 35 
7.3.5 
Specific restrictions/requirements on patients ....................................................... 35 
7.4 
Treatments .................................................................................................................. 36 
7.4.1 
Treatments administered ........................................................................................ 36 
7.4.2 
Identity of investigational medicinal products ...................................................... 36 
7.4.3 
Method of assigning patients to a treatment group ................................................ 37 
7.4.4 
Selection of doses .................................................................................................. 37 
7.4.5 
Selection of dose levels ......................................................................................... 37 
7.4.5.1 Dose level for Cohort 1 ..................................................................................... 37 
7.4.5.2 Dose levels for Cohort 2 and 3 ......................................................................... 38 
7.4.6 
Selection and timing of doses for each patient ...................................................... 39 
7.4.7 
Prior and concomitant therapy ............................................................................... 40 
7.4.8 
Treatment compliance ........................................................................................... 40 
7.5 
Efficacy, safety, pharmacokinetic, and pharmacodynamic assessments .................... 41 
7.5.1 
Study schedule ....................................................................................................... 41 
7.5.1.1 Schedule of events ............................................................................................ 41 
7.5.1.2 Screening ........................................................................................................... 51 
7.5.1.3 Baseline ............................................................................................................. 51 
7.5.1.4 Week 1 .............................................................................................................. 53 
7.5.1.5 Week 2 .............................................................................................................. 54 
7.5.1.6 Week 3 .............................................................................................................. 54 
7.5.1.7 Week 4 .............................................................................................................. 55 
7.5.1.8 Weeks 5 to 8 ...................................................................................................... 56 
7.5.1.9 Weeks 9 to 11 .................................................................................................... 56 
7.5.1.10 Week 12 ............................................................................................................ 57 
7.5.1.11 Weeks 13 to 23 .................................................................................................. 58 
7.5.1.12 Week 24 / last study visit .................................................................................. 58 
7.5.1.13 Treatment Withdrawal ...................................................................................... 60 
7.5.1.14 Estimated blood sampling volumes and sampling priority list ......................... 60 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 5 of 88 
Version 2.0 Final Date 06 Jul 2018 
7.5.2 
Medical history ...................................................................................................... 61 
7.5.2.1 MPS IIIA diagnosis ........................................................................................... 61 
7.5.2.2 Other diagnoses ................................................................................................. 61 
7.5.2.3 Other medical conditions .................................................................................. 61 
7.5.2.4 Prior medical procedures .................................................................................. 62 
7.5.3 
Demography .......................................................................................................... 62 
7.5.4 
Efficacy assessments ............................................................................................. 62 
7.5.4.1 Adaptive behavior ............................................................................................. 62 
7.5.4.2 Neurocognition ................................................................................................. 62 
7.5.4.3 Language ........................................................................................................... 63 
7.5.4.4 Motor function .................................................................................................. 64 
7.5.4.5 Sleep pattern ...................................................................................................... 64 
7.5.4.6 Magnetic resonance imaging ............................................................................ 65 
7.5.4.7 Quality of life and caregiver burden ................................................................. 65 
7.5.5 
Safety assessments ................................................................................................. 66 
7.5.5.1 Adverse events .................................................................................................. 66 
7.5.5.2 Laboratory safety assessments .......................................................................... 70 
7.5.5.3 Immunogenicity ................................................................................................ 71 
7.5.5.4 CRIM status ...................................................................................................... 72 
7.5.5.5 Vital signs ......................................................................................................... 72 
7.5.5.6 Electrocardiograms ........................................................................................... 73 
7.5.5.7 Other safety assessments ................................................................................... 73 
7.5.5.8 Appropriateness of measurements .................................................................... 74 
7.5.5.9 Safety review committee ................................................................................... 74 
7.5.5.10 Data safety monitoring board ............................................................................ 75 
7.5.6 
Pharmacokinetic assessments ................................................................................ 76 
7.5.6.1 Sampling procedures ......................................................................................... 76 
7.5.6.2 Bioanalytical method ........................................................................................ 77 
7.5.6.3 Pharmacokinetic calculations ............................................................................ 77 
7.5.7 
Pharmacodynamic assessments ............................................................................. 78 
7.5.7.1 Heparan sulfate ................................................................................................. 78 
7.5.7.2 Future bioanalytical research ............................................................................ 78 
7.5.7.3 Appropriateness of measurements .................................................................... 79 
8 
Quality control and quality assurance ............................................................................. 79 
9 
Statistical plan ................................................................................................................. 80 
9.1 
Determination of sample size ..................................................................................... 80 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 6 of 88 
Version 2.0 Final Date 06 Jul 2018 
9.2 
Definition of study populations .................................................................................. 80 
9.3 
Overall statistical and analytical plan ......................................................................... 80 
9.3.1 
General statistical issues ........................................................................................ 80 
9.3.2 
Demographics and baseline characteristics ........................................................... 81 
9.3.3 
Analysis related to primary objective .................................................................... 81 
9.3.4 
Analysis related to secondary objective ................................................................ 81 
9.3.5 
Analysis related to exploratory objectives ............................................................. 81 
9.3.6 
Analysis of safety and tolerability data ................................................................. 81 
9.3.6.1 Adverse events .................................................................................................. 81 
9.3.7 
Interim analysis ...................................................................................................... 82 
9.3.8 
Multiple comparison/multiplicity .......................................................................... 82 
9.3.9 
Handling of missing data ....................................................................................... 82 
10 
Data collection, handling and record keeping ................................................................. 82 
10.1 
Data standards ............................................................................................................ 82 
10.2 
Case report form ......................................................................................................... 82 
10.3 
Source data ................................................................................................................. 82 
10.4 
Database closure ......................................................................................................... 83 
10.5 
Record retention ......................................................................................................... 83 
11 
End of study .................................................................................................................... 83 
12 
Sponsor’s discontinuation criteria ................................................................................... 83 
13 
Dissemination and publication of results ........................................................................ 83 
14 
References ....................................................................................................................... 84 
 
 
 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 7 of 88 
Version 2.0 Final Date 06 Jul 2018 
Protocol Amendment History and Reasons for Amendment 
 
Version 
Date 
Reason for Amendment  
Version 1.0 
08 Dec 2017 
Original Protocol 
Version 2.0  
Non-substantial 
amendment 1 
06 Jul 2018 
All changes are administrative and updates are minor. The amendment is considered 
as non-substantial.  
 
Two additional countries, the Netherlands and Germany, are added to the 
study. Total number of study clinics are updated accordingly. 
 
Information added that the white blood cell isolation for sulfamidase activity 
and purification of fibroblasts from skin biopsy will, for non-US-samples, be 
assigned to Histalim in France. 
 
Description of the overall study design is slightly amended to clarify that 
patients are assigned to a dose cohort in consecutive order as the eligibility 
criteria have been confirmed, with prioritization of the younger patients.  
 
Storage temperature details have been removed from the section “Identity of 
investigational medicinal products” as this and further details are specified in 
the pharmacy manual for the study.   
 
There have been some updates for clarification to the Schedules of Events and 
in the text describing the visit assessments. 
 
The Detailed PK blood sampling schedule has been updated to clarify that PK 
sample will be taken peripherally during the Screening visit as no central 
access port is yet applied.  
 
Specified that blood for HS analysis should be collected at the same time as the 
CSF sampling and urine collected for HS analysis should be taken as close as 
possible to the CSF sampling.   
 
Clarified that for patients entering the extension study, all AEs and SAEs 
occurring after Week 24 visit, should be noted in the extension study SOBI003-
002 
 
 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 8 of 88 
Version 2.0 Final Date 06 Jul 2018 
1 
Synopsis 
STUDY IDENTIFIERS 
 
Title of study: 
An open, non-controlled, parallel, ascending multiple-dose, multicenter study to 
assess the safety, tolerability, pharmacokinetics and pharmacodynamics of 
SOBI003 in pediatric MPS IIIA patients 
Clinical study number: 
SOBI003-001 
Investigator(s): 
The coordinating investigator is: 
Paul Harmatz, MD, Associate Director in Gastroenterology 
UCSF Benioff Children's Hospital Oakland 
52nd Street, Oakland, CA 94609, U.S.A. 
There will be up to 4 additional investigators. 
Study center(s): 
The planned study centers are in the U.S.A., Turkey, Netherlands and Germany. 
The study will be conducted at up to 5 study centers.  
Type of study: 
Phase I/II; Human pharmacology and Therapeutic exploratory 
STUDY OBJECTIVES 
 
Primary objective: 
To evaluate the safety and tolerability of SOBI003 at different dose levels. 
Secondary objectives: 
1. To characterize the pharmacokinetic (PK) properties of SOBI003 following 
single and repeated administration by the use of non-compartmental analysis 
(NCA) 
2. To assess the immunogenicity of SOBI003 
3. To assess the pharmacodynamic (PD) effect of different dose levels and 
treatment duration of SOBI003 on heparan sulfate (HS) levels in 
cerebrospinal fluid (CSF), serum and urine  
4. To assess the effect of SOBI003 at different dose levels on neurocognition 
5. To assess the effect of SOBI003 at different dose levels on adaptive behavior 
6. To assess the effect of SOBI003 at different dose levels on gray matter 
volume 
7. To assess the effect of SOBI003 at different dose levels on Quality of Life  
Exploratory objectives: 
To explore the effect of SOBI003 at different dose levels on: 
1. Clinical manifestations of MPS IIIA as assessed by endpoints specified in 
exploratory endpoint section below   
2. To characterize the PK properties of SOBI003 following single and repeated 
administration by the use of population PK analysis 
3. To evaluate the PK/PD relationship between SOBI003 concentrations in 
serum and effect of SOBI003 on HS levels in CSF, serum and urine by the 
use of population modelling analysis 
 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 9 of 88 
Version 2.0 Final Date 06 Jul 2018 
Exploratory objectives 
continued: 
As local regulations permit and provided that additional separate caregiver 
consent is given, the exploratory objectives are also to: 
 
Collect and store a blood sample for future pharmacogenetic research aimed 
to explore genetic characteristics that may contribute to and/or modify the 
disease phenotype and /or with possible impact on safety, tolerability, 
immunogenicity, PK and PD related to SOBI003 treatment 
 
Collect and store serum, CSF and urine samples to enable analyses of 
biomarkers with possible relation to safety, tolerability, immunogenicity, PK 
and PD of SOBI003, as identified in future  
Serum, CSF, and urine samples for potential future pharmacogenetic and 
biomarker analyses will be stored for a maximum of 10 years following study 
completion. The results of any such analyses will not be included in the Clinical 
Study Report for this study, but reported separately when analyzed, thus enabling 
exploration of any emerging novel disease-related discoveries of e.g., previously 
unknown alleles, inflammatory cytokines, other HS biomarkers (e.g. HS 
metabolites), components of the complement system, and neurodegeneration. 
STUDY ENDPOINTS 
 
Primary endpoint: 
Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events 
(SAEs). 
Secondary endpoint(s): 
The secondary endpoints to evaluate the primary objective of the safety and 
tolerability of SOBI003 are: 
 
Vital signs (blood pressure, heart rate, body temperature, respiratory rate 
and oxygen saturation) 
 
Laboratory safety variables (hematology, coagulation, clinical chemistry 
and urine analysis) 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 10 of 88 
Version 2.0 Final Date 06 Jul 2018 
The endpoints relating to the 1st secondary objective are: 
 
Serum SOBI003 PK parameters at Weeks 1, 4, 12, and 24; tEnd of inf, 
CEnd of inf, Cmax, tmax, CPre-dose, CTrough, CL, AUC0-168h, t1/2 
 
CSF SOBI003 concentration at Weeks 12 and 24 
The endpoints relating to the 2nd secondary objective are: 
 
Occurrence of anti-drug antibodies (ADAs) against SOBI003 in serum 
(seroconversion rate, time to seroconversion, transient/persistent). For 
patients with confirmed ADA positive serum samples, the following 
additional endpoints apply; ADA titers and IgG subclasses in serum and 
presence of neutralizing antibodies (NAb) in serum. 
 
Occurrence of ADAs against SOBI003 in CSF (conversion rate, time to 
occurrence, transient/persistent). For patients with confirmed ADA 
positive CSF samples, the following additional endpoints apply; ADA 
titers and presence of NAb in CSF. 
The endpoints relating to the 3rd secondary objective are: 
 
Change from baseline in CSF HS at Weeks 12 and 24 
 
Change from baseline in serum HS at Weeks 2, 3, 4, 8, 12 and 24  
 
Change from baseline in urine HS at Weeks 2, 3, 4, 8, 12 and 24 
The endpoints relating to the 4th secondary objective are neurocognitive 
Development Quotient (DQ) and age-equivalence score (AEq) as assessed by the 
Bayley Scales of Infant and Toddler Development®, third edition (BSID-III) 
cognitive subtest or the Kaufman Assessment Battery for Children, Second 
edition (KABC™-II); change from baseline at Week 24.   
The endpoint relating to the 5th secondary objective is adaptive behavior age-
equivalence score (AEq) as assessed by Vineland™ Adaptive Behavior Scales, 
Expanded Interview Form, Second edition (VABS-II); change from baseline at 
Week 24.  
The endpoint relating to the 6th secondary objective is gray matter volume as 
assessed by brain volumetric magnetic resonance imaging (MRI); change from 
baseline at Week 24. 
The endpoint relating to the 7th secondary objective is Pediatric Quality of Life 
Inventory (PedsQL™) total score and PedsQL™ Family Impact Module total 
score; change from baseline at Week 24. 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 11 of 88 
Version 2.0 Final Date 06 Jul 2018 
Exploratory endpoint(s): 
The endpoints related to the 1st exploratory objective are: 
 
Adaptive behavior composite score as assessed by VABS-II; change from 
baseline at Week 24 
 
Neurocognitive composite score as assessed by the BSID-III cognitive 
subtest or the KABC-II; change from baseline at Week 24  
 
Expressive and receptive language as assessed by the BSID-III language 
subtests, or the KABC-II Expressive Vocabulary subtest, and the VABS-II 
communication domain; AEq change from baseline at Week 24 
 
Fine and gross motor function as assessed by the BSID-III motor subtests 
and the VABS-II; AEq change from baseline at Week 24 
 
Sleep pattern as determined by Children´s Sleep Habits Questionnaire 
(CSHQ) score  
 
Sleep pattern as determined by actigraphy including total sleep time, total 
day- and night time sleep duration, sleep latency, sleep efficiency, number of 
nocturnal awakenings, and wake after sleep onset; change from baseline at 
Weeks 12 and 24, respectively 
 
Compound ventricular volume as assessed by brain volumetric MRI; change 
from baseline at Week 24 
 
Fractional anisotropy (FA) and mean diffusivity (MD) of corpus callosum as 
assessed by diffusion tensor imaging MRI; change in from baseline at 
Week 24 
 
FA and MD of cerebral white matter as assessed by diffusion tensor imaging 
MRI; change from baseline at Week 24 
 
Cerebral white matter as assessed by susceptibility weighting imaging (SWI) 
MRI; change from baseline at Week 24 
 
Basal ganglia as assessed by susceptibility weighting imaging (SWI) MRI; 
change from baseline at Week 24 
 
Liver volume as assessed by abdominal MRI; change from baseline at 
Week 24 
 
Spleen volume as assessed by abdominal MRI; change from baseline at 
Week 24 
The endpoints related to the 2nd exploratory objective are: 
 
Population PK model parameter estimates and associated covariates 
describing intra- and inter-individual variability in respective parameter 
estimate. 
The endpoints related to the 3rd exploratory objective are: 
 
Population PK/PD model parameter estimates and associated covariates 
describing intra- and inter-individual variability in respective parameter 
estimate. The results of these analyses will not be included in the Clinical 
Study Report for this study, but reported separately. 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 12 of 88 
Version 2.0 Final Date 06 Jul 2018 
STUDY DESIGN AND METHODS 
 
Study design: 
This is an open-label, non-controlled, parallel, sequential ascending multiple-
dose, multicenter study to assess the dose related safety, tolerability, PK and PD 
of SOBI003 in pediatric MPS IIIA patients. 
SOBI003 is administered as weekly i.v. infusions over a period of time of 
4 hours. The study treatment period comprises 24 weekly infusions. Prior to 
initiation of each infusion, the patients are pretreated with a single dose of non-
sedative antihistamine. If infusion-related reactions occur, then the infusion 
duration may be expanded up to 24 hours and supportive medication may be 
administered, at the discretion of the investigator.  
The study is planned to consist of 3 dose cohorts, each comprising 3 patients, 
provided that no significant safety concern arise. An additional cohort comprising 
3 patients may be added, if deemed necessary to more accurately characterize the 
safety, tolerability, PK or PD.  
The screening visit can be performed up to 12 weeks prior to the first SOBI003 
infusion. At the screening visit, the MPS IIIA diagnosis is verified and the 
genotype is determined at a central laboratory. Patients are assigned to a dose 
cohort in strict consecutive order as the eligibility criteria have been confirmed.  
Treatment initiations will be staggered within each cohort in order to be able to 
observe, interpret and treat possible adverse reactions and to ensure that such 
reactions can be dealt with promptly. For each cohort, Safety Review Committee 
meetings are scheduled approximately 3 weeks after completion of the 3rd 
patient’s 4th dose administration. Based on the safety, immunogenicity, PK and 
PD data, the SRC will determine what dose to apply in the next cohort. 
An independent Data Monitoring Committee will monitor safety data at pre-
specified intervals. 
Upon completion of the 24-week treatment period with satisfactory tolerability, 
the patient is offered to receive continued SOBI003 treatment by participation in 
an extension study. 
Number of subjects 
planned: 
9 
In case of an additional 4th cohort and replacements of prematurely withdrawn 
patients, the number of patients will not exceed 15. 
Diagnosis and main 
criteria for inclusion: 
MPS IIIA patients, as confirmed by both a documented deficiency in sulfamidase 
enzyme activity in concordance with a diagnosis of MPS IIIA and normal enzyme 
activity level of at least one other sulfatase measured in leukocytes, that are ≥12 
to ≤72 months of age and that have a developmental age ≥12 months. Patients 
with at least one S298P mutation in the SGSH gene are excluded, as well as 
patients that have received prior stem cell or gene therapy, or enzyme 
replacement therapy for MPS IIIA. 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 13 of 88 
Version 2.0 Final Date 06 Jul 2018 
Assessments for safety 
and tolerability evaluation: 
Adverse events are recorded from the time of first investigational product 
administration until last study visit (Week 24).   
Blood pressure, heart rate, body temperature, respiratory rate and oxygen 
saturation are assessed at Screening, prior to each infusion, 2 hours after start of 
infusion and within 1 hour of completion of each infusion. Intensified 
assessments are applied for Weeks 1 to 8. The last assessments are done 3 days 
after last infusion.  
Blood and urine samples for central laboratory analyses of hematology, clinical 
chemistry and coagulation are collected at Screening and prior to each infusion at 
Weeks 1 to 8. Pre-infusion sampling also applies biweekly from Week 10 to 22. 
After each of the 3 first infusions, post-infusion samples are also collected 2 days 
after the infusions (Day 3). At Week 24, a post-infusion sample is obtained on 
Day 3. 
12-lead ECGs are obtained at Screening and prior to and post the infusions on 
Weeks 1 to 4, 6, 8, 12 and 24.  
A physical examination will be performed at Screening, Baseline and at Week 24. 
General appearance and skin are examined prior to and within 1 hour of 
completion of each infusion. A neurological examination will be performed at 
Screening and Week 24.   
Blood samples for central laboratory analyses of ADAs are collected at Baseline 
and pre-infusion at Weeks 2, 4, 8, 12 and 24. For patients not continuing in the 
extension study, immunogenicity and PK are assessed 30 to 40 days after last 
SOBI003 administration. 
CSF samples for central laboratory analysis of ADAs are collected at Baseline 
and at Weeks 12 and 24. 
For the determination of cross reactive immunological material (CRIM) status of 
the patients in fibroblasts, a skin biopsy is taken at Baseline. 
Assessments for 
pharmacokinetic (PK) and 
pharmacodynamics (PD) 
evaluation: 
Serum concentration vs time profiles are obtained for determination of SOBI003 
PK variables at Weeks 1, 4, 12 and 24. In addition, serum samples are collected 
when ADA samples are obtained. SOBI003 concentration in CSF is assessed at 
Weeks 12 and 24.  
HS is assessed in CSF at Baseline and Weeks 12 and 24. HS in serum is assessed 
at Baseline and at Weeks 2 to 4, 8, 12 and 24. HS in urine are assessed at 
Screening, Baseline, and at Weeks 2 to 4, 8, 12, and 24.  
Assessments for efficacy 
evaluation: 
Neurocognition is assessed by the BSID-III and/or KABC-II at Baseline and at 
Week 24. Adaptive behavior is assessed by the VABS-II at Baseline and at 
Week 24. Gray matter volume is assessed by MRIs at Baseline and at Week 24. 
The PedsQL is completed by the parent/primary caregiver at Baseline and at 
Weeks 12 and 24.  
Assessments for 
exploratory PD 
evaluation: 
Clinical manifestations, including language, motor function, and sleep pattern are 
assessed at Baseline and at Week 24. Sleep pattern is also assessed at Week 12. 
Brain and abdominal MRIs are performed at Baseline and at Week 24 to assess 
ventricles, white matter, basal ganglia, and liver and spleen volumes. 
Test product; dose and 
mode of administration: 
SOBI003, 20 mg/mL, concentrate for solution for i.v. infusion 
3 dose levels are planned. The dose level for Cohort 1 is 3 mg/kg. The planned 
mid and maximum dose levels for Cohorts 2 and 3 are 10 mg/kg and 20 mg/kg, 
respectively. The dose levels for Cohorts 2 and 3 will be determined by the Safety 
Review Committee and will be based on review of pre-specified safety, 
tolerability, immunogenicity, PK and PD data  


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 14 of 88 
Version 2.0 Final Date 06 Jul 2018 
Reference product; dose 
and mode of 
administration: 
Not applicable 
Duration of treatment(s): 
24 weeks 
Statistical methods: 
Safety tabulations of adverse event data and laboratory data are performed. 
Continuous variables are summarized using the number of patients, the mean, the 
standard deviation, the median, the minimum value, and the maximum value. 
Categorical variables are summarized using frequency counts and percentages. 
PK results are presented by dose level using descriptive statistics. In addition, 
results are presented by demographic characteristics e.g. age-group and body-
weight, as applicable. 
Immunogenicity is summarized using frequency counts and percentages by dose 
level. 
To assess the PD effect of different dose levels of SOBI003 on HS levels in CSF 
serum, and urine, linear mixed models are used to model the change from 
baseline in HS levels as dependent variable, for both logged HS levels and 
untransformed HS levels, and baseline level and age as continuous covariates, 
and dose and sex as factors. The analyses are conducted for each assessment time 
point: Weeks 12 and 24 for CSF, and Weeks 4, 8, 12 and 24 for serum and urine. 
In addition, linear mixed analyses with HS levels, both logged HS levels and 
untransformed HS levels, in CSF, serum, and urine, as dependent variable, and 
baseline level and age as continuous covariates, and dose and sex as factors will 
be performed across all assessments, with assessment as a repeated factor in a 
accumulating pattern: across weeks 12 and 24 for HS in CSF, and across Weeks 4 
and 8, across Weeks 4, 8 and 12, and across Weeks 4, 8, 12 and 24 for HS in 
serum. 
Endpoints relating to the neurocognition, adaptive behavior, gray matter volume 
and Quality of Life are summarized using descriptive statistics. 
 
 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 15 of 88 
Version 2.0 Final Date 06 Jul 2018 
2 
Abbreviations and definition of terms 
ADA 
Anti-drug antibody 
ADL 
Activities of daily living 
AE 
Adverse event 
AEq 
Age-equivalence 
ALT 
Alanine transaminase 
APTT 
Activated partial thromboplastin time 
AST 
Aspartate transaminase 
AUC 
Area under curve 
AUCτ,ss 
Area under the plasma concentration-time curve during a dosage 
interval (τ) 
AUC168h 
The area under the serum concentration-time curve from time 0 to 
168 after dose 
BBB 
Blood-brain barrier 
BSID-III 
Bayleys Scales of Infant and Toddler Development®, third edition 
CDISC 
Clinical data interchange standards consortium 
CL 
Clearance 
CEnd of inf 
The observed serum concentration at the end of infusion of 
SOBI003 
Cmax 
Maximum observed serum concentration 
CTrough 
The minimum observed serum concentration 
Cmax 
Maximum (peak) serum drug concentration  
CNS 
Central nervous system 
CPre-dose 
The observed serum concentration immediately before the start of 
infusion of SOBI003 
CRF 
Case report form 
CRIM 
Cross reactive immunological material 
CRO 
Contract research organization 
CSF 
Cerebrospinal fluid 
CSHQ 
Children´s sleep habits questionnaire 
DMC 
Data monitoring committee 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 16 of 88 
Version 2.0 Final Date 06 Jul 2018 
DQ 
Development quotient 
ECG 
Electrocardiogram 
ERT 
Enzyme replacement therapy 
FAS 
Full-analysis set 
GCP 
Good clinical practice 
GLP 
Good laboratory practice 
HS 
Heparan sulfate; throughout this protocol, the term “HS” is also 
used for the disaccharide levels detected in the bioanalytical assay 
(refer to Section 7.5.7.1) 
i.v. 
Intravenous 
ICF 
Informed consent form 
ICH 
International council for harmonisation 
IEC 
Independent ethics committee 
IL 
Interleukin 
IMP 
Investigational medicinal product 
IRB 
Institutional review board 
KABC-II 
Kaufman assessment battery for children, second edition 
LSD 
Lysosomal storage disease 
MABEL 
Minimal anticipated biological effect level  
MPS IIIA 
Mucopolysaccharidosis type IIIA 
MRI 
Magnetic resonance imaging 
MRSD 
Maximum recommended starting dose 
MTD 
Maximum tolerated dose 
NAb 
Neutralizing antibody 
NCA 
Non-compartmental analysis 
NCI CTC 
National cancer institute common terminology criteria 
NOAEL 
No observed adverse effect level 
NVI 
Nonverbal index 
PAD 
Pharmacologically Active Dose 
PD 
Pharmacodynamic 
PedsQL 
Pediatric quality of life inventory 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 17 of 88 
Version 2.0 Final Date 06 Jul 2018 
PK 
Pharmacokinetic 
PT/INR 
Prothrombine time/international normalized ratio 
SAE 
Serious adverse event 
SAF 
Safety analysis set 
SGSH 
N-Sulfoglucosamine sulfohydrolase 
Sobi 
Swedish Orphan Biovitrum AB (publ) 
SRC 
Safety review committee 
t 
Time 
tEnd of inf 
The time of the end of the infusion of SOBI003 
tmax 
The time at which the maximum serum concentration is observed  
t1/2 
Half-life 
TBV 
Total blood volume 
TEAE 
Treatment-emergent adverse event 
TNF 
Tumor necrosis factor 
ULN 
Upper limit of normal 
VABS-II 
Vineland adaptive behavior scales, second edition 
Vd 
Volume of distribution 
3 
Ethics 
3.1 
Independent ethics committee 
It is the responsibility of the investigator to obtain approval of the study protocol, possible 
amendments and the written patient information and informed consent form (ICF) from the 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC). The investigator should 
file all correspondence with the IRB/IEC. Copies of IRB/IEC correspondence and approvals 
should be forwarded to the contract research organization (CRO) INC Research.  
3.2 
Ethical conduct of the study 
This study will be conducted in compliance with this protocol, the International Council for 
Harmonisation (ICH) Guideline for Good Clinical Practice (GCP) [1], applicable regulatory 
requirements, and in accordance with the latest revision of the Ethical Principles for Medical 
Research Involving Human Subjects (the Declaration of Helsinki) [2]. 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 18 of 88 
Version 2.0 Final Date 06 Jul 2018 
3.3 
Patient information and consent 
It is the responsibility of the investigator to give each patient’s legally authorized 
representative(s), prior to any study related activities, full and adequate verbal and written 
information regarding the objective and procedures of the study and the possible risks involved. 
The patient’s legally authorized representative(s) must be informed about their right to withdraw 
from the study at any time. The written patient information and/or consent form must not be 
changed without prior discussion with Sobi. Before any revisions are implemented, the revised 
written patient information and/or consent form must be approved by the IRB/IEC. 
It is the responsibility of the investigator to obtain signed informed consent (or witnessed verbal 
consent according to applicable regulations) from the patient’s legally authorized 
representative(s) prior to any study related activities. The local regulations will be followed in 
the definition of legally authorized representative. Even where not legally required, if it is 
considered desirable by the investigator or IRB, informed consent can be obtained from both 
legally authorized representatives.  
The patient’s legally authorized representative(s) should receive a copy of the written 
information and signed ICF.   
Once the ICF has been signed, the patient will be assigned an Enrollment Number. 
4 
Study administrative structure 
4.1 
Sponsor 
The sponsor of the study is Swedish Orphan Biovitrum AB (publ), Stockholm, Sweden (Sobi). 
4.2 
Clinical research organizations 
4.2.1 
Study management 
The following study-related duties are transferred to INC Research LLC, with its principal place 
of business at 3201 Beachleaf Court, Raleigh, NC 27604-1547, U.S.A.: monitoring, development 
of master written patient information and ICF, pharmacokinetics (PK), data management, 
biostatistics, submission of Clinical Trial Application to applicable regulatory authorities, and 
investigational product management (including secondary packaging, labeling and distribution).   
Handling of serious adverse event (SAE) reporting is a shared responsibility between Sobi and 
INC Research. Upon receipt of an SAE report from a study site, INC Research will process the 
report and forward it to the Drug Safety Department at Sobi. Requests for complementary 
follow-up information are sent to investigators through INC Research. Notification of expedited 
SAEs to regulatory authorities is a shared responsibility of Sobi and INC Research. INC 
Research is responsible for notifications to IRB/IEC, investigators and the regulatory authorities 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 19 of 88 
Version 2.0 Final Date 06 Jul 2018 
except notifications to the regulatory authority in U.S.A., which are managed by Sobi. Sobi is 
responsible for the compilation of Development Safety Update Reports based on data outputs 
from INC Research and INC Research is responsible for the compilation of Periodic Line 
Listings, if applicable, and the submission of these periodic reports to applicable regulatory 
authorities, as well as distribution to IRB/IEC and investigators, when applicable. Sobi is 
responsible for the submissions of periodic reports to the regulatory authority in U.S.A. 
Contact relating to project management and monitoring are to be directed to INC Research. 
4.2.2 
Neurodevelopment assessments 
For the neurodevelopment assessments, the following study related duties are assigned to 
NeuroCog Trials Holdings, Inc., 3211 Shannon Road, Suite 300, Durham, NC 27707, U.S.A.: 
development of a study-specific assessment manual, study-specific training and certification of 
local child-development assessors, central data quality assurance of completed assessment forms, 
calculation of final scores and determination of Age Equivalence scores, and data management 
of adaptive behavior and neurocognition assessments.  
The development of the study-specific manual will be in collaboration with Shapiro 
Neuropsychology Consulting LLC, 820 NW 12 Ave. Apt. 304, Portland, OR 97209, U.S.A. 
4.3 
Central laboratories 
Five central laboratories are used in this study. The analyses of SOBI003, heparan sulfate (HS), 
and SOBI003 anti-drug-antibodies (ADA) in serum and cerebrospinal fluid, including method 
validations, are assigned to York Bioanalytical Solutions Limited, Cedar House, Northminster 
Business Park, Upper Poppleton, York YO26 6QR, United Kingdom. This is a Good Laboratory 
Practice (GLP) compliant laboratory. Storage of samples for future bioanalytical research is also 
assigned to York Bioanalytical Solutions Limited. 
The SGSH genotyping, assessment of potential cellular sulfamidase activity and levels of urine 
HS are assigned to Greenwood Genetic Center, 106 Gregor Mendel Cir, Greenwood, South 
Carolina 29646, U.S.A. This is a College of American Pathologists (CAP) and Clinical 
Laboratory Improvement Amendments (CLIA) accredited laboratory.  
The safety laboratory analyses are assigned to BARC USA Inc., 5 Delaware Drive, Lake Success 
NY 11042-1114, U.S.A. This is a GLP and CAP compliant laboratory.  
Analyses of neutralizing antibodies (NAbs) is assigned to BioAgilytix, Lademannbogen 10, 
22339 Hamburg, Germany. This is a GLP compliant laboratory.   
The determination of cross reactive immunological material (CRIM) status will be performed at 
Biochemical Genetics Laboratory, Duke University Health System, 801 Capitola drive, Suite 6, 
Durham, NC 27713, U.S.A.  


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 20 of 88 
Version 2.0 Final Date 06 Jul 2018 
The white blood cell isolation for sulfamidase activity and purification of fibroblasts from skin 
biopsy will, for non-US-samples, be assigned to Histalim, 126, rue Emile Baudot, Le Millénaire, 
34000 Montpellier, France. 
4.4 
Central MRI reading 
Dr Igor Nestrasil, at Quantims LLC, 3749 Foss Road, Saint Anthony, MN 55421, U.S.A., is 
assigned to develop a study-specific MRI manual specifying the MRI settings to be applied at 
study sites, validation of test-data from each site, quality assurance of completed MRI scans, and 
determination of the brain and abdominal variables from completed MRI assessments, as 
specified in Section 7.5.4.6.   
4.5 
Data monitoring committee 
A data monitoring committee (DMC), independent from Sobi and principal investigators (PIs), is 
assigned to monitor all safety and immunogenicity data at intervals specified in Section 7.5.5.10. 
The primary responsibility of the DMC is to provide safety oversight of the study conduct in 
order to protect study participants. The DMC is planned to comprise an independent statistician 
and two clinicians that, collectively, have experience from DMC, management of pediatric 
patients with lysosomal storage disease (LSD), clinical immunology, and the conduct of clinical 
trials with enzyme replacement therapy (ERT). A DMC charter will outline DMC membership, 
responsibilities, data review meeting details, and lines of communication with the study teams at 
Sobi and INC Research. 
4.6 
 Safety review committee 
The appointed SRC will comprise the principal investigators and relevant Sobi staff, including 
the Safety Physician, Clinical Pharmacologist, Study Statistician, Principal Scientist of 
Immunology, Toxicologist, Medical Director Clinical Development, and VP Head of Clinical 
Development. The primary responsibility of the SRC is to review emerging safety, PK and PD 
data during the dose-escalation phase in order to determine the continuation to the next cohort. 
Refer to Section 7.5.5.9 for further details. 
5 
Introduction 
Sobi is developing SOBI003, a chemically modified recombinant human sulfamidase, for 
enzyme replacement in patients with Mucopolysaccharidosis type IIIA (MPS IIIA); Sanfilippo A 
syndrome. MPS IIIA is a rare disease with rapid progression from early childhood, often 
resulting in death during the 2nd or 3rd decade of life. Currently there is no approved treatment 
and to date, therapy is limited to symptomatic treatment and relief of symptoms. The unmet 
medical need is therefore high.  


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 21 of 88 
Version 2.0 Final Date 06 Jul 2018 
This first-in-human Phase I/II study is designed to determine the safety, tolerability, PK and 
pharmacodynamics (PD) of SOBI003 in pediatric MPS IIIA patients. Healthy volunteers with 
normal enzyme levels are not a suitable population as they are not a representative population for 
assessment of safety, tolerability, immunogenicity and PD. 
5.1 
Background 
5.1.1 
MPS IIIA 
MPS IIIA or Sanfilippo A, is an inherited LSD that is progressive, life-shortening and rare. MPS 
IIIA is one of 4 distinct subtypes of MPS III (denoted IIIA, IIIB, IIIC and IIID) (3).  
MPS IIIA is an autosomal recessive disorder caused by mutations in the SGSH gene that result 
in absence of or a deficiency in the enzyme sulfamidase (N-sulfoglucosamine sulfohydrolase). 
Lack of sulfamidase activity leads to insufficient degradation of HS and lysosomal accumulation 
of HS and its metabolites in lysosomes throughout the body (4). As of today, 142 mutations have 
been described in the SGSH gene coding for sulfamidase (5). Data suggest a geno- and 
phenotype correlation and that patients homozygous or compound heterozygous for the S298P 
mutation have a slower progression of the disease (6).  
Depending on disease severity, patients have a median life-expectancy of about 15 years. The 
clinical course of MPS IIIA can be divided into 3 phases (7). In the first phase, which usually 
starts between 1 and 4 years of age, a developmental delay becomes apparent after an initial 
normal development during the first 1 to 2 years of life. The most prominent finding in this 
phase is speech delay (6,7,8).  
The diagnosis of MPS IIIA is usually established during the second phase, which generally starts 
around 3 to 4 years of age. This phase is characterized by increasing behavioral problems with 
hyperactivity, aggressive and destructive behavior as well as reduced attention span (7), which 
responds poorly to standard medications and behavioral-based interventions (9). A pronounced 
and rapid decline in cognitive skills becomes evident and the sleeping pattern is disturbed with 
extreme difficulty in falling asleep and with frequent awakening (10). 
In the third and final “quiet” phase, behavioral symptoms diminish while motor retardation 
emerges with walking and swallowing difficulties sometimes requiring percutaneous endoscopic 
gastrostomy (PEG) feeding. The progressive neurodegeneration causes spasticity, seizures, loss 
of speech, and severe dementia, which ultimately results in a vegetative state (9).  
Patients usually die from respiratory infections in the end of the second or beginning of the third 
decade of life (11,12) although patients with a slowly progressing phenotype may live longer (6). 
5.1.2 
SOBI003 
SOBI003 is a chemically modified variant of recombinant human sulfamidase. SOBI003 is a 
sterile solution for i.v. infusion after dilution. In this Phase I/II study, SOBI003 is administered 
once weekly. 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 22 of 88 
Version 2.0 Final Date 06 Jul 2018 
By modification of the sulfamidase glycans, the uptake of SOBI003 systemically is strongly 
reduced. This translates into a reduced serum clearance as demonstrated in mice. SOBI003 
passes the blood-brain barrier (BBB) presumably by adsorptive mediated transcytosis, whereby 
the increased plasma exposure facilitates generation of pharmacological relevant levels of 
SOBI003 in the central nervous system (CNS) compartment. Once SOBI003 enters the target 
cells and reaches the lysosomal compartment, it shows enzymatic activity and stability 
comparable to that of unmodified sulfamidase, as demonstrated in fibroblasts of MPS IIIA 
patients. 
5.1.3 
SOBI003 nonclinical development 
In a MPS IIIA mouse model with a spontaneous missense mutation of the SGSH gene, disease 
manifestations similar to the human conditions are obtained, including lysosomal storage of HS 
and neurological pathology. In these mice, repeated i.v. administration of SOBI003 resulted in a 
dose and time dependent clearance of HS in brain. The reduction in HS translated into 
improvements in terms of lysosomal size and neuroinflammation as well as beneficial effects on 
behavioral impairments.  
HS reduction in cerebrospinal fluid (CSF) correlated with reduction of HS in whole brain of 
MPS IIIA mice following repeated i.v. administration of SOBI003, thus supporting the use of HS 
reduction in CSF as a biomarker of disease modification. 
In MPS IIIA mice, a relationship between treatment effect and SOBI003 dose level and 
treatment duration was observed. The reduction of HS in brain was related to the accumulated 
active SOBI003 dose. The return to baseline HS biomarker levels after discontinuation of 
treatment was also a gradual process in this mouse model. To quantify and understand the dose, 
time, concentration and effect relationship in MPS IIIA mice, a semi-mechanistic in silico model 
was developed based on mouse PK, distribution of SOBI003 to the brain, SOBI003 entering 
target cells, the intracellular retention of SOBI003 and an intracellular SOBI003 concentration-
effect relationship on HS reduction. Human fibroblasts of an MPS IIIA patient (GM00879, 
Coriell Institute) were used for in vitro determination of SOBI003 cell entry rate, cell retention, 
and intracellular concentration-effect relationship. Allometric scaling from rat and cynomolgus 
monkey to human was applied to predict clearance and volume of distribution in patients (body 
weight 20 kg). Translating the mouse in silico model to human repeated weekly administration 
of 3 mg/kg, SOBI003 is predicted to gradually achieve a brain HS reduction of ~ 35 % after 3 
months and ~ 45 % after 6 months treatment. Thus, according to model-based simulations using 
the in silico model, the 3 mg/kg dose level is expected to gradually elicit a pharmacological 
effect in CNS in humans. Repeated weekly administration of 10 and 20 mg/kg SOBI003 is 
predicted to achieve a brain HS reduction of ~ 75 % and ~ 80 % after 3 months and ~ 80 % and  
~ 85 % respectively after 6 months treatment relative to baseline. 
Nonclinical safety assessments have been performed to support the SOBI003 development 
program. The nonclinical safety studies were performed in accordance to international standards 
for drug development and OECD Principles of GLP. A 3-month toxicity study was performed in 
MPS IIIA mice, a disease model to evaluate any potential interactions of the drug and the 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 23 of 88 
Version 2.0 Final Date 06 Jul 2018 
disease. A 1-month toxicity study in healthy non-human primates (cynomolgus monkey) was 
also performed. In addition, to support the clinical development in pediatric patients, juvenile 
rats were treated for one month from 10 days up to 5 weeks of age, which corresponds to a life-
span in humans ranging from neonates up to the age of 6 years. Throughout the nonclinical 
safety program SOBI003 was administered by i.v. infusion every third day following pre-
treatment with anti-histamine to appropriately resemble the clinical treatment regimen.  
In the species tested, the treated animals did not show any signs of adverse effects. Thus, the 
safety evaluation of SOBI003 has shown that it is well-tolerated. In favor of SOBI003 treatment 
was also improvements in the disease state in MPS IIIA mice, such as lower incidences and/or 
severity of microscopic findings and with lower kidney, liver and spleen weights. However, the 
histopathological examinations revealed that the treatment of all three species at higher doses 
were associated with an accumulation of eosinophilic material in the cytoplasm of macrophages 
of various origin; liver, lymph nodes and the heart. The observations were clearly dose 
dependent and did not cause any detected harmful effects or other negative consequences to the 
animals. The observations were partially reversible after 4 weeks withdrawal of treatment. The 
anomalies were judged to be a result of a normal physiological function of tissue macrophages to 
scavenge proteins and the observed accumulation may be due to the high protein load. Thus, 
since these findings were not considered as adverse the NOAEL was set to the highest dose 
administered in the three species tested, i.e., 300 mg/kg in the mice and rats and 150 mg/kg in 
the cynomolgus monkeys.  
The lowest SOBI003 serum exposures at the NOAEL dose levels in these species were observed 
in the mice following the 300 mg/kg dose, where mean Cmax,ss was 86.3 and 163 μmol/L and 
mean AUCτ,ss was 718 and 934 μmol*h/L in in male and female mice, respectively. Based on 
predicted steady state PK in patients (Cmax,ss 0.89, 3.0, and 5.9 μmol/L; AUCτ,ss 11.5, 38.5, and 
77.0 h·μmol/L at dose levels 3, 10 and 20 mg/kg), the margins to SOBI003 exposure in the 
pivotal toxicity studies are thus at least 100-fold for a starting dose of 3 mg/kg and at least 10-
fold for a dose of 20 mg/kg. Further details are presented in the SOBI003 investigator brochure. 
5.1.4 
SOBI003 immune mediated reactions 
In an initial explorative study in MPS IIIA mice, where the efficacy of 3 different sulfamidase 
derivatives was assessed (whereof SOBI003 was one), hypersensitivity reactions were 
encountered following treatment with SOBI003. Mice were given the test articles at 30 mg/kg 
every other day as a bolus injection without antihistamine pretreatment. The study was 
terminated due to hypersensitivity reactions in connection with the fifth i.v. dose. A second study 
was performed, where the mice were pretreated with the antihistamine chlorpheniramine, and the 
injection rate was extended to approximately 5 to 10 seconds per injection. The same test 
articles, doses, and dose frequencies were applied as in the initial study, and the second study 
could be finalized as planned without any abnormal observations (a 25-day treatment period with 
a total of 13 injections). Subsequently, antihistamine pretreatment was included in the chronic 
efficacy studies. 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 24 of 88 
Version 2.0 Final Date 06 Jul 2018 
The nonclinical studies in MPS IIIA mice show that ADAs are generated against SOBI003. The 
ADA response did not compromise safety or alter the exposure, as assessed at 24 hours after last 
dose administration. A number of chronic efficacy studies have been performed with 
antihistamine pretreatment in MPS IIIA mice without observing any obvious toxicities or lack of 
efficacy. In cynomolgus monkey a repeated dose paradigm with doses once every third day 
indicated that ADAs have an impact on SOBI003 exposure. ADAs did not appear to impact the 
Cmax in plasma, but possibly the AUC. Apart from these deviations, exposure after the last dose 
was similar to that observed after the first dose. No ADA development was seen in the pivotal 
juvenile rat toxicity study. 
Development of ADAs is a common finding in ERTs and correlates to the degree of endogenous 
enzyme expression (14, 15, 16, 17). Nonclinical assessments of immunogenicity of human 
proteins, applying in silico, in vitro, or animal models have, so far, shown only limited or no 
translatability to the clinical situation.  
The polypeptide sequence of SOBI003 is identical to human sulfamidase. However, as a result of 
use of the CHO expression system and the glycan modifications, through which some peripheral 
carbohydrate ring structures in the glycans are linearized, the overall structure of SOBI003 is not 
identical to human sulfamidase. Therefore, an immune reaction to SOBI003 may be expected in 
analogy to what occurs with other ERTs. ADAs and their impact on safety, PK and PD are 
monitored closely in the Phase I/II study. 
5.2 
Study rationale 
SOBI003 is being developed for treatment of MPS IIIA. Scientific advice on the nonclinical and 
chemistry, manufacturing and control (CMC) development was obtained from the FDA on 16 
February 2016 and from EMA on 28 June 2016. A pre-IND meeting was held with the FDA on 
21 June 2017 to obtain agreement on the conduct of this first-in-human study with SOBI003.  
This first-in-human study is designed to assess the safety, tolerability, PK, PD and 
immunogenicity of SOBI003 at 3 dose levels to provide knowledge needed to optimize the 
further evaluation of SOBI003 in patients with MPS IIIA.  
Given the above and that for ERTs, healthy volunteers are not a representative population for 
assessment of tolerability, immunogenicity or PD, the SOBI003 first-in-human study is 
conducted in MPS IIIA patients. The severity of disease and the limited number of patients with 
an acceptable level of mental and physical stability to allow study assessments warrant a 
condensed clinical development program. This integrated Phase I/II study will therefore also 
include the establishment of a clinically relevant PD dose-response relationship for SOBI003.   
5.3 
Potential risks and benefits 
MPS IIIA is an irreversible, progressive, life-shortening disease with no existing effective 
therapeutic alternative. SOBI003 provides a potential clinical benefit by reducing the levels of 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 25 of 88 
Version 2.0 Final Date 06 Jul 2018 
stored HS and its metabolites and thereby reducing neuroinflammation which potentially could 
reduce the clinical manifestations. 
Apart from ADA development in two species (MPS IIIA mouse and cynomolgus monkey) out of 
the three included in the pivotal toxicity program, which is an expected finding considering the 
foreign nature of a human protein to animal species, the nonclinical safety evaluation of 
SOBI003 did not show any signs of adverse effects, thus SOBI003 was well-tolerated.  
Given the observed pharmacological and toxicological profile in the non-clinical studies, it is 
judged that SOBI003 can be given to man in a carefully monitored First-In-Human study. 
Adherence to study inclusion/exclusion criteria, staggered dose escalation, close clinical 
monitoring, and stopping rules will be applied. 
Hypersensitivity reactions/immune-mediated adverse reactions, including anaphylaxis and 
infusion reactions, are commonly reported for lysosomal ERTs. To reduce the incidence and 
severity of these adverse reactions, slow infusion rates, prolonged infusion duration and 
pretreatment with antihistamines will be applied. Severe and potentially life-threatening adverse 
hypersensitivity/immune-mediated reactions may however still occur.  
Close clinical supervision by medical staff that are experienced with ERT treatment will be 
applied during and after the infusions. This will ensure early detection and adequate treatment of 
potential adverse reactions. Potential hypersensitivity reactions including anaphylactic events 
and infusion related reactions will be treated in accordance with the current anaphylactic 
algorithm (19) including treatment with antipyretics and additional antihistamines to manage 
milder hypersensitivity/immune-mediated reactions. Availability of cardiopulmonary 
resuscitation equipment and immediate access to emergency medical services will be secured. 
Potential delayed hypersensitivity reactions may occur outside the hospital setting (refer to 
Section 7.1. for minimum hospitalization periods during study participation). Parents/caregivers 
will be carefully informed of potential signs and symptoms of hypersensitivity reactions and of 
the importance to seek immediate medical attention.  
The potential clinical benefit of the 24-week treatment period of this study is expected to be 
limited as the need of ERT is expected to be life-long. Therefore, patients that complete the 24-
week treatment period will be offered to receive continued SOBI003 treatment by participation 
in an extension study. Furthermore, the dose-levels applied in this study are expected to be 
sufficiently pharmacologically active to result in peripheral and central reduction of HS, 
potentially also reducing or stabilizing neuroinflammation, and neurodegeneration with potential 
effect on clinical manifestations including amelioration of neurocognitive dysfunction in these 
patients with MPS IIIA. These predictions are based on current nonclinical data, and are thus to 
be confirmed in clinical studies.  
Potential study procedural risks include the use of sedation/general anesthesia, the surgical 
procedure and use of a central venous access port. To minimize study related risks, local hospital 
procedures will be applied for the procedures. The selection of anesthetic method will be in 
accordance with local hospital routines and as judged by pediatric anesthesiologist with prior 
experience from MPS patients. The local surgeon will make the decision on which vein to be 
used for the central venous access port for each individual patient. The parents/caregivers will be 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 26 of 88 
Version 2.0 Final Date 06 Jul 2018 
trained in management of the port, in accordance with local hospital routines. This includes the 
actions to take in case an infection is suspected. SAEs are captured from the time the ICF is 
signed and adverse events are captured from the start of the first SOBI003 infusion.  
In summary, the potential benefits of SOBI003 treatment are considered to outweigh the 
foreseeable risks. 
6 
Study objectives and endpoints 
6.1 
Primary objective  
The primary objective is: 
To evaluate the safety and tolerability of SOBI003 at different dose levels. 
6.1.1 
Primary endpoint 
The primary endpoint to evaluate the safety and tolerability of SOBI003 is: 
 Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) 
6.1.2 
Secondary endpoints related to the primary objective 
The secondary endpoints to evaluate the safety and tolerability of SOBI003 are: 
 Vital signs (blood pressure, heart rate, body temperature, respiratory rate and oxygen 
saturation) 
 Laboratory safety variables (hematology, coagulation, clinical chemistry and urine 
analysis) 
6.2 
Secondary objectives  
The secondary objectives are the following: 
1. To characterize the PK properties of SOBI003 following single and repeated 
administration by the use of non-compartmental analysis (NCA) 
2. To assess the immunogenicity of SOBI003 
3. To assess the PD effect of different dose levels and treatment duration of SOBI003 on HS 
levels in CSF, serum and urine  
4. To assess the effect of SOBI003 at different dose levels on neurocognition 
5. To assess the effect of SOBI003 at different dose levels on adaptive behavior 
6. To assess the effect of SOBI003 at different dose levels on gray matter volume 
7. To assess the effect of SOBI003 at different dose levels on Quality of Life 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 27 of 88 
Version 2.0 Final Date 06 Jul 2018 
6.2.1 
Secondary endpoints 
The endpoints relating to the 1st secondary objective are: 
 Serum SOBI003 PK parameters at Weeks 1, 4, 12, and 24; tEnd of inf, CEnd of inf, Cmax, tmax, 
CPre-dose, CTrough, CL, AUC0-168h, t1/2 
 CSF SOBI003 concentration at Weeks 12 and 24 
The endpoints relating to the 2nd secondary objective are: 
 Occurrence of ADAs against SOBI003 in serum (seroconversion rate, time to 
seroconversion, transient/persistent). For patients with confirmed ADA positive serum 
samples, the following additional endpoints apply; ADA titers and IgG subclasses in 
serum, and presence of neutralizing antibodies (NAb) in serum. 
 Occurrence of ADAs against SOBI003 in CSF (conversion rate, time to occurrence, 
transient/persistent). For patients with confirmed ADA positive CSF samples, the 
following additional endpoints apply: ADA titers and presence of NAb in CSF. 
The endpoints relating to the 3rd secondary objective are: 
 Change from baseline in CSF HS at Weeks 12 and 24 
 Change from baseline in serum HS at Weeks 2, 3, 4, 8, 12 and 24  
 Change from baseline in urine HS at Weeks 2, 3, 4, 8, 12 and 24 
The endpoint relating to the 4th secondary objective are neurocognitive Development Quotient 
(DQ) ad age-equivalence score (AEq) as assessed by the Bayley Scales of Infant and Toddler 
Development®, third edition (BSID-III) cognitive subtest or the Kaufman Assessment Battery 
for Children, Second edition (KABC™-II); change from baseline at Week 24 
The endpoint relating to the 5th secondary objective is adaptive behavior age-equivalence score 
(AEq) as assessed by Vineland™ Adaptive Behavior Scales, Expanded Interview Form, Second 
edition (VABS-II); change from baseline at Week 24.    
The endpoint relating to the 6th secondary objective is gray matter volume as assessed by brain 
volumetric magnetic resonance imaging (MRI); change from baseline at Week 24. 
The endpoints relating to the 7th secondary objective is Pediatric Quality of Life Inventory 
(PedsQL™) total score and PedsQL™ Family Impact Module total score; change from baseline 
at Week 24. 
6.3 
Exploratory objectives  
The exploratory objectives are to explore the effect of SOBI003 at different dose levels on: 
1. Clinical manifestations of MPS IIIA as assessed by endpoints specified in Section 6.3.1   
2. To characterize the PK properties of SOBI003 following single and repeated 
administration by the use of population PK analysis 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 28 of 88 
Version 2.0 Final Date 06 Jul 2018 
3. To evaluate the PK/PD relationship between SOBI003 concentrations in serum and effect 
of SOBI003 on HS levels in CSF, serum and urine by the use of population modelling 
analysis   
As local regulations permit and provided that additional separate caregiver consent is given, the 
exploratory objectives are also to: 
 Collect and store a blood sample for future pharmacogenetic research aimed to explore 
genetic characteristics that may contribute to and/or modify the disease phenotype and /or 
with possible impact on safety, tolerability, immunogenicity, PK and PD related to 
SOBI003 treatment 
 Collect and store serum, CSF and urine samples to enable analyses of biomarkers with 
possible relation to safety, tolerability, immunogenicity, PK and PD of SOBI003, as 
identified in future  
Serum, CSF, and urine samples for potential future pharmacogenetic and biomarker analyses 
will be stored for a maximum of 10 years following study completion. The results of any such 
analyses will not be included in the Clinical Study Report for this study, but reported separately 
when analyzed, thus enabling exploration of any emerging novel disease-related discoveries of 
e.g., previously unknown alleles, inflammatory cytokines, other HS biomarkers (e.g. HS 
metabolites), components of the complement system, and neurodegeneration.  
6.3.1 
Exploratory endpoints 
The endpoints related to the 1st exploratory objective are: 
 Adaptive behavior composite score as assessed by VABS-II; change from baseline at 
Week 24 
 Neurocognitive composite score as assessed by the BSID-III cognitive subtest or the 
KABC-II; change from baseline at Week 24  
 Expressive and receptive language as assessed by the BSID-III language subtests or the 
KABC-II Expressive Vocabulary subtest, and the VABS-II communication domain; AEq 
change from baseline at Week 24 
 Fine and gross motor function as assessed by the BSID-III motor subtests and the 
VABS-II; AEq change from baseline at Week 24 
 Sleep pattern as determined by Children´s Sleep Habits Questionnaire (CSHQ) score 
 Sleep pattern as determined by actigraphy including total sleep time, total day- and night 
time sleep duration, sleep latency, sleep efficiency, number of nocturnal awakenings, and 
wake after sleep onset; change from baseline at Weeks 12 and 24, respectively 
 Compound ventricular volume as assessed by brain volumetric MRI; change from 
baseline at Week 24 
 Fractional anisotropy (FA) and mean diffusivity (MD) of corpus callosum as assessed by 
diffusion tensor imaging MRI; change in from baseline at Week 24 
 FA and MD of cerebral white matter as assessed by diffusion tensor imaging MRI; 
change in from baseline at Week 24 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 29 of 88 
Version 2.0 Final Date 06 Jul 2018 
 Cerebral white matter as assessed by susceptibility weighting imaging (SWI) MRI; 
change in from baseline at Week 24 
 Basal ganglia as assessed by susceptibility weighting imaging (SWI) MRI; change in 
from baseline at Week 24 
 Liver volume as assessed by abdominal MRI; change from baseline at Week 24 
 Spleen volume as assessed by abdominal MRI; change from baseline at Week 24 
The endpoint related to the 2nd exploratory objective are: 
 Population PK model parameter estimates and associated covariates describing intra- and 
inter-individual variability in respective parameter estimate. 
The endpoints related to the 3rd exploratory objective are: 
 Population PK/PD model parameter estimates and associated covariates describing intra- 
and inter-individual variability in respective parameter estimate. The results of these 
analyses will not be included in the Clinical Study Report for this study, but reported 
separately. 
7 
Investigational plan 
7.1 
Overall study design and plan 
This is an open-label, non-controlled, parallel, sequential ascending multiple-dose, multicenter 
study to assess the dose related safety, tolerability, PK and PD of SOBI003 in pediatric 
MPS IIIA patients. 
SOBI003 is administered as weekly i.v. infusions over a period of time of 4 hours. The study 
treatment period comprises 24 weekly infusions. Prior to initiation of each infusion, the patients 
are pretreated with a single dose of non-sedative antihistamine. If infusion-related reactions 
occur, then the infusion duration may be expanded up to 24 hours and supportive medication 
may be administered, at the discretion of the investigator.  
The study is planned to consist of 3 dose cohorts, each comprising 3 patients. The principal 
investigator and Sobi may decide to replace patients withdrawn prematurely, when applicable. 
An additional cohort comprising 3 patients may be added, if deemed necessary to more 
accurately characterize the safety, tolerability, PK or PD. The total number of patients to be 
exposed to SOBI003 is not to exceed 15. 
The study population is MPS IIIA patients that are 1 to 6 years of age, excluding patients with 
the S298P genotype. The study is planned to be conducted in the U.S.A., Turkey, Netherlands 
and Germany, at up to five study sites in total. 
A central venous access port is used for SOBI003 infusions and for PK, PD and safety laboratory 
blood samplings. Blood sampling from additional peripheral line is applied in accordance with 
local hospital routine and also to verify PK analyses from the central line (Section 7.5.6.1). Refer 
to Section 7.5.1.3 for details on insertion of the port. 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 30 of 88 
Version 2.0 Final Date 06 Jul 2018 
At the start of screening, i.e., when the ICF is signed, the majority of patients are expected to 
already have a confirmed MPS IIIA diagnosis, either by genotyping or verification of reduced 
sulfamidase enzyme activity. The anticipated number of screen failures is therefore expected to 
be low, i.e., 10 to 20% or up to 2 patients. 
The screening visit can be performed up to 12 weeks prior to the first SOBI003 infusion. At the 
screening visit, the MPS IIIA diagnosis is verified and the genotype is determined at a central 
laboratory (see Section 7.5.2.1). To determine the patient’s developmental age, the VABS-II is 
assessed by interviewing the patient’s parent/caregiver and the mean of the subdomain age-
equivalence scores is determined. Once the patient eligibility has been confirmed, visits are 
scheduled for baseline assessments and insertion of a central venous access port (see Section 
7.5.1.3). The baseline assessments and procedures should be performed within 6 weeks prior to 
the first SOBI003 infusion. There should however be at least 2 weeks between the insertion of 
the venous access port and the first SOBI003 infusion, and the VABS-II and BSID-III/KABC-II 
should be assessed within 2 weeks prior to the first SOBI003 infusion. The total study duration 
for an individual patient will range from 31 to 36 weeks.  
Patients are assigned to a dose cohort in consecutive order as the eligibility criteria have been 
confirmed, with prioritization of the younger patients. There is thus no restriction or requirement 
regarding the site distribution of patients per cohort, i.e., patients within one cohort can be 
recruited at only one site or at multiple sites.  
Treatment initiations will be staggered within each cohort in order to be able to observe, interpret 
and treat possible adverse reactions and to ensure that such reactions can be dealt with promptly. 
For the first patient within each dose cohort, the investigator will review safety data, including 
the safety laboratory results, and signs and symptoms captured up to Day 6 of the dosed patient 
and notify Sobi in writing of his conclusion of adequate safety for exposing a new patient to the 
same SOBI003 dose level. Once the adequate safety has been concluded for the first patient, 
invasive baseline assessments of the next patients in the cohort can be initiated. There will be a 
minimum of 3 days between treatment initiations in the 2nd and 3rd patient within the cohort. 
Before the 3rd patient within the same dose cohort is exposed to SOBI003, the investigator will 
review available safety data and signs and symptoms of the dosed patient(s) at his/her site and 
notify Sobi in writing of his conclusion of adequate safety for exposing a new patient to the same 
SOBI003 dose level. Sobi will then confirm whether a new patient can be dosed. Should the 
investigator or Sobi have any safety concerns, then an ad hoc SRC meeting will be summoned to 
determine dosing of additional patients.  
For each cohort, SRC meetings are scheduled approximately 3 weeks after completion of the 3rd 
patient’s 4th dose administration. Prior to commencing invasive baseline assessments of patients 
for the next cohort, the SRC will review pre-specified safety, immunogenicity, and PK data to 
confirm that continued dosing is safe. In addition, PD data in terms of HS in serum and urine, as 
well as any available HS levels in CSF, will be reviewed. Based on the safety, immunogenicity, 
PK and PD data, the SRC will determine what dose to apply in the next cohort (see Section 
7.5.5.9). 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 31 of 88 
Version 2.0 Final Date 06 Jul 2018 
Figure 1 
Overview for study design for Study SOBI003-001 
 
Study-specific stopping criteria, both at individual patient level and at cohort(s) level are 
presented in Section 7.5.5.9.1.  
The dose level for Cohort 1 is selected on the basis of nonclinical data, the PK/PD in silico 
model and the emerging toxicology data (see Section 7.4.5.1).   
Close clinical monitoring of patients will be required during and after SOBI003 administration 
for any symptoms of anaphylaxis, hypersensitivity reactions, circulatory and/or respiratory 
changes, urticaria, or other signs of related reactions. Anaphylactic reactions will be treated in 
accordance with current anaphylaxis algorithm “Hypersensitivity to Biological Agents - Updated 
Diagnosis, Management, and Treatment” issued by the American Academy of Allergy, Asthma 
& Immunology (AAAI) (19).  
To secure the close monitoring of the patients and the intensified study assessments following 
the 4th, 12th and 24th infusions, the minimum hospitalization periods specified in Table 1 are 
applied: 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 32 of 88 
Version 2.0 Final Date 06 Jul 2018 
Table 1 Minimum hospitalization periods 
Infusion No. 
Minimum hospitalization period* 
1 to 3 
Admission; day prior to 1st infusion for pre-dose assessments 
Discharge; 48 hours after initiation of 3rd infusion 
4 to 8, 12, and 24 
Admission; day of infusion 
Discharge; 48 hours after initiation of each infusion 
9 to 11, 13 to 23 
Admission; day of infusion 
Discharge; 12 hours after initiation of each infusion 
* Extended as per local routine for admission/discharge and per patient need as determined by the investigator (e.g., 
concurrent illness, travel distance etc.) 
Prior to discharge following the third infusion, the parents/caregivers will be carefully informed 
of potential signs and symptoms of hypersensitivity reactions including rash, itching, sweating, 
swelling of lips/tongue/face, vomiting, noisy breathing, dizziness, fainting as well as late 
reactions such as dermatological events/skin reactions such as contact dermatitis, maculopapular 
rash/eruptions, bullous eruptions/dermatitis/exanthemas, pustular exanthemas, and of the 
importance to seek immediate medical attention. An emergency card containing details on how 
to seek medical help will be provided to each parent/caregiver and they will be instructed to 
always carry the emergency card with them. The card will also contain brief details on the study 
treatment and contact details to site staff in order to secure appropriate medical management of 
any emergency situation that has to be managed outside the study site. 
Depending on the distance and any travelling difficulties, the patient and parent(s) may be 
relocated for the full study duration. The families are reimbursed for travel and accommodation 
expenses and, if applicable, for caregiver meals during the hospitalization periods. Appointed 
study coordinators will assist the families with travel and accommodation arrangements.  
Upon completion of the 24-week treatment period with satisfactory tolerability, the patient is 
offered to receive continued SOBI003 treatment by participation in an extension study. 
A DMC will monitor safety data at pre-specified intervals throughout the 24-week and the 
extension studies.  
7.2 
Discussion of study design 
Regulatory advice on the design of the Phase I/II study was obtained from the FDA on 21 June 
2017.  
The non-controlled design of the FIH study is justified by the MPS IIIA disease severity, rapid 
progression, lack of available treatment and the limited number of potential patients for study 
participation. 
Three sequential dose levels with 3 patients in each cohort will enable assessment of safety and 
tolerability, as well as characterize a pharmacodynamic dose-response relationship.  


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 33 of 88 
Version 2.0 Final Date 06 Jul 2018 
A study duration of 24 weeks has been chosen to enable establishment of a dose-response 
relation in terms of reduction of HS in CSF.  
Patients between 1 and 6 years of age who have not received previous treatment for MPS IIIA 
with an ERT, gene- or stem cell therapy will be eligible to participate in this study. Patients 
carrying the S298P mutation, a mutation that is associated with a slower progression of disease, 
will be excluded to reduce the variability in HS levels in CSF.   
Patients below 1 year are considered more vulnerable and it would be preferable to initiate 
inclusion of such patients after the safety of SOBI003 has been established in older patients. In 
addition, the lower age limit of 1 year has been selected to reduce the potential variability in 
SOBI003 PK and to ensure that the blood sampling volumes needed for the Phase I/II study can 
be collected. Applying the European Commission guidance (20), the study-related blood loss 
should not exceed 3% of the total blood volume during a period of 4 weeks and should not 
exceed 1% at any single time. In an average 1 year-old child with a bodyweight of 10 kg, it is 
thus considered acceptable to draw blood volumes of 8 mL as a single draw and 24 mL over a 
4-week period, assuming an estimated blood volume of 80 mL/kg. These volumes are considered 
appropriate to adequately monitor safety and to generate data enabling conclusions on PK and 
PD. The upper age limit of 6 years has been selected to exclude patients that are close to 
progressing or who have progressed to a more severe state of disease which might interfere with 
protocol compliance.  
As a precautionary measure, staggered dosing is applied. For the first patient within each dose 
cohort, the investigator will review safety data, including the safety laboratory results, and signs 
and symptoms captured up to Day 6 of the dosed patient and notify Sobi in writing of his 
conclusion of adequate safety for exposing a new patient to the same SOBI003 dose level.  
There will be a minimum of 3 days between treatment initiations in the 2nd and 3rd patient within 
the cohort. This staggered treatment initiation is expected to be sufficient to monitor for acute 
and subacute adverse events prior to treating additional patients at the same dose level.  
For each cohort, SRC meetings are scheduled approximately 3 weeks after completion of the 3rd 
patient’s 4th dose administration. The 4-week treatment period prior to dose escalation is chosen 
to enable a detection of an early immunogenicity response following limited number of repeated 
doses. In addition, based on current data, steady-state of SOBI003 in serum is expected to have 
been approached at this time point. 
7.3 
Selection of study population 
7.3.1 
Inclusion criteria 
A patient must fulfill the following criteria in order to be included in the study: 
1. Informed consent obtained from the patient’s legally authorized representative(s) 
2. Patients with MPS IIIA, as confirmed by both: 
 A documented deficiency in sulfamidase enzyme activity in concordance with a 
diagnosis of MPS IIIA*, and 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 34 of 88 
Version 2.0 Final Date 06 Jul 2018 
 Normal enzyme activity level of at least one other sulfatase measured in 
leukocytes  
3. Chronological age of ≥12 and ≤72 months (i.e., 1 to 6 years) at the time of the first 
SOBI003 infusion and has a developmental age ≥12 months at screening as assessed by 
the Vineland Adaptive Behavior Scales, Second Edition (VABS-II)  
4. Medically stable patient who is expected to be able to comply with study procedures  
 
* as determined by the reference ranges applied by the Greenwood Genetic Center  
7.3.2 
Exclusion criteria 
The presence of any of the following will exclude a patient from inclusion in the study: 
1. At least one S298P mutation in the SGSH gene 
2. Contraindications for anesthetic procedures, surgical procedure (venous access port) MRI 
scans and/or lumbar punctures  
3. History of poorly controlled seizures 
4. Patients is currently receiving psychotropic or other medications which in the 
investigator's opinion, would be likely to substantially confound test results 
5. Significant non-MPS IIIA-related CNS impairment or behavioral disturbances, which in 
the investigator's opinion, would confound the scientific integrity or interpretation of 
study assessments  
6. Prior administration of stem cell or gene therapy, or ERT for MPS IIIA 
7. Concurrent or prior (within 30 days of enrolment into this study) participation in a study 
involving invasive procedures 
7.3.3 
Withdrawal of patients from treatment or study 
7.3.3.1 
Withdrawal from treatment 
A patient should be withdrawn from the study treatment if, in the opinion of the investigator, it is 
medically necessary, or if it is the wish of the patient’s primary caregiver(s). During the 
informed consent process, the investigator will clarify that it is essential for the patient’s safety 
to be willing to comply with the study protocol requirements, including study safety and 
immunogenicity assessments following a potential withdrawal of study treatment. 
When a patient is withdrawn from study treatment, the date and time of the last SOBI003 
infusion and the date and reason for treatment withdrawal should be clearly described in the 
relevant sections of the case report form (CRF). If a patient is removed from treatment because 
of an adverse event (AE), the reason for treatment withdrawal should always be stated as 
‘adverse event’ irrespective of whether this was the investigator’s or the patient’s primary 
caregiver(s) decision. The study assessments as specified in Section 7.5.1.13 should be 
completed as soon as possible after making the treatment withdrawal decision. If study treatment 
is withdrawn due to AE(s), additional safety assessments will be performed at the discretion of 
the investigator, as warranted by the AE(s) leading to treatment withdrawal. 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 35 of 88 
Version 2.0 Final Date 06 Jul 2018 
When possible, non-infusion-related study assessments should continue in accordance with the 
Schedule of Events (refer to Table 3) until completion of the Week 24 visit.  
7.3.3.2 
Withdrawal from study 
The patient’s legally authorized representative is free to withdraw the patient from the study at 
any time. A patient that is withdrawn from the study should be examined as soon as possible, 
whenever possible, irrespective of the reason for withdrawal.  
Refer to Sections 7.3.3.1and 7.5.1.13 for guidance on applicable study assessments to be 
completed when the decision to withdraw from the study coincides with the decision to withdraw 
study treatment. 
For any patient that is found to be ADA-positive after completion of the repeated Early 
Termination assessments (as specified in Sections 7.5.1.13 and Table 3), every effort should be 
made to continue ADA samplings at approximately monthly basis until the ADA has 
disappeared or titers have stabilized at a lower level (refer to Sections 7.5.5.3 and 7.5.6.1). 
Irrespective of the study assessments to be performed in case of treatment and/or study 
withdrawal, a patient that is withdrawn from study treatment due to an adverse event, should be 
followed up until the AE(s) leading to treatment withdrawal are either resolved or have stabilized 
even after the patient’s participation in the study is over. Each clinically significant abnormal 
laboratory value or other clinically meaningful abnormality should be followed until the 
abnormality resolves or until a decision is made that it is not likely to resolve. 
7.3.4 
Replacement of withdrawn patients 
The principal investigator and Sobi may decide to replace patients that are withdrawn 
prematurely from treatment, when applicable. Any new patient will be assigned to the same 
study cohort as the withdrawn patient. 
7.3.5 
Specific restrictions/requirements on patients 
The patients are required to remain hospitalized from the time of first SOBI003 infusion until at 
least 48 hours after initiation of the 3rd SOBI003 infusion. After discharge following the 3rd 
infusion and until admission for the 9th infusion, the patients are requested to stay within a 
reasonable distance from the site to allow timely follow-up of applicable AEs. For patients living 
far away from the study site, temporary accommodation may be provided. Following the 9th 
infusion, the patients may move back to their homes to attend the site weekly for the infusions at 
the site. All patients will however be required to be hospitalized up to 48 hours after initiation of 
the 12th and 24th infusions, due to the schedule of study assessments, including anesthesia.  


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 36 of 88 
Version 2.0 Final Date 06 Jul 2018 
7.4 
Treatments 
7.4.1 
Treatments administered  
In this open-label non-controlled study, the investigational medicinal product (IMP) is SOBI003. 
SOBI003 is administered as 4-hour i.v. infusions given once weekly for a duration of 24 weeks. 
In case of occurrence of infusion reactions, the infusion duration may be prolonged up to 
24 hours at the discretion of the investigator.  
Three dose levels of SOBI003 will be assessed, provided that the SRC concludes that the safety 
profile is acceptable. The planned lowest dose level is 3 mg/kg (cohort 1). For cohorts 2 and 3, 
the dose levels will be selected on basis of at least 4-week safety, PK, immunogenicity, and PD 
data of prior dose cohort(s) as well as applicable toxicology data (refer to Section 7.4.5). An 
additional cohort comprising 3 patients may be added, if deemed necessary for safety, 
tolerability, PK or PD evaluation.  
SOBI003 solution, 20 mg/mL, is mixed with NaCl 0.9% infusion solution prior to 
administration. For a bodyweight < 25 kg, the total infusion volume is 100 mL. For a 
bodyweight ≥ 25 kg, the total infusion volume is 250 mL.  
Actual materials to be used for mixing SOBI003 solution with NaCl infusion solution (i.e., 
infusion solutions, syringes and needles) and for administering the infusions (i.e., infusion lines, 
syringes, manifolds, venous access ports) must be preapproved by Sobi to secure that all 
materials are compatible with SOBI003.  
Detailed IMP preparation instructions are provided in a separate IMP manual. 
Table 2 
Investigational medicinal products 
Cohort 
Investigational 
product 
Dosage form 
Route 
Weekly dose 
Dosage regimen 
1 
SOBI003 
Solution for 
infusion 
i.v. 
3 mg/kg  
4-hour infusion given once weekly 
2 
SOBI003 
Solution for 
infusion 
i.v. 
X mg/kg1 
4-hour infusion given once weekly 
3 
SOBI003 
Solution for 
infusion 
i.v. 
Y mg/kg1 
4-hour infusion given once weekly 
1 
Actual dose levels are determined by SRC (refer to Section 7.4.5).  
7.4.2 
Identity of investigational medicinal products 
SOBI003 is provided as concentrate for solution for i.v. infusion, 20 mg/mL, in 5-mL injection 
vials. Each vial contains 4 mL. Ten vials are packed in one box/outer carton. Vial and outer 
carton labeling will comply with national regulatory requirements. To facilitate accurate drug 
accountability, vial-specific numbers are printed on the vial labels. 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 37 of 88 
Version 2.0 Final Date 06 Jul 2018 
The drug substance is manufactured by Swedish Orphan Biovitrum AB (publ), 
SE-112 76 Stockholm, Sweden. The drug product is manufactured by Rechon Life Science AB, 
SE-216 13 Limhamn, Sweden. Secondary packaging of vials and labeling of cartons is done by 
Almac Group, 4204 Technology Drive, Durham NC 27704, U.S.A. 
SOBI003 is shipped and stored at frozen conditions. 
Possible deficiencies related to the handling, storage and quality of the IMPs should be reported 
to the study monitor and also directly to complaints@sobi.com. 
7.4.3 
Method of assigning patients to a treatment group 
Upon provision of signed informed consent, patients are assigned a site-specific enrolment 
number in strict consecutive order. Upon completion of the screening assessments and 
confirmation of patient eligibility, including confirmation of sulfamidase enzymatic activity, 
patients are assigned a subject number and allocated to a dose cohort in strict consecutive order. 
The terminology of “enrolled patients” refer to patients that have been assigned an enrolment 
number. The terminology of “included patients” refer to patients that have been assigned a 
subject number (and hence, assigned to a specific cohort). 
The first 3 included patients are thus assigned to Cohort 1 and administrations of SOBI003 at 
3 mg/kg/week. 
7.4.4 
Selection of doses 
7.4.5 
Selection of dose levels 
7.4.5.1 
Dose level for Cohort 1 
The starting dose of 3 mg/kg has been selected based on the Maximum Recommended Starting 
Dose (MRSD) which is derived from the NOAEL defined in the pivotal toxicology studies and 
an estimation of the pharmacologically active dose (PAD).   
The nonclinical safety evaluation of SOBI003 did not show any signs of adverse effects. Thus, 
the safety evaluation of SOBI003 has shown that it is well-tolerated. Also, improvements in the 
disease state in MPS IIIA mice were shown. A dose dependent, partially reversible accumulation 
of eosinophilic material in the cytoplasm of macrophages of various origin was observed in all 
three species, but these were considered to be a result of a normal physiological function of 
tissue macrophages and were therefore not considered to be adverse. Consequently, the NOAEL 
was set to the highest dose administered in the three species tested, i.e., 300 mg/kg in the rodents 
and 150 mg/kg in the cynomolgus monkeys. Based on predicted steady state PK in patients 
(Cmax 0.89 μmol/L; AUCτ,ss 11.5 h·μmol/L for the dose level 3 mg/kg), the margins to SOBI003 
exposure in the pivotal toxicity studies are at least 100-fold for a starting dose of 3 mg/kg. 
Further details are presented in Section 5.3.13 of the investigator brochure.   


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 38 of 88 
Version 2.0 Final Date 06 Jul 2018 
The MRSD is estimated to 2.4 mg/kg and has been based on the NOAEL derived from the 
pivotal toxicology studies in MPSIII A mice. The lowest HED when calculated from the 
NOAELs was obtained from the MPS IIIA mice constituting the most sensitive species in the 
toxicology studies. The highest dose in this study, 300 mg/kg did not cause any adverse effects. 
The NOAEL can therefore be determined to be at least 300 mg/kg. The body weight-adjusted 
human equivalent dose (HED) can thus be calculated to be 24 mg/kg, and by using a 
10-fold-safety margin the MRSD will be 2.4 mg/kg. 
The PAD has been estimated to 3 mg/kg. This is based on model-based simulations using an in 
silico model where the 3 mg/kg dose level is expected to elicit a potential pharmacological effect 
in CNS. A repeated dose of 3 mg/kg SOBI003 in humans will gradually result in a HS reduction 
in the brain of ~35% after 3 months and ~45% after 6 months treatment, whereas only negligible 
effect is expected after a single dose of 3 mg/kg. 
The Minimal Anticipated Biological Effect Level (MABEL) for SOBI003 is based on peripheral 
HS reduction in liver, spleen, heart, and lung following single dose administration in MPS IIIA 
mice, and has been set to 0.1 mg/kg. The SOBI003 dose levels that are expected to produce a 
pharmacological effect in the CNS are much higher, and the SOBI003 exposure in the CNS is 
much lower than peripherally according to nonclinical distribution studies. 
A starting dose of 3 mg/kg is based on PAD and the estimated MRSD (2.4 mg/kg), which 
however is higher than the MABEL for peripheral effects (0.1 mg/kg). Sobi considers a starting 
dose of 3 mg/kg justified given the nature of the target, the low risk for off-target toxicities with 
biologics like SOBI003, that acute toxicities related to on-target sulfamidase enzyme activity are 
not expected and that SOBI003 does not possess any agonistic properties. Furthermore, the MPS 
IIIA mouse is considered a relevant pharmacology and toxicology species for SOBI003 (21). 
Finally, MPS IIIA is a chronically debilitating, progressive, irreversible, life-shortening disease 
with no effective curative treatment available where the favorable benefit/risk ratio for SOBI003 
supports the use of a PAD for the selection of the starting dose. 
7.4.5.2 
Dose levels for Cohort 2 and 3 
With a starting dose of 3 mg/kg and given adequate safety, the planned mid and maximum dose 
levels are 10 mg/kg and 20 mg/kg, respectively. The SRC will review pre-specified safety, 
tolerability, immunogenicity, pharmacokinetic and pharmacodynamic data to confirm that 
continued/escalating dosing is safe (see Section 7.5.5.9). SRC can also decide to await further 
safety data, apply the same or a lower dose level for the next cohort, halt or discontinue the 
study. The highest expected target dose of 20 mg/kg will be guided by emerging safety and 
tolerability data in this study. Predicted serum concentrations of SOBI003 at 20 mg/kg in 
humans are 5.9 µmol/L for Cmax,SS and 77.0 h*µmol/L for AUCτ,SS. This provides a 15-fold 
margin between predicted exposure at 20 mg/kg and the NOAEL in the most sensitive species 
(MPS IIIA mice) (for details, refer to Section 5.3.13 of the SOBI003 investigator brochure). 
Based on the preclinical PK/PD model translated to patients, the effect on HS reduction is 
predicted to be both time and exposure dependent. Repeated weekly administration of 10 and 20 
mg/kg SOBI003 is predicted to achieve a brain HS reduction of ~ 75 % and ~ 80 % after 3 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 39 of 88 
Version 2.0 Final Date 06 Jul 2018 
months and ~ 80 % and ~ 85 % respectively after 6 months treatment relative to baseline (refer 
to Section 7.1 of the SOBI003 investigator brochure) 
Dose escalations will continue until the maximum tolerated dose (MTD) is achieved (refer to 
Section 7.5.5.9.1) or expected target dose is reached. 
7.4.6 
Selection and timing of doses for each patient 
Upon completion of the screening assessments and confirmation of patient eligibility, including 
confirmation of sulfamidase enzymatic activity, patients are assigned a subject number and 
allocated to a dose cohort in strict consecutive order. 
At the time of the first SOBI003 infusion, the patient should not have clinically significant 
evidence of ongoing infection, as judged by the investigator, or ongoing treatment with 
antibiotics. In such cases, the first infusion should be postponed until the infection has resolved.  
SOBI003 is administered as 4-hour i.v. infusions given once weekly for a duration of 24 weeks. 
The infusions are administered by qualified health care professionals. Every effort should be 
made to have the infusions administered every 7th day. A +/- 1-day window is applied after the 
4th infusion. Therefore, if the first infusion was administered for instance on a Wednesday, then 
the 5th to the 24th infusions can be administered on Tuesdays, Wednesdays or Thursdays.  
In case of signs and/or symptoms of ongoing infection at subsequent infusion occasions, infusion 
may be postponed, as judged by the investigator. If the infusion needs to be postponed more than 
3 days, then the investigator should discuss with the Sponsor’s MD to determine the timing of 
the next infusion (i.e., whether to await the next scheduled infusion). 
Within 30 to 60 minutes prior to each infusion, a single dose of a non-sedative antihistamine 
should be administered. The antihistamine can either be e.g., cetirizine, levo-cetirizine, 
loratadine, des-loratadine or fexofenadine, and the administered doses will be in compliance with 
locally approved labeling. The antihistamine agent is selected at the discretion of the 
investigator. Antipyretic medication may also be administered, at the discretion of the 
investigator. 
The actual doses of SOBI003 to be administered should be based on the patient’s bodyweight at 
4-week intervals (i.e., the actual dose administered at Weeks 1 to 4 is based on the bodyweight 
obtained pre-infusion at Week 1, the actual dose administered at Weeks 5 to 8 is based on the 
bodyweight obtained pre-infusion at Week 5, etc.). The body weight is obtained either on the day 
prior to the infusion or the day of infusion. 
SOBI003 concentrated solution is diluted with NaCl 0.9% infusion solution prior to 
administration. For a bodyweight < 25 kg, the targeted total infusion volume is 100 mL. For a 
bodyweight ≥ 25 kg, the targeted total infusion volume is 250 mL. If the infusion bag contains an 
overfill volume, the infusion should continue until the infusion bag is emptied. 
The final concentration of SOBI003 in the infusion bag will be calculated based on the added 
volume of SOBI003 to the infusion bag, and the total volume in the infusion bag. 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 40 of 88 
Version 2.0 Final Date 06 Jul 2018 
A slower infusion rate is applied for the initial hour for all dose cohorts, targeting the delivery of 
3% of the total dose/infusion volume. The infusion rate will be set to deliver the remaining 97% 
of the dose/infusion volume over the next 3 hours. Infusion rate schedules are provided in a 
separate IMP manual.  
In case of occurrence of infusion reactions, the infusion duration may be prolonged up to 
24 hours at the discretion of the investigator. 
The drug accountability records will capture sufficient details to verify the amount of SOBI003 
administered at each infusion occasion.  
7.4.7 
Prior and concomitant therapy 
Other therapies considered necessary for the patient’s welfare including melatonin for sleep 
disorder may be given at the discretion of the investigator. Patients on low dose genistein 
(<10 mg/kg/day) may continue treatment on the same dose throughout the study. All such 
therapy that is administered or used from the time of enrolment until completion of the study 
must be recorded in the CRF. This includes prescription drugs, herbal products, vitamins, 
minerals, and over-the-counter medications and the anesthetic drugs administered during study 
procedures (oxygen is not captured). Preferably, the treatment regimen should be unaltered 
during the study and thus only adjusting dose or medication(s) when medically warranted.  
No other medicinal product under investigation may be used concomitantly with the IMP(s) in 
this study. In addition, prior exposure to stem cell or gene therapy and ERT for MPS IIIA will 
not be allowed.  
As described in Section 7.4.6, a single dose of an oral non-sedative antihistamine should be 
administered prior to start of each SOBI003 infusion. Each administration is recorded in the 
CRF. 
In case of identified infusion-related reactions, immediate treatment is given at the discretion of 
the investigator. Depending on symptoms, this may e.g., be antipyretics such as acetaminophen 
(paracetamol), corticosteroids or additional antihistamines. Anaphylactic reactions will be treated 
in accordance with current anaphylaxis algorithm “Hypersensitivity to Biological Agents - 
Updated Diagnosis, Management, and Treatment” issued by the AAAI (19). Necessary 
equipment for resuscitation must be available during study drug infusion. 
If clinically justified, patients who develop high titer antibodies that affects PK/PD and/or safety 
may benefit from the use of an immune tolerizing regimen. As there is no proven immune 
tolerizing approach established for ERTs in MPS IIIA, approaches used in other LSDs (24) may 
be applied at the discretion of the investigator after discussion with Sobi Medical Director. 
7.4.8 
Treatment compliance 
Product accountability records will be kept. The pharmacy and investigator must maintain 
accurate records demonstrating date and amount of IMP(s) received, to whom and by whom 


Sobi 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 41 of 88 
Version 2.0 Final Date 06 Jul 2018 
administered (patient-by-patient accounting), and accounts of returned IMP(s) and any IMP 
accidentally or deliberately destroyed. 
All unused IMP will be counted. At the end of the study, any remaining IMP(s) will be returned 
to Sobi for destruction, or destroyed locally. In either case, a certificate of destruction must be 
issued. 
7.5 
Efficacy, safety, pharmacokinetic, and pharmacodynamic 
assessments 
7.5.1 
Study schedule 
7.5.1.1 
Schedule of events 
 
 


Sobi 
 
SOBI003 
 
 
Clinical Study No: SOBI003-001 
Confidential 
 
 
 
 
 
Page 42 of 88 
Version 2.0 Final Date 06 Jul 2018 
Table 3 
Schedule of events – Screening to Week 24 
 
Screeninga 
Baselineb 
Treatment period (24 weeks) 
ETc 
Week 
-12 to -7 
-6 to -1  
1 
2 
3 
4 
5 
6 
8 
9 
12 
13 
17 
20 
22 
24/END 
 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demography 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eligibility criteria 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prior & concomitant therapyd  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examinatione  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Neurological examination 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
Height & head circumference 
 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
X 
X 
Weightf 
X 
X 
X 
 
 
 
X 
 
 
X 
X 
 
X 
 
 
X 
X 
Vital signsg 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
12-lead ECGh 
X 
 
X 
X 
X 
X 
 
X 
X 
 
X 
 
 
 
 
X 
X 
Echocardiography 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
Antihistaminei 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
SOBI003 administrationi 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Adverse events 
Xj 
Xj 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xj 
Anesthesia/sedationk for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Venous access port 
 
Xl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CSF sampling (PK, ADA, 
  HS, future researchm) 
 
Xm 
 
 
 
 
 
 
 
 
X 
 
 
 
 
Xm 
 
  MRI (brain, spleen, liver) 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 


Sobi 
 
SOBI003 
 
 
Clinical Study No: SOBI003-001 
Confidential 
 
 
 
 
 
Page 43 of 88 
Version 2.0 Final Date 06 Jul 2018 
 
Screeninga 
Baselineb 
Treatment period (24 weeks) 
ETc 
Week 
-12 to -7 
-6 to -1  
1 
2 
3 
4 
5 
6 
8 
9 
12 
13 
17 
20 
22 
24/END 
 
Blood sampling for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Sulfamidase activityn 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  SGSH genotyping 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Safety laboratoryo 
X 
Xp 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
 
X 
X 
X 
X 
  Immunogenicity 
 
X 
 
X 
 
X 
 
 
X 
 
X 
 
 
 
 
X 
X 
  HS 
 
X 
 
X 
X 
X 
 
 
X 
 
X 
 
 
 
 
X 
X 
  PKq 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
X 
 
 
 
X 
X 
  Future researchm 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
X 
Urine collection for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Safety laboratory (Dipstick)o 
X 
 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
 
X 
X 
X 
X 
  HS 
X 
X 
 
X 
X 
X 
 
 
X 
 
X 
 
 
 
 
X 
X 
  Future researchm 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
X 
CRIM status (skin fibroblasts) 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Actigraphy (sleep pattern)r 
 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
X 
 
BSID-III/KABC-II 
(neurocognition, language, motor 
function)s 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Parent/caregiver questionnaires: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  VABS-II 
X 
Xt 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
  CSHQr 
 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
X 
 
  PedsQL, incl. Family Impact 
  Module 
 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
X 
 
a  Screening assessments do not need to be performed on the same day, but should be completed to allow baseline assessments to be completed within 6 weeks prior to first 
SOBI003 infusion. 
b Baseline assessments/procedures are not performed on the same day, but should be completed within 6 weeks prior to first SOBI003 infusion. The venous access port 
should be inserted at least 2 weeks prior to first SOBI003 infusion. 
c In case of Early Termination of SOBI003 treatment, the assessments should be completed as soon as possible after decision of treatment withdrawal. When possible, all 
study assessments should continue in accordance with the Schedule of Events until completion of the Week 24 visit. At a minimum, the Early Termination assessments 


Sobi 
 
SOBI003 
 
 
Clinical Study No: SOBI003-001 
Confidential 
 
 
 
 
 
Page 44 of 88 
Version 2.0 Final Date 06 Jul 2018 
should be repeated 30 to 40 days after the last SOBI003 administration. Patients with ADA-positive samples should continue to be followed in accordance with 
Section 7.5.5.3. 
d Prior and concomitant therapy are recorded continuously from screening until completion of the Week 24 visit. 
e General appearance and skin at the infusion site are examined prior to start of each infusion and within 1 hour of completion of each infusion. 
f  During the treatment period, weight is assessed at approximately 4-week intervals to determine the actual SOBI003 to be administered. Weight is therefore obtained prior to 
preparation of the SOBI003 infusions solution at Weeks 1, 5, 9, 12, 17, 21 and 24. The weight is obtained either the day prior to the infusion or the day of infusion. 
g  Vital signs includes blood pressure, heart rate, body temperature, respiratory rate and oxygen saturation. At each infusion, assessments are done pre-infusion, 2 hours after 
start of infusion and within 1 hour after end of infusion. At Weeks 1 to 8, assessments are also done at 1, 3, 6 to 7, and 8 to 12 hours after start of infusion, and on Days 2 
and 3. In addition, at Weeks 1 and 2 assessments are done on Day 5. At Weeks 12 and 24, assessments are also done on Day 3. Continuous pulse oximetry is applied from 
start of infusion until the completion of each of the 4 first infusions. 
h  ECGs are obtained on Day 1 at pre-infusion and 4-5 hours after start of infusion (i.e., within an hour after completion of the infusion).  
i 
Within 30 to 60 minutes prior to each SOBI003 infusion, a single dose of a non-sedative antihistamine should be administered. SOBI003 is administered as weekly
 
infusions; +/- 1-day window is applied after the 4th infusion. 
j  SAE(s) are reported from the time point when ICF is signed until 28 days past last SOBI003 infusion. AEs are reported from start of first SOBI003 infusion.  
k  Use of general anesthesia or sedation is per local hospital routine and anesthesiologist judgement, as well as selection of anesthetic/sedative agents. If all Baseline 
procedures are not completed in one session, then local hospital routine determines minimum time between consecutive anesthetic/sedation episodes.  
l    The port should be inserted at least 2 weeks prior to first SOBI003 infusion. 
m Only applicable when separate consent has been provided for future research. At Week 22, blood is collected for future genetic research. At Baseline and Week 22, blood 
and urine are collected for future biomarker research. CSF is collected at Baseline and Week 24 for future biomarker research. In case of Early Termination of SOBI003 
treatment, blood and urine is collected for storage for future biomarker and genetic research. 
n  Central laboratory analyses of sulfamidase activity in leucocytes. 
o  Sampling time points;  
Weeks 1 to 3: pre-infusion (Day 1) and Day 3. For patients <15 kg body weight, blood sampling on Day 3 at Week 3 is NOT applicable. 
Weeks 4 to 8: pre-infusion.  
Weeks 10 to 22: biweekly pre-infusion, i.e., Weeks 10, 12, 14 etc.  
Week 24: Day 3.   
p  Blood sampling for only hsCRP, IL-1ra, TNFα, IgE, and tryptase. Baseline sample analyzed only in case acute infusion/anaphylactic reaction occur during SOBI003 
treatment to facilitate the determination of reaction etiology.    
q  Frequent PK blood sampling is conducted at Weeks 1, 4, 12, and 24. Samples are also collected before start of infusion and at completion of the infusion at weeks 2, 3 and 
8. PK blood sampling will be adjusted based on the patient´s bodyweight in order not to exceed blood draw volume limits. At Baseline, the PK and immunogenicity samples 
should be taken on the day of CSF sampling for HS analysis. Details on PK blood sampling are given in Table 6.  
r 
Sleep pattern is assessed by actigraph recordings for 7 consecutive days at Baseline and at Weeks 11-12 and 23-24, i.e., Baseline assessment should preferably be completed 
prior to any anesthetic/sedation is applied and prior to PK and HS blood samplings. . At Weeks 11 and 23, the aim should be to have the recordings completed prior to the 
SOBI003 infusions on Day 1 at Weeks 12 and 24.  A sleep diary is completed during the days of actigraphy. Parents should complete the CSHQ upon completion of each 
actigraph assessment (i.e., at Weeks 12 and 24 this will be during the infusion days).  
s  In case both BSID-III and KABC-II are to be administered, the BSID-III should be administered first, and there should be at least 2 days between the BSID-III and 
KABC-II assessments. Attempts should be made to have the assessment(s) performed at least 5 days after any anesthesia/sedation. The Baseline assessment should be 
completed within 2 weeks prior to the first SOBI003 infusion.   


Sobi 
 
SOBI003 
 
 
Clinical Study No: SOBI003-001 
Confidential 
 
 
 
 
 
Page 45 of 88 
Version 2.0 Final Date 06 Jul 2018 
t  The Baseline assessment should be completed within 2 weeks prior to the first SOBI003 infusion. 
 


Sobi 
 
SOBI003 
 
 
Clinical Study No: SOBI003-001 
Confidential 
 
 
 
 
 
Page 46 of 88 
Version 2.0 Final Date 06 Jul 2018 
Table 4 
Detailed schedule of events – Weeks 1 to 4 
 
Weeks 1, 2, 3 and 4 
Day 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
3 
5 
6 
Time 
Pre-inf 
0 
1:00 
2:00 
3:00 
4:00 
4:01 - 5:00 
6:00 – 7:00 
8:00 - 12:00  
 
 
 
 
Medical history 
Xa 
 
 
 
 
 
 
 
 
 
 
 
 
Eligibility criteria 
Xa 
 
 
 
 
 
 
 
 
 
 
 
 
Prior & concomitant medication  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examinationb 
X 
 
X 
X 
X 
 
X 
X 
X 
X 
X 
Xd 
 
Weight 
Xc 
 
 
 
 
 
 
 
 
 
 
 
 
Vital signs 
X 
 
X 
X 
X 
 
X 
X 
X 
X 
X 
Xd 
 
Continuous pulse-oximetrye 
→ 
→ 
→ 
→ 
→ 
→ 
← 
 
 
 
 
 
 
12-lead ECG 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
Antihistaminef 
X 
 
 
 
 
 
 
 
 
 
 
 
 
SOBI003 administration: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Start of infusion 
 
X 
 
 
 
 
 
 
 
 
 
 
 
  Stop of infusion 
 
 
 
 
 
X 
 
 
 
 
 
 
 
Adverse events 
Xg 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Blood sampling for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Safety laboratory   
X 
 
 
 
 
 
 
 
 
 
Xh 
 
 
  Immunogenicity 
Xi 
 
 
 
 
 
 
 
 
 
 
 
 
  HS 
Xj 
 
 
 
 
 
 
 
 
 
 
 
 
  PK 
Xj 
 
 
 
 
 
X 
Xk 
Xk 
Xk 
Xk 
Xk 
Xk 
Urine collection for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Safety laboratory (Dipstick) 
X 
 
 
 
 
 
 
 
 
 
Xh 
 
 
  HS 
Xj 
 
 
 
 
 
 
 
 
 
 
 
 
a  Only applicable at Week 1. Medical conditions present pre-infusion are recorded as medical history. At the time of the 1st infusion, the patient should not have evidence of
 
ongoing infection, as judged by the investigator. In such case, the 1st infusion should be postponed until the infection has resolved. 
b  General appearance and skin 


Sobi 
 
SOBI003 
 
 
Clinical Study No: SOBI003-001 
Confidential 
 
 
 
 
 
Page 47 of 88 
Version 2.0 Final Date 06 Jul 2018 
c  Only applicable at Week 1. Weight obtained pre-infusion at Week 1 determines the actual SOBI003 dose to be administered at Weeks 1 to 4. 
d  Only applicable at Weeks 1 and 2  
e  Continuous monitoring up to 24 hours after start of infusion  
f  Within 30 to 60 minutes prior to each SOBI003 infusion, a single dose of a non-sedative antihistamine should be administered. 
g  SAE(s) are reported from the time point when ICF is signed until 28 days past last dose of IMP. AEs are reported from start of first SOBI003 infusion. 
h  NOT applicable at Week 4 and blood sampling is not applicable at Week 3 for patients < 15 kg body weight. 
i  Only applicable for Weeks 2 and 4. 
j   NOT applicable for Week 1 
k   Only applicable for Weeks 1 and 4. PK sampling time points are pre-dose, 4h (end of infusion), 6, 12, 24, 48, 96, 120 and 168 h after start of infusion. In case SOBI003 
infusion is prolonged, applicable adjustments the PK sampling time points are applied (refer to Table 6). 
 
 
 


Sobi 
 
SOBI003 
 
 
Clinical Study No: SOBI003-001 
Confidential 
 
 
 
 
 
Page 48 of 88 
Version 2.0 Final Date 06 Jul 2018 
Table 5 
Detailed schedule of events – Weeks 12 and 24 
 
 
Weeks 12 and 24 
Week 
12 
Week 
24 END 
Day 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
3 
5 
6 
7 (8a) 
7 (8a) 
Time 
Pre-inf 
0 
1:00 
2:00 
3:00 
4:00 
4:01 - 5:00 
6:00 – 7:00 
8:00 – 12:00 
 
 
 
 
 
 
Prior & concomitant medication  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
X 
Physical examination 
Xb 
 
 
 
 
 
Xb 
 
 
 
 
 
 
 
X 
Neurological examination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Height & head circumference 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
Weight 
Xk 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Vital signs 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
 
 
 
12-lead ECG 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
 
Xc 
Echocardiography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Xc 
Antihistamined 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOBI003 administration: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Start of infusion 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Stop of infusion 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
Adverse events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
X 
Anesthesia for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CSF sampling (PK, 
  ADA, HS, future researche) 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
  MRI (brain, spleen, liver) 
 
 
 
 
 
 
 
 
 
Xf 
 
 
 
 
 
Blood sampling for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Safety laboratory  
Xg 
 
 
 
 
 
 
 
 
 
Xf 
 
 
 
 
  Immunogenicity 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  HS 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
  PK 
X 
 
 
 
 
 
Xh 
Xh 
Xh 
Xh 
Xh 
Xh 
Xh 
Xh 
Xh 


Sobi 
 
SOBI003 
 
 
Clinical Study No: SOBI003-001 
Confidential 
 
 
 
 
 
Page 49 of 88 
Version 2.0 Final Date 06 Jul 2018 
 
 
Weeks 12 and 24 
Week 
12 
Week 
24 END 
Day 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
3 
5 
6 
7 (8a) 
7 (8a) 
Time 
Pre-inf 
0 
1:00 
2:00 
3:00 
4:00 
4:01 - 5:00 
6:00 – 7:00 
8:00 – 12:00 
 
 
 
 
 
 
Urine collection for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Safety laboratory (Dipstick) 
Xg 
 
 
 
 
 
 
 
 
 
Xf 
 
 
 
 
  HS 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
Actigraph device collection 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BSID-III and/or KABC-II 
(neurocognition, language, 
motor function)i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Parent/caregiver questionnaires: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  VABS-II 
 
 
 
 
 
 
 
 
 
 
Xf 
 
 
 
 
  CSHQj 
------- 
---- 
------ 
------ 
-X- 
----- 
------------ 
------ 
------ 
 
 
 
 
 
 
  PedsQL incl. Family Impact 
  Module 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
a  Only PK sampling applicable on Day 8. All other assessments performed on Day 7. 
b  General appearance and skin at the infusion site are examined prior to start of each infusion and within 1 hour of completion of each infusion 
c  If it is not practically feasible to conduct echocardiography and ECG on Day 7, these can be done during Days 3 to 7. 
d  Within 30 to 60 minutes prior to each SOBI003 infusion, a single dose of a non-sedative antihistamine should be administered. 
e  Only applicable when separate consent has been provided for future research. 
f  Only applicable for Week 24  
g Only applicable for Week 12 
h  PK sampling time points are 4 h (end of infusion), 6, 12, 24, 48, 96, 120 and 168 h after start of infusion. The 168h sample at Week 12 is thus taken prior to start of infusion 
on Day 1 of Week 13. The 168h sample at Week 24 is thus taken on Day 8 (For patients continuing in the Extension study, this is prior to start of infusion on Day 1 of the 
Extension study). 
i  In case both BSID-III and KABC-II are to be administered, the BSID-III should be administered first, and there should be at least 2 days between the BSID-III and 
KABC-II assessments (i.e., the BSID-III should then be administered on Days 4 or 5 of Week 24 and the KABC-II on Day 7 of Week 24). A +7-day window is applied for 
the BSID III/KABC-II assessments. 
j  CSHQ is completed any time during the infusion days 
k Weight is obtained prior to preparation of  the SOBI003 infusions solution at Week 12. The weight is obtained either the day prior to the infusion or the day of infusion. 
 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 50 of 88 
Version 2.0 Final Date 06 Jul 2018 
Table 6 
Detailed PK blood sampling schedule 
Week 
 
Time 
 
 BW  
≥20 kg 
No of samplesa 
BW  
15 to <20 kg 
No of samplesa 
BW  
10 to <15 kg 
No of samplesa 
 
Screening 
1 
1 
1 
 
Baseline 
1 
1 
1 
Week 1 
4h / End of Infusion b (Day 1) 
2 
2 
2 
 
6h b (Day 1) 
2 
 
 
 
12hb (Day 1) 
2 
 
 
 
24h (Day 2) 
2 
2 
 
 
48h (Day 3) 
1 
 
 
 
96h (Day 5) 
1 
1 
 
 
120h (Day 6) 
1 
1 
 
Week 1 (2) 
168h/Pre-infusion (Day 8) 
1 
1 
1 
 
4h / End of Infusion 
2 
2 
 
Week 3 
Pre-infusion 
1 
1 
 
 
4h / End of Infusion 
2 
2 
 
Week 4 
Pre-infusion 
1 
1 
1 
 
4h / End of Infusionb(Day 1) 
2 
2 
2 
 
6hb (Day 1) 
2 
2 
 
 
12hb (Day 1) 
2 
2 
 
 
24h (Day 2) 
2 
2 
2 
 
48h (Day 3) 
1 
1 
 
 
96h (Day 5) 
1 
1 
1 
 
120h (Day 6) 
1 
1 
 
Week 4 (5) 
168h/ Pre-infusion (Day 8) 
1 
1 
1 
Week 8 
Pre-infusion 
1 
1 
1 
 
4h / End of Infusion 
2 
2 
2 
Week 12  
Pre-infusion 
1 
1 
1 
 
4h / End of Infusionc (Day 1) 
2 
2 
2 
 
6hc (Day 1) 
2 
2 
 
 
12hc (Day 1) 
2 
2 
 
 
24h (Day 2) 
2 
2 
2 
 
48h (Day 3) 
1 
1 
 
 
96h (Day 5) 
1 
1 
1 
 
120h (Day 6) 
1 
1 
 
Week 12 (13) 
168h/ Pre-infusion (Day 8) 
1 
1 
1 
Week 24 
Pre-infusion 
1 
1 
1 
 
4h / End of Infusionb (Day 1) 
2 
2 
2 
 
6hb (Day 1) 
2 
2 
 
 
 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 51 of 88 
Version 2.0 Final Date 06 Jul 2018 
 
12hb (Day 1) 
2 
2 
 
 
24h (Day 2) 
2 
2 
2 
 
48h (Day 3) 
1 
1 
 
 
96h (Day 5) 
1 
1 
1 
 
120h (Day 6) 
1 
1 
 
 
168h (Day 8) 
1 
1 
1 
If Early 
Termination 
Eerly termination of 
SOBI003 treatment 
1 
1 
1 
After final 
infusion  
(If additional 
Immunogenicity 
samples) 
Day 30-40 after final 
infusion 
1 
1 
1 
 
Additional time-point 1 
1 
1 
1 
Additional time-point 2 
1 
1 
1 
 
Additional time-point 3 
1 
1 
1 
a  If Number = 1; PK blood sample is collected from central venous access port. If Number =2; One PK sample will 
be collected from the central venous access port and one PK sample will be collected from a peripheral venous line. 
At the Screening visit 1; from peripheral venous line as no central access port has yet been placed.   
b  If infusion is prolonged, PK samples will be collected 2h and 8h after End of infusion. Thereafter PK sampling 
will be conducted according to ordinary PK sampling schedule (refer to Section 7.5.6.1). 
7.5.1.2 
Screening 
The screening assessments are initiated after completion of the informed consent process, 
including the provision of signed consent for study participation. The patient is assigned a site-
specific enrollment number once the informed consent has been signed. 
SAEs are reported from the time point when the ICF has been signed.  
Information on medical history, demography and prior and concomitant medications are 
obtained. Neurological and physical examinations are performed. Vital signs, 12-lead ECG and 
echocardiography are performed. Weight is assessed. Blood and urine samples are obtained for 
central laboratory analyses of safety laboratory variables (see Section 7.5.5.2). Screening 
assessment results are used to confirm medical stability and exclusion of contraindications for 
anesthesia, lumbar puncture, and MRI. 
Leucocytes are obtained for central laboratory analyses of sulfamidase enzyme activity (Section 
7.5.2.1). Blood is obtained for central laboratory SGSH genotyping and PK analysis (Sections 
7.5.2.1 and 7.5.6.1). Urine is collected for central laboratory analyses of HS (Section 7.5.7.1.2). 
The VABS-II is assessed by interviewing the parent/caregiver (see Section 7.5.4.1). 
All Screening assessments do not have to be completed on the same day, but should be 
completed to allow Baseline assessments to be completed within 6 weeks prior to first SOBI003 
infusion. 
If SAEs have occurred since the informed consent was signed, these are reported in accordance 
with Section 7.5.5.1.4. 
7.5.1.3 
Baseline 
Once patient eligibility is confirmed, including the central laboratory results of the patient’s 
sulfamidase activity and SGSH genotype, the baseline procedures are initiated. Applicable 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 52 of 88 
Version 2.0 Final Date 06 Jul 2018 
hospital visits and/or hospitalizations are scheduled to have the baseline assessments and 
procedures completed within 6 weeks prior to first planned SOBI003 administration.  
Information on medical history and prior and concomitant medications are obtained. This 
includes events observed/diagnosed during the baseline period. If SAEs have occurred since the 
informed consent was signed, these are reported in accordance with Section 7.5.5.1.4. 
Height, head circumference and weight are obtained. A physical examination is performed. 
The parent/caregiver is given an actigraph together with the actigraph log and is instructed on 
how to apply and use the device and how to complete the log (see Section 7.5.4.5). Written 
instructions are also provided, including on when to make the 7-day baseline assessment of sleep 
pattern. The aim should be to have the recording completed prior to any anesthesia/sedation is 
applied. 
Blood is collected to have a baseline assessment of hsCRP, IL-1ra, TNFα, IgE and tryptase in 
case of occurrence of an acute reaction or anaphylactic reaction during the study treatment 
period. For patients for whom separate informed consent has been provided for future research, 
whole blood, serum and urine (for biomarker analyses) is collected and sent for storage at the 
central laboratory. When possible, these baseline blood samples should be collected at least 4 
weeks prior to the planned start of SOBI003 infusion in order to minimize the total blood volume 
drawn within one-month timeframes.  
A central venous access port is inserted. The surgical procedure is performed in accordance with 
local hospital routines, including the applicable anesthetic procedure to apply, the selection of 
central vein, and confirmation of subsequent venous access by X-ray. The brand and type of port 
must however be preapproved by Sobi (see Section 7.4.1). The parents/caregivers will be trained 
in the management of the port in accordance with local hospital routines. This includes the 
actions to take in case an infection is suspected. There should be at least 2 weeks between the 
insertion of the venous access port and the first SOBI003 infusion. 
A skin biopsy is taken for assessment of CRIM status in fibroblasts. The biopsy should 
preferably be obtained at least 2 weeks prior to the first SOBI003 infusion. 
General anesthesia/sedation is applied in accordance with local hospital routines and as 
determined by the anesthesiologist. CSF sampling (a total of 0.9 mL) for PK, ADA and HS 
assessments and MRI scanning of brain, liver and spleen are completed while the patient is 
anesthetized. The order of the procedures should preferably be as stated. Should this not be 
feasible, then effort should be made to have the assessments performed in the same order at each 
assessment time point (i.e., at Baseline and Week 24) for an individual patient. When separate 
consent for future research has been provided, then CSF (1.0 mL) will also be collected for 
storage at the central laboratory. 
At the day of CSF sampling, serum samples are collected for PK, HS and immunogenicity 
analysis and a urine sample is collected for analysis of HS.  
The VABS-II is assessed by interviewing the parent/caregiver (see Section 7.5.4.1). The 
VABS-II should be completed within 2 weeks prior to first SOBI003 infusion. Based on the 
patient’s chronological age and the adaptive behavior age-equivalent score, as determined by the 
VABS-II, the BSID-III and/or KABC-II tests are conducted for assessment of neurocognition, 
language and motor function (see Sections 7.5.4.2, 7.5.4.3, and 7.5.4.4, respectively). The BSID-
III/KABC-II should be completed within 2 weeks prior to first SOBI003 infusion. Attempts 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 53 of 88 
Version 2.0 Final Date 06 Jul 2018 
should be made to have the neurocognition, language, and motor skills assessed at least 5 days 
after any anesthesia/sedation.  
Any SAEs should be reported in accordance with Section 7.5.5.1.4. 
The parent/caregiver completes the CSHQ and PedsQL questionnaires. The completion of the 
questionnaires should be distributed over the Baseline visit in order to avoid that the 
parent/caregiver spends more than one hour at a time for questionnaire completion.   
7.5.1.4 
Week 1  
The patient is admitted to the hospital the day prior to the first SOBI003 infusion.  
Prior to start of the infusion, the following is performed: 
 Body weight is obtained either the day prior to the infusion or the day of infusion 
 Medical history and prior and concomitant medication are obtained 
 General appearance and skin are assessed 
 Vital signs are assessed and a 12-lead ECG is obtained 
 Blood and urine is collected for safety laboratory assessments 
The results of the above assessments will constitute the patient’s baseline. 
The patient should not have evidence of ongoing infection, as judged by the investigator. In such 
case, the 1st infusion should be postponed until the infection has resolved. Antibiotic treatment 
should also be completed, when applicable, prior to start of SOBI003 treatment.   
Within 30 to 60 minutes prior to start of the SOBI003 infusion, a single dose of an oral non-
sedative antihistamine is administered. A pulse-oximeter is applied and SOBI003 infusion is 
initiated. Refer to Section 7.4.6 for infusion details. Day 1 of Week 1 constitutes the day of the 
first SOBI003 infusion.  
Adverse events and concomitant medications are captured continuously from the start of the first 
infusion until study completion. 
At hourly intervals during the infusion, (i.e., at approximately 1, 2 and 3 hours after start of 
infusion) vital signs, general appearance and skin are assessed.  
Upon completion of the 4-hour infusion, and as soon as practically possible, a PK blood sample 
is obtained. Within an hour of completion of the infusion, vital signs, general appearance and 
skin are assessed. In addition, a 12-lead ECG is obtained and the continuous pulse oximetry is 
discontinued. 
Vital signs (including oxygen saturation), general appearance and skin are assessed on Day 1 
(within 6 to 7 hours after start of infusion, and also within 8 to 12 hours after start of infusion) 
and on Days 2, 3 and 5.  
Blood and urine is collected for safety laboratory analyses on Day 3. Blood is collected for PK 
analyses at Days 1, 2, 3, 5, and 6 at time points specified in Section 7.5.6.1. 
Well in advance of discharge at Week 3, the parents/caregivers will be trained on signs and 
symptoms of acute and delayed hypersensitivity reactions (both verbally and in writing), and 
informed on the importance to seek immediate medical attention if hypersensitivity reactions 
occurs. Acute hypersensitivity reactions include rash, itching, sweating, swelling of 
lips/tongue/face, vomiting, noisy breathing, dizziness, fainting, and delayed reactions includes 
dermatological events/skin reactions such as contact dermatitis, maculopapular rash/eruptions, 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 54 of 88 
Version 2.0 Final Date 06 Jul 2018 
bullous eruptions/dermatitis/exanthemas and pustular exanthema. They will be instructed on 
whom to contact in such cases and these details will also be specified on an emergency card that 
the parent/caregiver is provided. The parent/caregiver will be instructed to always carry the 
emergency card with them. The card will also contain brief details on the study treatment and 
contact details to site staff in order to secure appropriate medical management of any emergency 
situation that has to be managed outside the study site. 
7.5.1.5 
Week 2 
Prior to start of the second infusion (Day 1 of Week 2), the following is performed: 
 General appearance and skin are assessed 
 Vital signs are assessed and a 12-lead ECG is obtained 
 Blood is obtained for safety laboratory assessments, immunogenicity, HS and PK 
assessments  
 Urine is collected for safety laboratory assessments and HS analysis 
 Within 30 to 60 minutes prior to start of the SOBI003 infusion, a single dose of an oral 
non-sedative antihistamine is administered 
 A pulse-oximeter is applied 
SOBI003 is administered in accordance with Section 7.4.6.  
At hourly intervals during the infusion, (i.e., at approximately 1, 2 and 3 hours after start of 
infusion) vital signs, general appearance and skin are assessed.  
Upon completion of the 4-hour infusion, and as soon as practically possible, a PK blood sample 
is obtained. Within an hour of completion of the infusion, vital signs, general appearance and 
skin are assessed. In addition, a 12-lead ECG is obtained and the continuous pulse oximetry is 
discontinued. 
Vital signs (including oxygen saturation), general appearance and skin are assessed on Day 1 
(within 6 to 7 hours after start of infusion, and also within 8 to 12 hours after start of infusion) 
and on Days 2, 3 and 5.  
Blood and urine is collected for safety laboratory analyses on Day 3. 
Concomitant medications and adverse events (including any clinically significant findings from 
the vital signs, ECG and physical examinations) are recorded continuously.  
7.5.1.6 
Week 3 
Prior to start of the third infusion (Day 1 of Week 3), the following is performed: 
 General appearance and skin are assessed 
 Vital signs are assessed and a 12-lead ECG is obtained 
 Blood is obtained for safety laboratory, HS and PK assessments.  
 Urine is collected for safety laboratory assessments and HS analysis 
 Within 30 to 60 minutes prior to start of the SOBI003 infusion, a single dose of an oral 
non-sedative antihistamine is administered 
 A pulse-oximeter is applied 
SOBI003 is administered in accordance with Section 7.4.6.  


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 55 of 88 
Version 2.0 Final Date 06 Jul 2018 
At hourly intervals during the infusion, (i.e., at approximately 1, 2 and 3 hours after start of 
infusion) vital signs, general appearance and skin are assessed.  
Upon completion of the 4-hour infusion, and as soon as practically possible, a PK blood sample 
is obtained. Within an hour of completion of the infusion, vital signs, general appearance and 
skin are assessed. In addition, a 12-lead ECG is obtained and the continuous pulse oximetry is 
discontinued. 
Vital signs, general appearance and skin are assessed Day 1 (within 6 to 7 hours after start of 
infusion, and also within 8 to 12 hours after start of infusion) and on Days 2 and 3.  
Blood is collected for safety laboratory analyses on Day 3 except for patients <15 kg body 
weight and urine is collected for safety laboratory analyses on Day 3.  
Concomitant medications and adverse events (including any clinically significant findings from 
the vital signs, ECG and physical examinations) are recorded continuously,  
The patient may be discharged from the hospital 48 hours after start of the 3rd infusion. Based on 
investigator judgement of social and medical circumstances (e.g., distance between hospital and 
home/relocation accommodation, patient’s family situation, patient’s general medical condition 
etc.) the patient may however continue to remain hospitalized. 
Prior to discharge, the parent/caregiver will be reminded to always carry the emergency card. 
7.5.1.7 
Week 4 
Patients being discharged during Week 3 will return to the hospital the day prior to or on Day 1 
of Week 4. Adverse events and use of concomitant medications during non-hospital stay are 
captured.  
Prior to start of the fourth infusion (Day 1 of Week 4), the following is performed: 
 General appearance and skin are assessed 
 Vital signs are assessed and a 12-lead ECG is obtained 
 Blood is obtained for safety laboratory assessments, immunogenicity, HS and PK 
assessments 
 Urine is collected for safety laboratory assessments and HS analysis 
 Within 30 to 60 minutes prior to start of the SOBI003 infusion, a single dose of an oral 
non-sedative antihistamine is administered 
 A pulse-oximeter is applied 
SOBI003 is administered in accordance with Section 7.4.6.  
At hourly intervals during the infusion, (i.e., at approximately 1, 2 and 3 hours after start of 
infusion) vital signs, general appearance and skin are assessed.  
Upon completion of the 4-hour infusion, and as soon as practically possible, a PK blood sample 
is obtained. Within an hour of completion of the infusion, vital signs, general appearance and 
skin are assessed. In addition, a 12-lead ECG is obtained and the continuous pulse oximetry is 
discontinued. 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 56 of 88 
Version 2.0 Final Date 06 Jul 2018 
Vital signs (including oxygen saturation), general appearance and skin are assessed on Day 1 
(within 6 to 7 hours after start of infusion, and also within 8 to 12 hours after start of infusion) 
and on Days 2 and 3.  
Blood is collected for PK analyses on Days 1, 2, 3, 5, and 6 at time points specified in Section 
7.5.6.1. 
The patient may be discharged from the hospital 48 hours after start of the 4th infusion. The 
patient will then return to the hospital for PK samplings on Days 5 and 6. 
7.5.1.8 
Weeks 5 to 8 
SOBI003 is administered as weekly infusions; a +/- 1-day window is applied. The patients will 
return to the hospital the day prior to or on the day of each infusion. Adverse events and use of 
concomitant medications during non-hospital stay are captured.  
Prior to start of infusion blood and urine is collected for safety laboratory analyses. 
Prior to start of each infusion, vital signs and general appearance and skin are assessed. At Week 
5, body weight is also assessed to determine the SOBI003 dose to be administered at Weeks 5 to 
8. The body weight is obtained either on the day prior to the infusion or the day of infusion. At 
Weeks 6 and 8, 12-lead ECGs are obtained. Within 30 to 60 minutes prior to start of each 
SOBI003 infusion, a single dose of an oral non-sedative antihistamine is administered.  
SOBI003 is administered in accordance with Section 7.4.6.  
At hourly intervals during the infusion, (i.e., at approximately 1, 2 and 3 hours after start of 
infusion) vital signs (including oxygen saturation) are assessed. Assessments are also done 
within an hour of completion of the infusion and within 6 to 7 hours and within 8 to 12 hours 
after start of infusion, as well as on Days 2 and 3. 
Within an hour of completion of the 4-hour infusion, general appearance and skin are assessed.  
On Day 1 of Weeks 5 and 8, PK blood samples are collected prior to start of infusion. At 
Week 8, upon completion of the 4-hour infusion, and as soon as practically possible, another PK 
sample is obtained. 
On Day 1 (prior to start of infusion) of Week 8, blood is collected for immunogenicity and HS 
assessments and urine is collected for analysis of HS. 
On Day 1 of Weeks 6 and 8, 12-lead ECGs are obtained within an hour of completion of the 
4-hour infusion.  
The patient may be discharged from the hospital 48 hours after start of each infusion. 
7.5.1.9 
Weeks 9 to 11 
SOBI003 is administered as weekly infusions; a +/- 1-day window is applied. The patients will 
return to the hospital the day prior to or on the day of each infusion. Adverse events and use of 
concomitant medications during non-hospital stay are captured. Prior to start of each infusion, 
vital signs and general appearance and skin are assessed. At Week 9, body weight is also 
assessed to determine the SOBI003 dose to be administered at Weeks 9 to 12. The body weight 
is obtained either on the day prior to the infusion or the day of infusion. Within 30 to 60 minutes 
prior to start of each SOBI003 infusion, a single dose of an oral non-sedative antihistamine is 
administered.  


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 57 of 88 
Version 2.0 Final Date 06 Jul 2018 
Prior to start of infusion at Week 10, blood and urine is collected for safety laboratory analyses. 
SOBI003 is administered in accordance with Section 7.4.6.  
Vital signs (including oxygen saturation) are assessed at approximately 2 hours after start of 
infusion as well as within an hour of completion of the infusion.  
Within an hour of completion of the 4-hour infusion, general appearance and skin are assessed.  
Prior to discharge at Week 10, the parent/caregiver is given the actigraph and the accompanying 
diary. The parent/caregiver is instructed to start the sleep assessment 7 days prior to attendance 
for the 12th infusion.  
The patient may be discharged from the hospital 12 hours after start of each infusion.   
7.5.1.10 
Week 12 
SOBI003 is administered as weekly infusions; a +/- 1-day window is applied. The patients will 
return to the hospital the day prior to or on the day of each infusion. Adverse events and use of 
concomitant medications during non-hospital stay are captured. The actigraph and accompanying 
diary are collected. 
Prior to start of the infusion, the following is performed: 
 Vital signs and a 12-lead ECG is obtained  
 General appearance and skin are assessed 
 Blood is obtained for immunogenicity, HS and PK assessments 
 Urine is collected for HS analysis 
 Blood and urine is collected for safety laboratory analyses 
 Body weight is assessed to determine the SOBI003 dose to be administered at Weeks 12 
to 16. The body weight is obtained either on the day prior to the infusion or the day of 
infusion. 
Within 30 to 60 minutes prior to start of SOBI003 infusion, a single dose of an oral non-sedative 
antihistamine is administered. SOBI003 is administered in accordance with Section 7.4.6.  
Vital signs are assessed approximately 2 hours after start of infusion. Upon completion of the 
4-hour infusion, and as soon as practically possible, a PK blood sample is obtained. Within an 
hour of completion of the infusion, vital signs and general appearance and skin are assessed, and 
a 12-lead ECG is obtained.  
The parent/caregiver completes the CSHQ questionnaires, preferably during Day 1.  
On Day 2, CSF sampling (a total of 0.9 mL) is performed for PK, ADA, and HS analysis under 
general anesthesia/sedation in accordance with local hospital routines. When separate consent for 
future research has been provided, then CSF (1.0 mL) will also be collected for storage at the 
central laboratory. Blood for HS analysis should be collected at the same time as the CSF 
sampling and urine collected for HS analysis should be taken as close as possible to the CSF 
sampling.   
On Day 3, vital signs are obtained. The VABS-II is assessed by interviewing the parent/caregiver 
(refer to Section 7.5.4.1). 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 58 of 88 
Version 2.0 Final Date 06 Jul 2018 
On Days 1, 2, 3, 5 and 6, and 8 blood samples are collected for PK assessments at time points 
specified in Section 7.5.6.1. On Day 7, height and head circumference are assessed. The body 
weight is also obtained either on Day 7 of Week 12 OR pre-infusion on Day 1 of Week 13 in 
order to determine the SOBI003 dose to be administered at Weeks 13 to 16. 
The parent/caregiver completes the PedsQL questionnaire, preferably during Day 6. 
The patient may be discharged from the hospital 48 hours after start of the 12th infusion. The 
patient will then return daily to the hospital for study assessments on Days 2 to 4, and on Day 6. 
7.5.1.11 
Weeks 13 to 23 
SOBI003 is administered as weekly infusions; a +/- 1-day window is applied. The patients will 
return to the hospital the day prior to or on the day of each infusion. Adverse events and use of 
concomitant medications during non-hospital stay are captured.  
Prior to start of each infusion, vital signs and general appearance and skin are assessed. At 
Weeks 17 and 21, body weight is also assessed to determine the SOBI003 dose to be 
administered at Weeks 17 to 20 and 21 to 24, respectively. The body weight is obtained either on 
the day prior to the infusion or the day of infusion. Within 30 to 60 minutes prior to start of each 
SOBI003 infusion, a single dose of an oral non-sedative antihistamine is administered.  
Biweekly, prior to start of each infusion (i.e., at Weeks 14, 16, 18, 20, and 22), blood and urine is 
collected for safety laboratory analyses. At Week 22, for patients for whom separate informed 
consent has been provided for future research, blood and urine is collected and sent for storage at 
the central laboratory. 
On Day 1 of Week 13, a PK blood sample is collected prior to start of infusion. SOBI003 is 
administered in accordance with Section 7.4.6.  
Vital signs are assessed approximately 2 hours after start of infusion. Within an hour of 
completion of the 4-hour infusion, vital signs and general appearance and skin are assessed. 
Prior to discharge at Week 22, the parent/caregiver is given the actigraph and the accompanying 
diary. The parent/caregiver is instructed to start the sleep assessment 7 days prior to attendance 
for the 24th infusion.  
The patient may be discharged from the hospital 12 hours after start of each infusion.   
7.5.1.12 
Week 24 / last study visit 
SOBI003 is administered as weekly infusions; a +/- 1-day window is applied. The patients will 
return to the hospital the day prior to or on the day of the last infusion. Adverse events and use of 
concomitant medications during non-hospital stay are captured. The actigraph and accompanying 
diary are collected. 
Prior to start of the infusion, the following is performed: 
 Vital signs and a 12-lead ECG is obtained  
 General appearance and skin are assessed 
 Blood is obtained for immunogenicity, HS and PK assessments 
 Urine is collected for HS analysis 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 59 of 88 
Version 2.0 Final Date 06 Jul 2018 
Within 30 to 60 minutes prior to start of each SOBI003 infusion, a single dose of an oral non-
sedative antihistamine is administered. SOBI003 is administered in accordance with Section 
7.4.6.  
Vital signs are assessed approximately 2 hours after start of infusion. Upon completion of the 4-
hour infusion, and as soon as practically possible, a PK blood sample is obtained. Within an hour 
of completion of the infusion, vital signs and general appearance and skin are assessed, and a 12-
lead ECG is obtained.   
The parent/caregiver completes the CSHQ questionnaires, preferably during Day 1.  
On Day 2, blood is collected for HS and PK assessment at the same time point as CSF sampling 
is performed. Urine is collected for HS analyses as close as possible to the CSF sampling. 
General anesthesia is applied in accordance with local routines at the study site. CSF sampling (a 
total of 0,9 mL) for PK, ADA, and HS assessments and MRI scanning of brain, liver and spleen 
are completed while the patient is anesthetized. The order of the procedures should preferably be 
as stated. Should this not be feasible for an individual patient, then effort should be made to have 
the assessments performed in the same order as they were performed at Baseline. When separate 
consent for future research has been provided, CSF (1.0 mL) will also be collected for storage at 
the central laboratory.  
On Day 3, blood and urine are collected for safety laboratory analyses. Blood is also collected 
for PK analysis. Vital signs are obtained. The VABS-II is assessed by interviewing the 
parent/caregiver (refer to Section 7.5.4.1). 
In addition, PK blood samples are collected on Days 5, 6 and 8 (approximately 168h after start of 
SOBI003 infusion) at time points specified in Section 7.5.6.1. 
The parent/caregiver completes the PedsQL questionnaire, preferably during Day 6. 
Based on the patient’s developmental age, as determined by the VABS-II score, the BSID-III 
and/or KABC-II tests are conducted for assessment of neurocognition, language and motor 
function (see Sections 7.5.4.2, 7.5.4.3, and 7.5.4.4, respectively). If only BSID-III or only 
KABC-II is to be assessed, then this should be done on Day 7. If both BSID-III and KABC-II 
should be assessed, then the BSID-III should be administered on Day 4 or 5 and the KABC-II on 
Day 7.  
On Day 7, a neurological and a physical examination are performed and height, weight and head 
circumference are obtained. A 12-lead ECG and echocardiography are performed. Should Day 7 
not be practically feasible, then the ECG and echocardiography can be performed during Days 3 
to 7. 
The patient may be discharged from the hospital 48 hours after start of the infusion. The patient 
will then return to the hospital for study assessments on Days 4, 5, 6 and 7. 
On Day 7, height, weight and head circumference are assessed and the investigator will assess 
patient eligibility for enrolment in the extension study SOBI003-002.  
For patients that are permanently discontinuing SOBI003 treatment, i.e., not continuing in the 
extension study, serum samples for PK and ADA analyses should be obtained 30 to 40 days after 
last SOBI003 infusion. Patients with ADA-positive samples should continue to be followed in 
accordance with Sections 7.5.5.3 and 7.5.6.1.  


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 60 of 88 
Version 2.0 Final Date 06 Jul 2018 
7.5.1.13 
Treatment Withdrawal   
If the patient is withdrawn from study treatment, the patient should be examined as soon as 
possible after making the withdrawal decision. Adverse events and use of concomitant 
medications are captured. Blood and urine are collected for safety laboratory, immunogenicity, 
HS and PK assessments. When separate consent for future research has been provided, blood and 
urine are also collected for storage at the central laboratory for future biomarker research, and if 
the patient is also withdrawn from the study blood is collected for future genetic research. Vital 
signs are assessed and a neurological and a physical examination are performed. A 12-lead ECG 
is obtained and an echocardiography is performed. Height, weight and head circumference are 
obtained. Additional safety assessments will be performed at the discretion of the investigator, as 
warranted by any AE(s) leading to treatment withdrawal.   
When possible, non-infusion-related study assessments should continue in accordance with the 
Schedule of Events (refer to Table 3) until completion of the Week 24 visit. At minimum, the 
Early Termination assessments should be repeated 30 to 40 days after the last SOBI003 
administration. Patients with ADA-positive samples should continue to be followed in 
accordance with Sections 7.5.5.3 and 7.5.6.1.  
7.5.1.14 
Estimated blood sampling volumes and sampling priority list  
Applying the European Commission guidance (20), the study-related blood loss should not 
exceed 3% of the total blood volume during a period of 4 weeks and should not exceed 1% at 
any single time. Examples of recommended blood draw volume limits per the European 
Commission guidance are provided in Table 7.  
Local and/or regional guidelines regarding blood draw volumes may also apply. 
Information of blood volumes per assessment type and sampling occasion are provided in a 
separate study-specific Laboratory Manual. An overview is presented in Appendix 1. 
Blood sampling necessary for the clinical management of the patient will prevail over any study 
specific sampling. 
Should the blood volume be restricted at any of the sampling time points, then the analyses 
should be prioritized in the following order: 
1. Immunogenicity (ADA) 
2. Coagulation 
3. PK 
4. Hematology 
5. Blood chemistry 
6. HS 
7. Blood sample collection for future pharmacogenetics research  
8. Serum collection for future biomarker analyses 
 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 61 of 88 
Version 2.0 Final Date 06 Jul 2018 
Table 7 
Examples of recommended blood draw volume limits 
Patient Weight (kg)  
Blood Draw Limits (mL)(a) 
Single Occasion(b) 
4 weeks (c) 
10.0 
8.0 
24.0 
15.0 
12.0 
36.0 
20.0 
16.0 
48.0 
25.0 
20.0 
60.0 
a  European Commission guidance (20) 
b  Representing 1% of total blood volume, where total blood volume is estimated to 80 ml/kg body weight 
c  Representing 3% of total blood volume, where total blood volume is estimated to 80 ml/kg body weight 
7.5.2 
Medical history 
7.5.2.1 
MPS IIIA diagnosis 
Information on diagnosis date and prior MPS IIIA diagnostic procedures are captured, including 
assessment date, diagnostic method used, and test result (positive/negative). The following 
diagnostic methods are of particular interest; urinary glycosaminoglycan (GAG), serum HS, 
sulfamidase enzyme activity in leucocytes or fibroblasts, and SGSH genotyping. Moreover, 
information is collected regarding MPS IIIA disease in older siblings and if prenatal diagnosis 
has been conducted.   
At Screening, blood (5 mL) is obtained for SGSH genotyping and extraction of leucocytes for 
assessments of sulfamidase enzyme activity at a central laboratory (Greenwood Genetic Center). 
Blood sampling details are provided separately in the Study laboratory manual. The central 
laboratory results are used for confirmation of the eligibility criteria.  
7.5.2.2 
Other diagnoses 
Information on prior and current other diagnoses obtained within 6 years prior to study 
enrolment are captured (diagnosis and date of diagnosis), with emphasis on conditions that are 
frequent in the MPS IIIA population. This includes inguinal and umbilical hernias, cardiac valve 
disease, epilepsy/seizures, spasticity, congenital joint stiffness, hip dysplasia, scoliosis, kyphosis, 
lumbar lordosis, carpal tunnel syndrome, trigger digits, joint contractions, autism, hyperactivity 
or attention deficit disorder (ADD). 
7.5.2.3 
Other medical conditions 
Information on prior and current other medical conditions within 1 year prior to study enrolment 
are captured (symptom, frequency when applicable and month of onset of most recent episode), 
with emphasis on conditions that are frequent in the MPS IIIA population. This includes hepato- 
and/or splenomegaly, ear-nose-throat (ENT) infections, diarrhea, sleep disorder, 
swallowing/eating difficulties, hearing loss and/or visual acuity problems. 
The definition of prior medical conditions includes signs, symptoms, and diagnoses made prior 
to the informed consent is signed.  
The definition of current medical conditions includes all signs, symptoms, and diagnoses made 
from the time informed consent is signed until completion of the Baseline assessments, i.e., until 
the first SOBI003 infusion is about to be initiated on Day 1 at Week 1.  


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 62 of 88 
Version 2.0 Final Date 06 Jul 2018 
7.5.2.4 
Prior medical procedures 
Information on prior medical procedures performed within 6 years prior to study enrolment are 
captured (procedure and month/year conducted), with emphasis on conditions that are frequent in 
the MPS IIIA population. This includes tonsillectomy, adenoidectomy, myringotomy, 
gastrostomy, and jujenostomy. 
7.5.3 
Demography 
The following demographic data are captured at Screening; date of birth, gestational age at birth, 
gender, ethnicity, race, country of residence and native language. In addition, information on the 
patient’s siblings is captured, including age and MPS IIIA diagnostic status (confirmed as non-
affected/confirmed as affected/under current investigation). For sibling(s) with confirmed 
diagnosis, the sibling’s age at diagnosis and genotype are also captured, when known. 
7.5.4 
Efficacy assessments 
7.5.4.1 
Adaptive behavior 
The VABS-II is assessed at Screening, Baseline (within 2 weeks prior to first SOBI003 infusion) 
and at Week 24. The screening assessment is used to determine patient eligibility in terms of 
developmental age.  
The patients’ ability to cope with changes, to demonstrate independence and to learn new skills 
are assessed by use of the Expanded Interview Form of the VABS-II. This measures five 
competence domains: communication, socialization, daily living skills, motor skills and an 
adaptive behavior composite of the first four domains.  
The VABS-II is assessed by parent/caregiver interviews performed by child development 
specialists/psychologists with prior experience of MPS IIIA patients. Prior to study initiation, 
additional study-specific assessment training is provided in order to reduce between-site 
variability. Every effort will be made to have the same parent/caregiver interviewed at each 
assessment time point (i.e., at Screening, Baseline and Week 24). In addition, each patient’s 
parent/caregiver should preferably have the same interviewer throughout the study in order to 
reduce potential variability.  
The developmental age at Screening is determined as the mean of the subdomain age-equivalent 
scores including the communication, socialization, daily living skills, and motor skills domains. 
The adaptive behavior age-equivalent score is determined as the mean of the subdomain age-
equivalent scores including the communication, socialization, and daily living skills (thus, 
excluding the motor skills domains).  
Completed assessment forms will be sent to a central reader (NeuroCog Trials), for data quality 
assurance of completed assessment forms, calculation of final scores and determination of Age 
Equivalence scores, and data management. 
7.5.4.2 
Neurocognition 
Neurocognition is assessed at Baseline (within 2 weeks prior to first SOBI003 infusion) and at 
Week 24, by use of the neurocognition domain of the BSID-III and/or the KABC-II Nonverbal 
Index (NVI).  


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 63 of 88 
Version 2.0 Final Date 06 Jul 2018 
The patient’s chronological age in combination with the patient’s adaptive behavior age-
equivalent score as established by VABS-II, will determine which neurocognitive test(s) to 
apply. The algorithm in Table 8 is applied and the test(s) administered at Baseline should also be 
used at Week 24. 
Table 8 Selection of neurocognitive assessment method  
Chronological age at the 
assessment time point 
VABS-II adaptive behavior age-
equivalence  
Neurocognitive test to apply 
<42 months 
Any age-equivalence 
BSID-III 
≥42 months 
<36 months 
BSID-III 
≥42 months 
36 to 42 months 
BSID-III + KABC-II* 
≥42 months  
>42 months 
KABC-II 
* The BSID-III should be administered first, and there should be at least 2 days until the KABC-II assessment in 
order to reduce KABC-II outcome bias of patient tiredness. 
The neurocognitive developmental age (months) is derived on the basis of the BSID-III cognitive 
total raw score and BSID-III age-normative data. 
The neurocognitive developmental age (months) is derived from the mean AEq scores on the 
NVI of the KABC-II. 
The Development Quotient (DQ) is obtained by dividing the neurocognitive developmental age 
with chronological age. 
Neurocognition assessments are performed by child development specialists/psychologists with 
prior experience of MPS IIIA patients. Prior to study initiation, additional study-specific 
assessment training is provided in order to reduce between-site variability.  
Each patient should preferably have the same assessor throughout the study in order to reduce 
within-patient variability. Attempts should be made to have the assessments made at least 5 days 
after any anesthesia/sedation. When practically feasible, the aim should be to have the 
assessments performed in rested children early during the day, i.e., prior to 1 pm. The aim should 
also be to roughly keep the same assessment time point for an individual child, i.e., 
morning/afternoon. 
To ensure that the BSID-III and KABC-II assessments are performed in accordance with the 
study instructions, completed assessment forms will be sent to a central reader (NeuroCog 
Trials) for data quality assurance, calculation of final scores and determination of Age 
Equivalence scores.  
7.5.4.3 
Language 
Language is assessed at Baseline and at Week 24.  
Expressive and receptive language are assessed by the BSID-III language module and the 
VABS-II communication domain. In addition, written language is assessed by the VABS-II 
communication domain. 
For those patients taking the KABC-II for cognitive assessment, the Expressive Vocabulary from 
the KABC-II will be applied to assess language development.    


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 64 of 88 
Version 2.0 Final Date 06 Jul 2018 
7.5.4.4 
Motor function 
Motor function is assessed at Baseline and at Week 24.  
Fine and gross motor skills are assessed by the BSID-III motor function module and the 
VABS-II motor skills domain. 
7.5.4.5 
Sleep pattern  
The patients’ sleep pattern is evaluated using the CSHQ and by use of actigraphy.  
Two additional items are added to the original CSHQ questionnaire to further characterize 
common MPS IIIA specific issues with sleep, i.e., disruptive behavior at night and dangerous 
behavior at night. The CSHQ is completed by the primary caregiver at Baseline and prior to the 
infusions at Weeks 12 and 24. This CSHQ will capture the child’s sleep habits during the past 
week. Every effort will be made to have the same caregiver completing the CSHQ at each 
assessment time point. 
An actigraph (ActiGraph GT9X Link) will be applied to the non-dominant wrist or ankle and 
recordings will be made for 7 consecutive days and nights at Baseline and at Weeks 11 and 23. 
The wrist or ankle placement should be used consistently throughout the study. At Baseline, the 
aim should be to have the recording completed prior to any anesthesia/sedation is applied and 
prior to blood samplings. At Weeks 11 and 23, the aim should be to have the recordings 
completed prior to the SOBI003 infusions on Day 1 at Weeks 12 and 24. 
The device will be worn constantly during the recording periods only allowing removal for 
washing and bathing. The aim is to ensure that at least 5 days of evaluable recordings are 
obtained on each occasion. A daily wear time of 20 hours per day will be regarded as a 
compliant recording. The recording will be supported by an actigraph log. Recorded actigraph 
data will be evaluated using the accompanying software developed by the manufacturer. A 
subset of the actigraphy data is coded to be analyzed in a subsequent separate blinded analysis of 
the manually edited dataset.   
The following parameters will be determined on the basis of recordings in the actigraph log: 
 Bedtime (Clock time child is put to bed) 
 Wake time (Clock time of child is taken out of bed) 
 Time in bed (Time between Bedtime and Wake time) 
The following variables are derived as obtained from the actigraph software:  
 Sleep onset (Clock time for ﬁrst appearance of a predetermined number of consecutive 
min of sleep) 
 Sleep offset (Clock time for last of a predetermined number of consecutive min of sleep) 
 Sleep period (Time between sleep onset and sleep offset) 
 Total sleep time (TST, Duration of sleep in sleep period) 
 Wake after sleep onset (WASO, number of minutes scored as wake during sleep period) 
 Sleep efﬁciency (Percentage sleep: TST/time in bed) 
 Night waking frequency (number of night wakings) 
 Night waking duration (Sum of minutes scored as night waking) 
 24 h sleep duration (amount of sleep in a 24-h period) 
Sleep onset latency is determined as Time between bedtime (as recorded on the actigraph log) 
and sleep onset (as captured by the actigraph software) 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 65 of 88 
Version 2.0 Final Date 06 Jul 2018 
The Sadeh algorithm (25) is used for determining which epochs (1-minute recordings) are 
marked as “sleep” versus which are marked as “awake”. The Tudor-Locke method is applied to 
determine sleep periods, where 5 consecutive minutes of recorded “sleep” defines Sleep onset 
and where 10 consecutive minutes of “awake” time defines Sleep offset.   
7.5.4.6 
Magnetic resonance imaging 
MRI scanning protocols including details on sequence parameters and scanning guidelines are 
provided to the clinical sites under the coordination of the central MRI reader. MRI field strength 
should be a minimum of 1.5, preferable, 3.0 tesla.  
Preferably, the same MRI technician should perform all study related scans. The separate MRI 
assessment protocol provided prior to the study start should be followed for each scan. Study 
specific training is provided and test scans will be reviewed by the central MRI reader prior to 
initiation of any study assessments at the site. 
Brain and abdominal MRI are performed under general anesthesia at Baseline and Week 24. 
MRI data are sent to the central reader for quantitative analyses. 
The brain MRI assessment protocol includes: 
1. 
3D T1-weighted MPRAGE (~6 min) for volumetric analysis 
2. 
DTI and gre fieldmap (~10 min) for white matter analysis 
3. 
3D FLAIR and T2 (~8 min) for volumetric analysis 
4. 
4.SWI (~10 min) for iron content analysis 
The abdominal MRI assessment protocol includes: 
1. 
T1 3D VIBE (~2 min.) 
2. 
T2 HASTE (~2 min.) 
Liver /spleen volumes are evaluated by MRI using a standard MRI protocol. 
7.5.4.7 
Quality of life and caregiver burden 
The parent proxy-report format of the PedsQL questionnaire (Version 4.0 [26]) will be used to 
assess the child’s quality of life. The Family impact Module of the PedsQL (Version 2.0) will be 
used to assess the caregiver burden. The PedsQL will be completed at Baseline and at Weeks 12 
and 24. Every effort should be made to have the same parent/caregiver responding to the PedsQL 
questions at each assessment time point (i.e., at Baseline and Weeks 12 and 24). 
The PedsQL version (i.e., infant/toddler/young children) will be selected on the basis of the 
chronological age of the patient.  


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 66 of 88 
Version 2.0 Final Date 06 Jul 2018 
7.5.5 
Safety assessments 
7.5.5.1 
Adverse events 
 
Definitions 
Adverse event 
An Adverse event (AE) is any untoward medical occurrence in a patient or trial subject 
administered a pharmaceutical product; the event does not necessarily have a causal relationship 
with the treatment or usage. 
Adverse events include the following: 
 Abnormal test findings, as specified below. 
 Clinically significant signs and symptoms. 
 Changes in physical examination findings. 
 Unexpected progression/worsening of underlying disease. 
In addition, signs and symptoms resulting from the following should also be handled according 
to the same principles as Adverse Events: 
 Overdose. 
 Withdrawal of treatment. 
 Interactions. 
 Abuse. 
 Misuse. 
Abnormal test findings 
An abnormal test finding, e.g. abnormal laboratory analysis results, vital signs or ECG, should be 
recorded as an Adverse Event in any of the following situations: 
 The test is associated with accompanying symptoms. Note, that the symptom, not the test 
result, should be recorded as an AE. 
 The test result leads to a medical/surgical intervention including withdrawal of IMP(s) or 
discontinuation from the study. Repeat/confirmatory testing is not considered a medical 
intervention. 
 The investigator considers the test result to be clinically significant. 
Preexisting conditions  
A preexisting condition (i.e., a disorder present before the adverse event reporting period started 
and noted on the pretreatment medical history/physical examination form) should not be reported 
as an adverse event unless the condition worsens or episodes increase in frequency during the 
adverse event reporting period.  


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 67 of 88 
Version 2.0 Final Date 06 Jul 2018 
Procedures 
Diagnostic and therapeutic non-invasive and invasive procedures, such as surgery, should not be 
reported as adverse events. However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an adverse event. For example, an 
acute appendicitis that begins during the adverse event reporting period should be reported as the 
adverse event and the resulting appendectomy entered in the comments section of the CRF. 
Serious adverse event (SAE) 
An adverse event that meets one or more of the following criteria/outcomes is classified as 
serious: 
 Results in death. 
 Is life-threatening (i.e., at immediate risk of death). 
 Requires in-patient hospitalization or prolongation of existing hospitalization. 
 Results in persistent or significant disability/incapacity. 
 Is a congenital anomaly/birth defect (i.e., in an offspring to the study subject). 
Other medically important adverse events that may not result in death, be life threatening, or 
require hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the patient or subject or may require medical or surgical 
intervention to prevent one of the outcomes listed above. Examples of such events are intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization or development of dependency or abuse. 
Serious also includes any other event that the investigator or company judges to be serious. Any 
suspected transmission of an infectious agent via IMP shall also be considered serious. 
Hospitalization 
Hospitalization includes transfers within a hospital (e.g. from the hospital ward to the intensive 
care unit) and also includes admissions less than 24 hours. The following situations are not 
considered hospitalizations (although other SAE criteria may still apply): 
 Outpatient procedures / ambulatory care. 
 Emergency department visits. 
Hospitalization in the absence of an adverse event occurring during the study should not be 
considered an SAE. This includes: 
 Hospitalization due to a pre-existing condition not associated with a worsening of the 
pre-existing condition. 
 Protocol specified admission. 
 Elective admission, e.g. due to cosmetic surgery. 
 Pre-planned admission for a condition specified at Baseline for the patient. 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 68 of 88 
Version 2.0 Final Date 06 Jul 2018 
Treatment-emergent adverse event (TEAE) 
TEAE is any AE with onset or worsening reported from the time that the first dose of IMP is 
administered until completion of or withdrawal from the study. 
 
Adverse event reporting period 
The period for recording adverse events, including SAEs, on the CRF begins upon receiving the 
first dose of investigational medication and ends at completion of the Week 24 visit.  
In addition, SAEs should be reported, from the time the ICF is signed until 28 days past the last 
dose of IMP. Furthermore, any SAE should be reported to Sobi irrespective of the time of 
occurrence if a causal relationship between the event and the IMP(s) is suspected. 
 
 
Eliciting and recording adverse event information 
The investigator is to record all directly observed adverse events, and all adverse events 
spontaneously reported by the parent/patient, in the CRF using concise medical terminology.   
When possible and appropriate, a diagnosis rather than individual signs and symptoms shall be 
recorded. The investigator is responsible for obtaining sufficient information to determine 
seriousness, causality and outcome of each adverse event. 
Severity assessment 
For the purpose of consistency, the investigator will use the grading provided in Table 9 to 
describe the maximum intensity of the adverse event. The grading is based on the NCI CTCAE 
(version 4.03).  
Table 9 
Severity grade definitions according to NCI CTCAE (version 4.03) 
Grade I 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated 
Grade II 
Moderate; minimal, local or non-invasive intervention indicated; limiting 
age-appropriate instrumental Activities of Daily Living (ADL) 
Grade III 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self-care ADL 
Grade IV 
Life-threatening consequences; urgent intervention indicated 
 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 69 of 88 
Version 2.0 Final Date 06 Jul 2018 
Note the distinction between the seriousness (serious/non-serious) and the intensity (severity) of 
an adverse event. Severe is a measure of intensity; thus, a severe reaction is not necessarily a 
serious reaction. For example, a headache may be severe in intensity, but would not be classified 
as serious unless it met one of the criteria for serious events listed above. 
Causality assessment 
For each adverse event, the investigator or sub-investigator must make a causality assessment on 
the basis of his/her clinical judgment to determine if there is a reasonable possibility that the 
IMP(s) caused the adverse event. The adverse event is assessed as related or not related to the 
IMP(s) with the following definitions: 
Related 
The AE follows a reasonable temporal sequence from the study product administration, 
and cannot be reasonably explained by the subject’s clinical state or other factors 
(e.g., disease under study, concurrent diseases, or concomitant medications). 
 
Not Related 
The AE does not follow a reasonable temporal sequence from study product 
administration, or can be reasonably explained by the subject’s clinical state or other 
factors (e.g., disease under study, concurrent diseases, and concomitant medications).  
 
Serious adverse event reporting 
Both serious and non-serious adverse events are to be reported on the adverse event page of the 
CRF as specified in the CRF instructions. The form for collection of SAE information is not the 
same as the general adverse event CRF page. Where the same data are collected, the forms must 
be completed in a consistent manner. For example, the same adverse event term should be used 
on both forms. 
Any SAE must be reported by the investigator if it occurs during the clinical study whether or not the 
SAE is considered to be related to the investigational product. An SAE report consists of the SAE 
form including medical history and concomitant medications. A copy of these forms must be emailed 
or faxed within 24 hours at:  
• SAE reporting email address: INCDrugsafety@INCResearch.com  
• SAE reporting toll fax number: +1 877 464 7787  
• SAE reporting country specific toll-free fax numbers  
In addition, to the SAE reporting to INC, the investigator must via email notify the Sobi 
Medical Director and Drugsafety@sobi.com. 
The investigator shall provide INC Research with sufficient information to enable a complete 
medical assessment of the reported event. Best efforts shall be made by the investigator to 
provide INC Research with additional information related to any SAE as requested.  
The investigator should not wait to receive additional information to document fully the event 
before notification of a SAE, though additional information may be requested. Where applicable, 
information from relevant laboratory results, hospital case records, and autopsy reports should be 
obtained. All new information obtained, relevant to an SAE report, should be forwarded to INC 
Research within the same timeframe as the initial information. 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 70 of 88 
Version 2.0 Final Date 06 Jul 2018 
Instances of death, congenital abnormality, or an event that is of such clinical concern as to 
influence the overall assessment of safety, if brought to the attention of the investigator at any 
time after cessation of study drug administration and linked by the investigator to this study, 
should be reported to the study monitor.  
Sobi and/or INC Research will promptly notify all relevant investigators and the regulatory 
authorities of findings that could adversely affect the safety of subjects, impact on the conduct of 
the study or alter the independent ethics committee (IEC)/institutional review board (IRB) 
approval/favorable opinion of the study. In addition, INC Research, on behalf of Sobi, will 
expedite the reporting to all concerned investigators, to the IECs/IRBs, where required, and to 
the regulatory authorities of all adverse reactions that are both serious and unexpected. The 
expedited reporting to the regulatory authority in the U.S.A. will however be managed by Sobi.  
 
Follow-up of unresolved adverse events 
All adverse events should be followed until they are resolved or the investigator assesses them as 
chronic or stable, or the patient’s participation in the study ends, i.e., until completion of the 
Week 24 visit. For patients entering the extension study, all AEs and SAEs occurring after Week 
24 visit, should be noted in the extension study SOBI003-002. How to report changes in an 
ongoing adverse event during a patient's participation in the study is described in the CRF 
instructions.  
In addition, all serious and non-serious adverse events assessed by the investigator as related to 
SOBI003 should continue to be followed until they resolve or until the investigator assesses 
them as “chronic” or “stable”, even after the patient's participation in the study is over.  
7.5.5.2 
Laboratory safety assessments 
Biochemistry, hematology, coagulation and urine analyses are conducted at a central laboratory 
(BARC). The time points for sample collection are summarized in Table 10 as well as the 
analyses performed at each sampling occasion. 
At the discretion of site personnel, urine collection bags will be used as needed. 
In case of acute infusion reaction or anaphylactic reaction (AE grade III or greater but may also 
include grade II at the discretion of the investigator), blood is collected for central laboratory 
analyses of C-reactive protein (hsCRP), IL-1ra, TNFα, IgE, and tryptase. To facilitate 
interpretation of the analyses results, blood is also collected at Baseline to enable comparison. 
When possible, the Baseline blood sample should be collected at least 4 weeks prior to the 
planned start of SOBI003 infusion in order to minimize the total blood volume drawn within 
one-month timeframes. 
Depending on the severity of the reaction and at the discretion of the investigator additional 
analyses may be performed at local laboratory to better understand the mechanism of the 
reaction. 
Clinically significant laboratory values should be reported as adverse events (see Section 
7.5.5.1.1 for details).  
Sampling details are provided separately in the study-specific Laboratory Manual. 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 71 of 88 
Version 2.0 Final Date 06 Jul 2018 
Table 10 
Safety laboratory assessment time points 
Analyses 
Study visit 
Sampling time point(s) 
Biochemistry (1.5 mL blood): Aspartate 
aminotransferase (AST), Alanine 
aminotransferase (ALT), Total bilirubin (if 
>upper limit of normal [ULN] then also 
direct and indirect bilirubin), Creatinine, 
Albumin, Potassium (K), Sodium (Na), 
Calcium (Ca), non-fasting Glucose, and C-
reactive protein (CRP). 
Hematology (0.5 mL blood): Hemoglobin 
(Hb), Erythrocytes, White blood cell count 
(WBC), Differential blood count and 
Platelet count. 
Coagulation (1.7 mL): PT/INR, APTT, 
and Fibrinogen. 
Urinalysis (dip-stick analyses, central 
laboratory): pH, Glucose, Proteins, and 
Blood 
Screening 
 
Weeks 1 to 3 
pre-infusion (Day 1) and Day 3 
Weeks 4 to 8 
 pre-infusion 
Weeks 10, 12, 14, 16, 18, 20, 
and 22 
 pre-infusion 
Week 24 
Day 3 
C-reactive protein (hsCRP), IL-1ra, TNFα, 
IgE, and tryptase (6.4 mL blood) 
Baseline 
 
In case of 
infusion/anaphylactic reaction 
 
7.5.5.3 
Immunogenicity 
Serum and CSF samples are collected for central laboratory analysis (York Bioanalytical 
Solutions Limited, York YO26 6QR, United Kingdom) of SOBI003 ADAs by a validated 
immunoassay method. Assays are being developed for assessment of neutralizing antibodies, 
both for antibodies inhibiting cellular uptake and for enzyme activity inhibiting antibodies 
(BioAgilytix, Lademannbogen 10, 22339 Hamburg, Germany). At each sampling occasion, a 
blood volume of 1.5 mL will be collected. 
Serum samples are collected at Baseline (same time as the CSF sample is collected) and prior to 
start of SOBI003 infusion at Weeks 2, 4, 8, 12, and 24, and if applicable at Early Termination of 
SOBI003 treatment. Triplicate aliquots are required for each sampling time point. 
CSF samples (0.5 mL) are collected at Baseline and at Weeks 12 and 24. 
For patients with an ADA-positive serum sample, the following will also be determined in 
serum: ADA titer, IgG subclasses, and presence of NAb. 
For patients with an ADA-positive CSF sample, the following will also be determined in CSF: 
ADA titer and presence of NAb. 
Should any patient permanently discontinue SOBI003 treatment prior to Week 24, then serum 
samples for ADA assessments should be obtained as soon as possible after the decision of Early 
Termination of SOBI003 treatment as well as 30 to 40 days after the last SOBI003 
administration. Should the latter sample be ADA-positive, then ADA samplings will continue at 
approximately monthly basis until the ADA has disappeared or titers have stabilized at a lower 
level. 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 72 of 88 
Version 2.0 Final Date 06 Jul 2018 
The impact of ADAs on the safety, tolerability, and PK of SOBI003 will be explored, as well as 
the potential impact on HS levels in CSF, serum and urine. 
Sampling details are provided separately in the study-specific Laboratory Manual. 
7.5.5.4 
CRIM status 
At the Baseline visit, a skin biopsy is obtained for isolation of fibroblasts for assessment of 
CRIM status at the central laboratory (Biochemical Genetics Laboratory, Duke University 
Health System, 801 Capitola drive, Suite 6, Durham, NC 27713, U.S.A). The biopsy should 
preferably be obtained at least 2 weeks prior to the first SOBI003 infusion. 
7.5.5.5 
Vital signs 
Vital signs (blood pressure, heart rate, body temperature, respiratory rate, and oxygen saturation) 
are measured at the screening visit and at each infusion.  
At Weeks 1 to 4, continuous pulse oximetry is applied to assess oxygen saturation from pre-
infusion until completion of SOBI003 infusion. Blood pressure, heart rate, body temperature and 
respiratory rate are assessed pre-infusion, 1 hour (+/- 5 minutes), 2 hours (+/- 5 minutes) and 3 
hours (+/- 5 minutes) after start of infusion, and within 1 hour after end of infusion. Blood 
pressure, heart rate, body temperature, respiratory rate and oxygen saturation are assessed within 
8 to 12 hours after start of infusion, as well as on Days 2 and 4. In addition, at Weeks 1 and 2 the 
assessments are also done on Day 5. 
At Weeks 5 to 8, blood pressure, heart rate, body temperature, respiratory rate and oxygen 
saturation are assessed pre-infusion, 1 hour (+/- 5 minutes), 2 hours (+/- 5 minutes) and 3 hours 
(+/- 5 minutes) after start of infusion, within 1 hour after end of infusion, within 8 to 12 hours 
after start of infusion, as well as on Days 2 and 4. 
At Weeks 9 to 24, blood pressure, heart rate, body temperature, respiratory rate and oxygen 
saturation are assessed pre-infusion, 2 hours (+/- 5 minutes) after start of each infusion and 
within 1 hour after end of each infusion. At Weeks 12 and 24, the assessments are also done on 
Day 3.  
In case of prolonged SOBI003 infusions (i.e., > 4 hours) and regardless of which Study Week, 
the assessment schedule should be adjusted so that vital signs are assessed every hour during 
infusion and within an hour of completion of the infusion. After completed SOBI003 infusion, 
vital signs are also assessed on Days 2 and 3 (where Day 1 equals the start of the SOBI003 
infusion). Depending on the duration of the infusion, the assessment at 8 to 12 hours after start of 
infusion may also apply. In case of need to prolong infusions (i.e., > 4 hours) at any time during 
the study, pulse oximetry monitoring will be applied, as judged by the investigator. 
Blood pressure and heart rate are measured in accordance to each clinic´s standard procedures. 
When the clinical situation allows, the assessments should preferably be done in supine position 
after the patient has rested comfortably for at least 5 minutes. Body temperature is measured in 
degrees Celsius using a tympanic thermometer according to each clinic´s standard procedures. 
The pulse oximetry sensor device is placed on a fingertip or earlobe (according to standard 
routines at the study site).  
Clinically significant abnormal vital signs values should be reported as adverse events (see 
Section 7.5.5.1.1 for details).   


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 73 of 88 
Version 2.0 Final Date 06 Jul 2018 
7.5.5.6 
Electrocardiograms 
12-lead ECGs are obtained at Screening and at Weeks 1 to 4, 6, 8, 12 and 24. During the 
treatment period, ECGs are obtained pre-infusion and within an hour after end of infusion, i.e., 
4 to 5 hours after start of the infusion. ECG machines Mortara ELI 250c with VERITAS™ 
resting ECG interpretation algorithm will be provided to the sites. 
Any ECG that is auto-interpreted as abnormal should be assessed for clinical significance by a 
healthcare professional with sufficient competence and experience of interpreting pediatric 
ECGs. If a patient shows an abnormal ECG, additional safety recordings may be made and the 
abnormality followed to resolution if required. 
If the clinical situation allows, attempts should be made to have the 12-lead ECG recordings 
obtained after the patients have been resting in a supine position for at least 5 minutes. The 
patients should preferably avoid any postural changes during the ECG recordings and clinical 
staff will ensure that patients are awake during the ECG recording.  
Paper printouts of the ECGs are to be stored as source documents to allow the possibility of 
retrospectively analyzing the ECGs. A Study ECG manual will be provided. 
Clinically significant abnormal ECG findings should be reported as adverse events (see Section 
7.5.5.1.1 for details). 
7.5.5.7 
Other safety assessments 
 
Echocardiography 
At screening, an echocardiography is performed in accordance with local hospital routines. The 
investigator and the pediatric cardiologist should determine if there are any cardiac safety 
concerns that would prevent the patient to participate in the study.  
The echocardiography should be repeated at Week 24. 
 
Physical examination and anthropometry 
The physical examination performed at Screening, Baseline and at completion of the Week 24 
visit will include an assessment of the following: general appearance, skin (including any 
potential reaction around the infusion site), eyes, ears, nose, neck, lymph nodes, throat, heart, 
lungs, abdomen, musculo-skeletal system and extremities.  
At Weeks 1 to 4, general appearance and skin at the infusion site are examined prior to start of 
each infusion, 1 hour (+/- 5 minutes), 2 hours (+/- 5 minutes) and 3 hours (+/- 5 minutes) after 
start of infusion, within 1 hour after end of infusion, and 6 to 7 and 8 to 12 hours after start of 
infusion. At Weeks 1 and 2, the examinations are repeated on Days 2, 3 and 5. At Weeks 3 and 
4, the examinations are repeated on Days 2 and 3.  
At Weeks 5 to 24, general appearance and skin at the infusion site are examined prior to start of 
each infusion and within 1 hour after end of infusion. 
Weight is assessed at Screening, Baseline, approximately every 4 weeks during the treatment 
period in order to determine the actual SOBI003 dose to be administered (Section 7.4.6), and at 
completion of the Week 24 visit. Weight is hence obtained prior to start of infusion at Weeks 1, 
5, 9, 12, 17, and 21. The body weight is obtained either on the day prior to the infusion or the 
day of infusion.  


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 74 of 88 
Version 2.0 Final Date 06 Jul 2018 
Height and head circumference are assessed at Baseline, at Week 12 and at completion of the 
Week 24 visit (if applicable, also at Early Termination of SOBI003 treatment).   
Anthropometric measurements should be performed according to standard routines at the study 
site. Shoes must however be taken off during height and weight assessments.  
Height and head circumference are recorded in centimeters and weight in kilograms. For all 
weight assessments, a scale with at least 100-g accuracy should be used. 
 
Neurological examination  
At Screening and at completion of the Week 24 visit (if applicable, also at Early Termination of 
SOBI003 treatment), a pediatric neurologist conducts an applicable age-related neurological 
examination including: 
 Cranial Nerves 
 Cerebellar function 
 Sensory function 
 Reflexes 
 Motor function   
Normal/abnormal status will be captured, and any abnormalities will be specified. 
7.5.5.8 
Appropriateness of measurements 
The safety assessments in this study are widely used and generally recognized as reliable, 
accurate, and relevant. 
7.5.5.9 
Safety review committee 
The appointed SRC will comprise the principal investigators and relevant Sobi staff, including 
the Safety Physician, Clinical Pharmacologist, Study Statistician, Principal Scientist of 
Immunology, Toxicologist, Medical Director and VP Head of Clinical Development. It is the 
responsibility of the SRC to determine: 
 whether dosage of ongoing cohort(s) can continue 
 if the infusion rate of subsequent administrations in ongoing cohort(s) should be altered 
 whether it is safe to continue to the next cohort, i.e., to expose new study patients to 
SOBI003 treatment 
 the SOBI003 dose to be administered in the next cohort 
The SRC will adhere to the pre-defined stopping criteria that are specified in Section 7.5.5.9.1.   
An SRC charter will specify the operating procedures including SRC membership, voting 
members, responsibilities, data review meeting details, and lines of communication with the 
study teams at Sobi, INC Research, and investigational sites. 
For each cohort, SRC meetings are scheduled approximately 3 weeks after completion of the 3rd 
patient’s 4th dose administration. The SRC will review pre-specified safety, PK, immunogenicity 
and PD data (HS in serum and urine, HS in CSF will also be included when analysis results are 
available) of the current cohort, as well as for previous cohort(s). It should be recognized that 
based on patient enrolment rate, each individual patient’s total treatment duration will vary at the 
time points of the SRC meetings. Hence, at the time of the SRC meeting for cohort 1, there will 
be more than 4-week data available for the 1st included patient.  


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 75 of 88 
Version 2.0 Final Date 06 Jul 2018 
The safety data made available for the SRC reviews will comprise the adverse events, safety 
laboratory analyses, physical examination, vital signs and ECG data obtained up to at least 
3 days after start of the 4th infusion. It should be noted that the data summaries will only be made 
available for the SRC and for the INC Research staff compiling the data. Other staff at Sobi and 
INC Research, or study sites, will not have access to the data summaries. 
Additional SRC meetings will be scheduled ad hoc as per principal investigator or Sobi SRC 
member requests. 
 
Stopping rules 
In the context of this study, the term toxicity means clinically significant drug related adverse 
reaction(s). In case of serious toxicity defined as a Grade III-V SAE, an ad hoc SRC meeting 
will be held within 24 hours after Sobi awareness of the adverse event. SRC will decide on the 
impact on an individual, cohort or entire study level, continue trial unchanged, continue trial with 
modifications, or to put the trial on hold.  
Standard toxicity grading according to the NCI CTCAE are used to grade AEs and to decide on 
suspension level.  
 The study will be halted if a patient develops a Grade IV-V SAE suspected to be IMP 
related.  
 The treatment arm will be halted if at least 2 out of 3 patients in the same cohort 
experience a similar drug-related Grade III SAE.  
 Study treatment will be discontinued on an individual level if assessment by an ad hoc 
SRC or the investigator conclude significant risk to the subject’s safety. 
If at least 2 out of 3 patients in the same cohort experience a drug-related Grade III AE in 
different organ systems, the SRC will base the dose level selection for the next cohort(s) on the 
nature of the adverse events observed. An ad hoc DMC meeting may be held to provide 
recommendation if requested by the SRC. 
Table 11 
Toxicity grade definitions according to NCI CTCAE (version 4.03) 
Grade I 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated 
Grade II 
Moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate 
instrumental Activities of Daily Living (ADL) 
Grade III 
Severe or medically significant but not immediately life-threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; limiting self-care ADL 
Grade IV 
Life-threatening consequences; urgent intervention indicated 
Grade V 
Death related to AE 
7.5.5.10 
Data safety monitoring board 
In addition to the SRC, a DMC is assigned to monitor safety and immunogenicity data. The 
primary responsibility of the DMC is to provide additional safety oversight of the study conduct 
in order to further protect study participants.   
The DMC is planned to comprise an independent statistician and two clinicians that, collectively, 
have experience from DMC, management of pediatric patients with LSD, clinical immunology, 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 76 of 88 
Version 2.0 Final Date 06 Jul 2018 
and the conduct of clinical trials with ERT. The DMC members must not be investigators in the 
study or otherwise associated with the sponsor.  
A DMC charter will specify the operating procedures including DMC membership, 
responsibilities, data review meeting details, and lines of communication with the study teams at 
Sobi and INC Research. There are two scheduled DMC review meetings, one upon all patients’ 
completion of Week 12 and one upon all patients’ completion of Week 24. If requested by the 
SRC, additional ad hoc meetings may be held to provide recommendations to the SRC. 
7.5.6 
Pharmacokinetic assessments 
7.5.6.1 
Sampling procedures 
The sampling procedures are briefly described below and are described in more detail in the 
study-specific Laboratory Manual. Blood samples are obtained through the central venous access 
port from the Baseline visit onwards to characterize SOBI003 PK in serum. Separate blood 
samples from a peripheral venous line are collected in parallel for samples (marked with * 
below) in order to compare serum SOBI003 concentrations in samples collected from a 
peripheral line with samples from the central venous access port line, which is used also for the 
i.v. administration of SOBI003. The purpose of these parallel samples is to confirm that the 
SOBI003 i.v. infusion does not interfere with the blood sampling. A blood volume of 0.3 mL 
will be collected from the central venous access port and an additional 0.3 mL blood will be 
collected from the peripheral venous line when applicable. Duplicate serum aliquots will be 
prepared at all sampling time points to allow for re-analysis if needed.  
Serum samples are collected at Screening and Baseline. Thereafter, frequent sampling is 
conducted at Weeks 1, 4, 12, and 24 at the following time points: 4 h* (end of infusion), 6*, 12*, 
24*, 48, 96, 120 and 168 h after start of infusion. In addition, samples are collected before start 
of infusion and at completion of the infusion at Weeks 2, 3 and 8. In case SOBI003 infusion is 
prolonged, PK sampling time points will be adjusted. PK samples will be collected 2 h and 8 h 
after end of infusion and thereafter 24 h after start of infusion, and thereafter as for the ordinary 
PK-sampling schedule for the 4 h infusion. A reduced PK blood sampling schedule is applied for 
patients with low bodyweight to avoid exceeding blood draw volume limits. Details on PK blood 
sampling are given in Table 6. Acceptable deviations from these planned sampling time points 
are: 4 h (end of infusion) (+0.5h), 6 (± 0.5h), 12 (± 0.5h), 24 (± 0.5h), 48 (± 0.5h), 96 (±1h), 120 
(± 1h) and 168 (- 1h). 
CSF samples (0.5 mL) are collected during general anesthesia at Baseline and at Weeks 12 and 
24 for determination of SOBI003. Triplicate aliquots are required for each sampling time-point. 
At the time of CSF sample collection, a blood sample will also be collected for determination of 
SOBI003 in serum. In case the time point for the CSF sample is deviating from the planned time-
point, the blood sampling should be adjusted accordingly.  
In addition, at each time point a sample is collected for immunogenicity, a blood sample is 
obtained for determination of SOBI003 in serum. In case of a time deviation for the 
immunogenicity sample, the time for the PK sample should be adjusted accordingly, or an 
additional PK sample may have to be collected.  
Should any patient permanently discontinue SOBI003 treatment prior to Week 24, then a PK and 
an immunogenicity sample should be obtained as soon as possible after the decision of early 
treatment withdrawal, as well as 30 to 40 days after the last SOBI003 administration. For 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 77 of 88 
Version 2.0 Final Date 06 Jul 2018 
patients with confirmed ADA levels, blood samples for PK and immunogenicity analysis should 
continue in accordance with Section 7.5.5.3. 
The exact time of the SOBI003 infusion start and completion as well as of each PK sampling are 
recorded in the CRF for each patient. 
Sampling, storage and shipment details are provided separately in the study-specific Laboratory 
Manual. 
7.5.6.2 
Bioanalytical method 
SOBI003 concentrations in serum and CSF are determined at a central laboratory (York 
Bioanalytical Solutions Limited, York YO26 6QR, United Kingdom) by the use of a validated 
immunoassay. The bioanalytical method may not be specific for SOBI003 and may cross-react 
with endogenous sulphamidase. Potential endogenous pre-dose sulphamidase concentrations are 
taken into consideration in the PK analysis e.g. by subtracting these levels from post-dose 
SOBI003 concentrations 
7.5.6.3 
Pharmacokinetic calculations 
PK calculations, based on serum concentrations, are performed in Phoenix WinNonlin by means 
of NCA. Results on PK parameters calculated by NCA will be available continuously during the 
study in order to support dose escalation decisions at SRC meetings.  
Individual serum concentration data from each patient and the exact time points for blood 
sampling are used throughout the analyses. Samples with serum concentrations below the lower 
limit of quantification (LLOQ) appearing in the terminal samples will be omitted from the 
analysis. The following PK parameters are determined for SOBI003: 
 
 
At Weeks 1, 2, 3, 4, 8, 12, 24:  
 The observed serum concentration immediately before the start of infusion of SOBI003, 
CPre-dose  
At Weeks 1, 2, 3, 4, 8, 12, 24: 
 The time of the end of the infusion of SOBI003, tEnd of inf  
 The observed serum concentration at the end of infusion of SOBI003, CEnd of inf 
At Weeks 1, 4, 12 and 24:  
 The minimum observed serum concentration, CTrough 
 The maximum observed serum concentration, Cmax 
 The time at which the maximum serum concentration is observed, tmax 
 Clearance, CL 
 The area under the plasma concentration-time curve from time 0 to last sample, AUC168h 
 The half-life, t½ 
The area under the plasma concentration-time curve from time 0 to last sample, AUC168h 
calculated according to the linear log trapezoidal method. Other PK parameters may be 
calculated as applicable. 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 78 of 88 
Version 2.0 Final Date 06 Jul 2018 
7.5.7 
Pharmacodynamic assessments 
7.5.7.1 
Heparan sulfate 
 
Heparan sulfate in serum and CSF  
Blood (0.3 mL) is collected at Baseline and pre-infusion at Weeks 2 to 4, 8, 12, and 24, and if 
applicable at Early Termination of SOBI003 treatment, for analysis of HS in serum. In addition, 
serum is also collected on Day 2 at Weeks 12 and 24. 
CSF (0.2 mL) is collected at Baseline and at Weeks 12 and 24 for analyses of HS.  
The HS analyses are performed at a central laboratory (York Bioanalytical Solutions Limited, 
York YO26 6QR, United Kingdom). The HS polymer itself is highly heterogeneous and 
therefore it is not possible to analyze at the intact molecule level. The detection of HS levels is 
initiated by depolymerization of the polymer mixture enzymatically, followed by analysis of the 
constituent disaccharides (22). The polymer mixture includes the HS polymer as well as 
accumulated intermediate HS degradation products. Throughout this protocol, the term “HS” is 
used for the assessed disaccharide levels. 
Effects of SOBI003 on HS storage in affected cells are assessed by measuring HS in serum and 
CSF using liquid chromatography tandem mass spectrometry (LC-MS/MS). The total level of 
HS is measured by analyzing selected disaccharides derived from enzymatic digestion 
(adaptation of method described in Naimy et al. 2016 [22). 
Sampling, storage and shipment details are provided separately in the study-specific Laboratory 
Manual. 
 
Heparan sulfate in urine   
Urine (3 mL) samples are collected at Screening, Baseline, and pre-infusion at Weeks 2 to 4, 8, 
12 and 24, and if applicable, at Early Termination of SOBI003 treatment, for analysis of HS. In 
addition, urine is also collected on Day 2 at Weeks 12 and 24. 
The urine HS analyses are performed at a central laboratory (Greenwood Genetic Center, 
106 Gregor Mendel Cir, Greenwood, South Carolina 29646, U.S.A.). HS is quantified using 
stable isotope dilution-tandem mass spectrometry. The urine sample is treated with methanol to 
produce HS polymer dimers that are separated by ultra-performance liquid chromatography 
(UPLC) and analyzed by electrospray ionization tandem mass spectrometry (MS/MS). The assay 
reports the concentration of HS relative to the creatinine concentration in the urine. 
Sampling, storage and shipment details are provided separately in the study-specific Laboratory 
Manual. 
7.5.7.2 
Future bioanalytical research 
As local regulations permit and provided that additional separate caregiver consent is given, 
blood, urine and CSF samples are collected for future analyses. At Baseline, blood (2 mL), urine 
(2 mL) and CSF (1 mL) samples are collected for future biomarker analyses. At Week 22, blood 
and urine are collected for future biomarker analyses and additional blood (2 mL) is collected for 
future genetic research. At Week 24, CSF is collected for future biomarker analyses.  


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 79 of 88 
Version 2.0 Final Date 06 Jul 2018 
When possible, the baseline blood sample should be collected at least 4 weeks prior to the 
planned start of SOBI003 infusion in order to minimize the total blood volume drawn within 
one-month timeframes.  
The samples will be stored at a central laboratory (York Bioanalytical Solutions Limited, York 
YO26 6QR, United Kingdom) for a maximum of 10 years following study completion (i.e., last 
patient’s last visit in this study).  
MPS IIIA is a very rare and severe disease for which there is a lot of research ongoing to further 
increase the understanding of disease pathology as well as diagnosis. The purpose of the sample 
storage is to allow future exploration/confirmation of new research findings. This includes:  
 SGSH genotypes  
 Geno- and/or phenotype associated correlations with possible impact on safety, 
tolerability, immunogenicity, PK and PD related to SOBI003 treatment 
 Biomarkers in serum, urine and/or CSF with possible relation to the safety, tolerability, 
immunogenicity, PK and PD of SOBI003  
The results of any such analyses will not be included in the Clinical Study Report for this study, 
but reported separately when analyzed, thus enabling exploration of any emerging novel disease-
related discoveries of e.g., previously unknown disease alleles, inflammatory cytokines (e.g., 
IL1Ra, TNFα, calprotectin, neopterin), other HS biomarkers (e.g. HS metabolites), components 
of the complement system, and neurodegeneration (e.g., T-tau, hepatocyte growth factor, 
calbindin D).  
Sampling details are provided separately in the study-specific Laboratory Manual. 
7.5.7.3 
Appropriateness of measurements 
Storage of HS in brain lysosomes causes pathological changes such as neuroinflammation and 
inhibition of autophagy in the MPS IIIA mouse model (23). As demonstrated in nonclinical 
studies, SOBI003 treatment reduces blood and brain HS levels, has favorable effects on 
pathophysiological parameters such as neuroinflammation and lysosomal size and shows trends 
towards normalization of behavior in mice. Furthermore, the levels of HS derivatives in brain 
homogenate and CSF are strongly correlated, and the HS reduction at different dose levels of 
SOBI003 is paralleled in these two compartments.  
Patients with MPS IIIA have elevated CSF HS levels in CSF as compared to healthy individuals 
(24). Also in humans, a reduction of HS in CSF is expected to mirror the reduction in brain and 
thus be a useful PD tool for dose selection. 
8 
Quality control and quality assurance 
This study will be conducted in compliance with this protocol, study specific procedures, INC 
Research SOPs, the ICH Guideline for Good Clinical Practice, and applicable regulatory 
requirements. 
Monitoring visits to the study site are performed periodically during the study, to help ensure 
compliance with the protocol, study specific procedures and applicable regulatory requirements. 
Source documents are reviewed for verification of agreement with data in CRFs. All patient 
informed consent forms are reviewed. The investigator or institution guarantees access to source 
documents by Sobi, its representatives, and appropriate regulatory agencies. 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 80 of 88 
Version 2.0 Final Date 06 Jul 2018 
The study site may be subject to a quality assurance audit by Sobi or its representatives, as well 
as inspection by appropriate regulatory agencies. 
It is important that the investigator(s) and the(ir) relevant personnel are available during the 
monitoring visits and possible audits and that sufficient time is devoted to the process. 
9 
Statistical plan 
9.1 
Determination of sample size 
Given that this is a first-in-human study and with no formal hypothesis tests, no sample size 
calculation has been performed. Three sequential dose levels with 3 patients in each cohort has 
been evaluated to be sufficient to allow assessment of safety and tolerability concerns, as well as 
characterize a PD dose-response relationship in this rare population with a high unmet medical 
need. 
9.2 
Definition of study populations 
The following analysis sets will be used in the statistical analyses.  
Safety set (SAF): The SAF will consist of all patients who received at least 1 dose of IMP.  
Full-analysis set (FAS): The FAS is the efficacy analysis set and will consist of all patients who 
have a baseline and at least 1 post baseline assessment of any secondary or exploratory 
assessment.  
PK analysis set (PK): This PK set will comprise patients where at least one SOBI003 dose has 
been administered correctly and where SOBI003 serum or CSF concentration data is available 
without any protocol deviation interfering with these results. 
The SAF is used for the safety analysis, the FAS is used for the secondary and explorative 
efficacy variables. 
Patients in this study who are up to 30 months of age and was initially assigned a dose at least as 
high as the dose selected for a planned phase III study will be included in a future primary 
analysis population for demonstrating efficacy. Efficacy will be evaluated using combined data 
from the FIH study and the extension study, a planned Phase III trial and the corresponding 
patients in a recent NH study (24), the latter serving as control patients and consisting of the 5 
patients with a rapid progressive MPS IIIA disease and a baseline age of 12 to 30  months. 
9.3 
Overall statistical and analytical plan 
9.3.1 
General statistical issues 
A detailed description of the statistical analyses to be performed will be documented in a 
statistical analysis plan to be completed prior to database lock. 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 81 of 88 
Version 2.0 Final Date 06 Jul 2018 
9.3.2 
Demographics and baseline characteristics 
Demographic and other baseline characteristics are listed and summarized with descriptive 
statistics. 
9.3.3 
Analysis related to primary objective 
Safety tabulations of adverse event data, vital signs data, and laboratory data are performed. 
Continuous variables are summarized using the number of patients, the mean, the standard 
deviation, the median, the minimum value, and the maximum value. Categorical variables are 
summarized using frequency counts and percentages. 
9.3.4 
Analysis related to secondary objective  
PK results are presented by dose level using descriptive statistics. In addition, results are 
presented by demographic characteristics, e.g., age-group and bodyweight, as applicable.    
Immunogenicity is summarized using frequency counts and percentages by dose level. 
To assess the PD effect of different dose levels of SOBI003 on HS levels in CSF, serum, and 
urine, linear mixed models are used to model the change from baseline in HS levels as dependent 
variable, for both logged HS levels and untransformed HS levels, and baseline level and age as 
continuous covariates, and dose and sex as factors. The analyses are conducted for each 
assessment time point: Weeks 12 and 24 for CSF, and Weeks 4, 8, 12 and 24 for serum and 
urine. 
In addition, linear mixed analyses with HS levels, both logged HS levels and untransformed HS 
levels, in CSF serum, and urine, as dependent variable, and baseline level and age as continuous 
covariates, and dose and sex as factors will be performed across all assessments, with assessment 
as a repeated factor in a accumulating pattern: across weeks 12 and 24 for HS in CSF, and across 
Weeks 4 and 8, across Weeks 4, 8 and 12, and across Weeks 4, 8, 12 and 24 for HS in serum. 
Endpoints relating to the neurocognition, adaptive behavior, gray matter volume and Quality of 
Life are summarized using descriptive statistics. 
9.3.5 
Analysis related to exploratory objectives 
Continuous variables are summarized using the number of patients, the mean, the standard 
deviation, the median, the minimum value, and the maximum value. Categorical variables are 
summarized using frequency counts and percentages. 
9.3.6 
Analysis of safety and tolerability data 
9.3.6.1 
Adverse events 
Reported AE(s) during the study are coded using MedDRA and severity of AEs is graded using 
NCI CTCAE v.03. The number of patients with any AE are is summarized in frequency tables 
by treatment dose level, body system, preferred term, relation to IMP and maximum severity. 
Listings of AE subgroups such as SAE(s) and adverse events leading to discontinuation are also 
presented. 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 82 of 88 
Version 2.0 Final Date 06 Jul 2018 
9.3.7 
Interim analysis 
No interim analysis is planned for this 24-week study. 
9.3.8 
Multiple comparison/multiplicity 
Since no hypothesis tests will be performed, there will be no adjustments for multiplicity.  
9.3.9 
Handling of missing data 
No imputation for missing data will be used. 
10 
Data collection, handling and record keeping 
10.1 
Data standards 
Collection of data should be performed in the Clinical Data Acquisition Standards 
Harmonization (CDASH) format, according to the Clinical Data Interchange Standards 
Consortium (CDISC). The standards should be used to the extent possible and/or required for the 
specific study/project. The minimum requirement of the CDISC standard is to collect all core 
variables specified as ‘Required’ in the Study Data Tabulation Model (SDTM) format.  
10.2 
Case report form 
A CRF is required and should be completed for each included patient. In this study an electronic 
CRF will be used. The completed original CRFs are the sole property of Sobi and should not be 
made available in any form to third parties, except for authorized representatives of appropriate 
regulatory authorities, without written permission from Sobi. 
It is the responsibility of the investigator to ensure completion and to review and approve all 
CRFs. CRFs must be signed electronically by the investigator. These signatures serve to attest 
that the information contained on these CRFs is correct. At all times, the investigator has final 
responsibility for the accuracy and authenticity of all clinical and laboratory data entered on the 
CRFs.  
10.3 
Source data 
Patient source documents are the physician’s patient records maintained at the study site. In most 
cases, the source documents will be the hospital’s or the physician’s chart. In those cases, the 
information collected on the CRFs must match those charts. In addition to the physician’s patient 
records, the printed 12-lead ECGs are source. For the MRIs and actigraph assessments, the 
digital files are the source. For the VABS-II, BSID-III and the KABC-II, the completed test 
forms and the central reader’s confirmation of total scores and age-equivalence scores are the 
source. 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 83 of 88 
Version 2.0 Final Date 06 Jul 2018 
10.4 
Database closure 
Prior to database closure, all tasks or criteria defined in the data management plan must be 
completed and documented. The study database must be locked before generation of any final 
results. The database lock will be approved by relevant study personnel and all edit accesses will 
be removed. The study database can only be unlocked in case critical errors, affecting the main 
conclusions of the study, are discovered. 
10.5 
Record retention 
To enable evaluations and/or audits from Health Authorities and/or Sobi (or delegates), the 
investigator agrees to keep records in accordance with the essential documents defined in the 
ICH GCP Guidelines [1], including the identity of all participating patients (sufficient 
information to link records, e.g., CRFs and hospital records), all original signed informed 
consent forms, copies of all paper CRFs (i.e., completed paper questionnaires and BSID-
III/KABC-II assessments forms), an archival copy on compact disc of the electronic CRFs 
provided by INC Research and detailed records of IMP accountability. The records should be 
retained by the investigator according to local regulations or as specified in the Clinical Trial 
Agreement. 
If the investigator relocates, retires, or for any reason withdraws from the study, the study 
records may be transferred to an acceptable designee, such as another investigator, another 
institution, or to Sobi. The investigator must obtain Sobi’s written permission before disposing of 
any records. 
11 
End of study 
The end of this study is defined as the date of last patient out, i.e., the last patient’s last visit. 
12 
Sponsor’s discontinuation criteria 
Sobi reserves the right to discontinue the study prior to inclusion of the intended number of 
patients, but intends only to exercise this right for valid scientific or administrative reasons. After 
such a decision, the investigator must contact all participating patients within 2 weeks. All study 
materials must be collected and all the CRFs completed to the greatest extent possible. 
13 
Dissemination and publication of results 
Sobi will register the study and post study results regardless of outcome on a publicly accessible 
website in accordance with applicable laws and regulations, e.g. on www.clinicaltrials.gov and 
EudraCT.  
For this rare indication, patients enrolled in this Phase I/II study may form part of the pivotal 
efficacy population by continuation into the extension study. Cognition is the primary efficacy 
outcome in MPS IIIA, therefore the cognition and adaptive behavior results at Week 24 of this 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 84 of 88 
Version 2.0 Final Date 06 Jul 2018 
Phase I/II study may be withheld from publishing in order to prevent the risk of inadvertent bias 
of cognition and adaptive behavior assessments in the extension study. 
Sobi follows the principals of the International committee of medical journal editors 
recommendations for the conduct, reporting, editing, and publication of scholarly work in 
medical journals [27]. After completion of this Phase I/II study, the data may be considered for 
reporting at a scientific meeting or for publication in a scientific journal. The sponsor will be 
responsible for these activities and will work with the investigators to determine how the 
publication is written, the number and order of authors, the journal or scientific meeting to which 
it will be submitted, and other related issues. The results of the study, or any part thereof, shall 
not be published without the prior written consent and approval of Sobi, such consent and 
approval not to be unreasonably withheld. 
 
14 
References 
1 
ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R2) 
Current Step 5 version dated 15 December 2016. Available from: 
http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html  
2 
World Medical Association Declaration of Helsinki; Ethical Principles for Medical 
Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, 
Helsinki, Finland, June 1964, latest amendment at the 59th WMA General Assembly, 
Seoul, South Korea, October 2008. Available from: 
http://www.wma.net/en/30publications/10policies/b3/ 
3  
Van de Kamp JJP, Niermeijer MF, von Figura K and Giesberts MAH. Genetic 
heterrogeneity and clinical variability in the Sanfilippo syndrome (types A, B and C). 
Clinical Genetics 1981; 20:152-60. 
4  
Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo 
syndrome: a mini-review. J Inherit Metab Dis. 2008;31(2):240-52 
5  
Jakobkiewicz-Banecka J, Gabig-Ciminska M, Kloska A, Malinowska M, Piotrowska E, 
Banecka-Majkutewicz Z, et al. Glycosaminoglycans and mucopolysaccharidosis type III. 
Front Biosci (Landmark Ed). 2016;21:1393-409. 
6  
Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter GJ, Wevers RA, et al. 
Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype 
correlations. Ann Neurol. 2010;68(6):876-87. 
7  
Cleary MA, Wraith JE. Management of mucopolysaccharidosis type III. Arch Dis Child. 
1993;69(3):403-6. 
8  
Buhrman D, Thakkar K, Poe M, Escolar ML. Natural history of Sanfilippo syndrome 
type A. J Inherit Metab Dis. 2014;37(3):431-7. 
9  
Wijburg FA, Wegrzyn G, Burton BK, Tylki-Szymanska A. Mucopolysaccharidosis type 
III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 85 of 88 
Version 2.0 Final Date 06 Jul 2018 
deficit hyperactivity disorder or autism spectrum disorder. Acta Paediart. 
2013;102(5):462-70. 
10  
Fraser J, Wraith JE, Delatycki MB. Sleep disturbance in mucopolysaccharidosis type III 
(Sanfilippo syndrome): a survey of managing clinicians. Clin Genet. 2002;62(5):418-21. 
11  
Delgadillo V, O'Callaghan Mdel M, Gort L, Coll MJ, Pineda M. Natural history of 
Sanfilippo syndrome in Spain. Orphanet J Rare Dis. 2013;8:189. 
12 
Lavery C, Hendriksz CJ, Jones SA. Mortality in patients with sanfilippo syndrome. 
Orphanet J Rare Dis. 2017;12(1):168. 
13 
GM00879, Coriell Institute 
(https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM00879&Produ
ct=CC) 
14  
Brooks DA. Immune response to enzyme replacement therapy in lysosomal storage 
disorder patients and animal models. Mol Genet Metab. 1999;68(2):268-75. 
15  
Kakavanos R, Turner CT, Hopwood JJ, Kakkis ED, Brooks DA. Immune tolerance after 
long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis 
I. Lancet 2003;361:1608–13. 
16  
Kishnania PS, Goldenberga PC, DeArmeya SL, Hellerb J, Benjaminc D, Younga S, et al.  
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease 
infants. Mol Genet Metab. 2010;99(1):26–33. 
17  
Barbier AJ, Bielefeld, B, Whiteman DAH, Natarajan M, Pano A, Amato DA. The 
relationship between anti-idursulfase antibody status and safety and efficacy outcomes in 


Sobi 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 86 of 88 
Version 2.0 Final Date 06 Jul 2018 
attenuated mucopolysaccharidosis II patients aged 5 years and older treated with 
intravenous idursulfase. Mol Genet Metab. 2013;110:303–310. 
18  
Neufeld E, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly 
WS, Valle D, Childs B, Kinzler KW, et al. The Metabolic and Molecular Basis of 
Inherited Disease. 8 edition. New York: McGraw-Hill; 2001:3421-52. 
19 
Galvão VR, Castells MC. Hypersensitivity to biological agents - updated diagnosis, 
management, and treatment J Allergy Clin Immunol Pract. 2015;3(2):175-185.    
20  
European Commission 2017. Ethical considerations for clinical trials on medicinal 
products conducted with the paediatric population. 
https://ec.europa.eu/health/documents/eudralex/vol-10_en  
21  
Crawley AC, Gliddon BL, Auclair D, Brodie SL, Hirte C, King BM, et al. 
Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type 
IIIA. Brain Res. 2006;1104(1):1-17. 
22 
Naimy H, Powell KD, Moriarity JR, Wu J, McCauley TG, Haslett PAJ, et al. A novel 
LC–MS/MS assay for heparan sulfate screening in the cerebrospinal fluid of 
mucopolysaccharidosis IIIA patients. Bioanalysis. 2016;8(4):285–295. 
23 
Archer LD, Langford-Smith KJ, Bigger BW and Fildes JE. Mucopolysaccharide 
diseases: A complex interplay between neuroinflammation, microglial activation and 
adaptive immunity. J Inherit Metab Dis, 2014; 37(1): 1-12. 
24 
Shapiro EG, Nestrasil I, Delaney KA, Rudser K, Kovac V, Nair N, et al. A prospective 
natural history study of mucopolysaccharidosis type iiia. J Pediatr, 2016;170:278-287 
e271-274. 
25 
Sadeh A, Sharkey KM, Carskadon MA. Activity-based sleep-wake identification: an 
empirical test of methodological issues. Sleep, 1994;17(3):201-7. 
26 
Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric 
Quality of Life Inventory version 4.0 generic core scales in healthy and patient 
populations. Med Care. 2001;39(8):800-12. 
27 
International Committee of Medical Journal Editors. Recommendations for the conduct, 
reporting, editing, and publication of scholarly work in medical journals: updated 
December 2016 [Internet]. International Committee of Medical Journal Editors (ICMJE); 
2016. [cited 2017 Jan 12]. Available from: http://www.icmje.org/recommendations/ 


Sobi
 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 87 of 88 
Version 2.0 Final Date 06 Jul 2018 
Appendix 1 
Blood sampling volume overview 
Table 12 
Blood sampling volumes (mL) per study visit 
Sample  
SA, SGSH 
genotype  
Acute  
reactions 
Safety 
Immuno- 
genicity 
HS 
Pharmacokineticsa  
Future 
research 
Total blood volume (mL) 
Week 
 
 
 
 
 
BW 
≥20 kg 
BW 
15 to <20 kg 
BW 
10 to <15 
kg 
 
BW 
≥20 kg 
BW 
15 to <20 
kg 
BW 
10 to <15 kg 
-12 to -7 
5,0 
 
3,7 
 
 
0,3 
0,3 
0,3 
 
9,0 
9 
9 
-6 to -2  
 
6,4 
 
 
 
 
 
 
2 
8,4 
8,4 
8,4 
-1 
 
 
 
1,5 
0,3 
0,3 
0,3 
0,3 
 
2,1 
2,1 
2,1 
1 
 
 
7,4 
 
 
3,3 
1,8 
0,6 
 
10,7 
9,2 
8 
2 
 
 
7,4 
1,5 
0,3 
0,9 
0,9 
0,3 
 
10,1 
10,1 
9,5 
3 
 
 
7,4b 
 
0,3 
0,9 
0,9 
0 
 
8,6 
8,6 
4 
4 
 
 
3,7 
1,5 
0,3 
3,6 
3,6 
1,8 
 
9,1 
9,1 
7,3 
5 
 
 
3,7 
 
 
0,3 
0,3 
0,3 
 
4 
4 
4 
6 
 
 
3,7 
 
 
 
 
 
 
3,7 
3,7 
3,7 
7 
 
 
3,7 
 
 
 
 
 
 
3,7 
3,7 
3,7 
8 
 
 
3,7 
1,5 
0,3 
0,9 
0,9 
0,9 
 
6,4 
6,4 
6,4 
10 
 
 
3,7 
 
 
 
 
 
 
3,7 
3,7 
3,7 
12 
 
 
3,7 
1,5 
0,6 
3,6 
3,6 
1,8 
 
9,4 
9,4 
7,6 
13 
 
 
 
 
 
0,3 
0,3 
0,3 
 
0,3 
0,3 
0,3 
14 
 
 
3,7 
 
 
 
 
 
 
3,7 
3,7 
3,7 
16 
 
 
3,7 
 
 
 
 
 
 
3,7 
3,7 
3,7 
18 
 
 
3,7 
 
 
 
 
 
 
3,7 
3,7 
3,7 
20 
 
 
3,7 
 
 
 
 
 
 
3,7 
3,7 
3,7 
22 
 
 
3,7 
 
 
 
 
 
4,0 
7,7 
7,7 
7,7 
24 
 
 
3,7 
1,5 
0,6 
3,9 
3,9 
2,1 
 
9,7 
9,7 
7,9 
a   168 h samples are counted to the following week, except for week 24 
b   In children with a body weight < 15 kg, the volume will be 3,7 mL, since no safety sample will be collected on Day 3 of Week 3 


Sobi
 
 
 
SOBI003 
Clinical Study No: SOBI003-001 
Confidential 
Page 88 of 88 
Version 2.0 Final Date 06 Jul 2018 
Table 13 
Blood sampling volumes (mL) per 4-week study periods 
Sample  
SA, SGSH 
genotype  
Acute  
reactions 
Safety 
Immuno- 
genicity 
HS 
Pharmacokineticsa  
Future 
research 
Total blood volume (mL) 
Week 
 
 
 
 
 
BW 
≥20 kg 
BW 
15 to <20 kg 
BW 
10 to <15 
kg 
 
BW 
≥20 kg 
BW 
15 to <20 
kg 
BW 
10 to <15 kg 
-1 to 3 
 
 
22,2b 
3 
0,9 
5,4 
3,9 
1,2 
0 
31,5 
30 
23,6 
4 to 7 
 
 
14,8 
1,5 
0,3 
3,9 
3,9 
2,1 
0 
20,5 
20,5 
18,7 
8 to 11 
 
 
7,4 
1,5 
0,3 
0,9 
0,9 
0,9 
0 
10,1 
10,1 
10,1 
12 to 15 
 
 
7,4 
1,5 
0,6 
3,9 
3,9 
2,1 
0 
13,4 
13,4 
11,6 
16 to 19 
 
 
7,4 
0 
0 
0 
0 
0 
0 
7,4 
7,4 
7,4 
20 to 23 
 
 
7,4 
0 
0 
0 
0 
0 
4 
11,4 
11,4 
11,4 
Total 
 
 
66,6c 
7,5c 
2,1c 
14,1c 
12,6c 
6,3c 
4c 
121,4d 
119,9 d 
108,1 d 
a   168 h samples are counted to the following week, except for week 24 
b   In children with a body weight < 15 kg, the volume will be 18,5 mL, since no safety sample will be collected on Day 3 of Week 3 
c   From -1 to Week 23 
d   Total study = Week -12 to Week 24 
 

SAP_001.pdf: 


 
SOBI003-001 
Confidential 
Page 2 of 67 
Version 1.0, Final 24 Mar 2020 
 
Table of contents 
1 
Abbreviations and definition of terms ................................................................................... 6 
2 
Introduction ............................................................................................................................ 9 
3 
Study objectives and endpoints .............................................................................................. 9 
3.1 
Primary objective .............................................................................................................. 9 
3.2 
Secondary objectives ......................................................................................................... 9 
3.3 
Exploratory objectives .................................................................................................... 10 
3.4 
Study endpoints ............................................................................................................... 10 
3.4.1 Primary safety endpoint ........................................................................................... 10 
3.4.2 Secondary endpoints ................................................................................................ 10 
3.4.3 Exploratory endpoints .............................................................................................. 11 
4 
Study methods ...................................................................................................................... 12 
4.1 
Overall study design and plan ......................................................................................... 12 
4.2 
Selection of study population .......................................................................................... 24 
4.2.1 Inclusion criteria ...................................................................................................... 24 
4.2.2 Exclusion criteria ..................................................................................................... 24 
4.3 
Method of treatment assignment and randomization ...................................................... 24 
5 
Sequence of planned analysis .............................................................................................. 25 
5.1 
Safety review committee ................................................................................................. 25 
5.2 
Data safety monitoring committee .................................................................................. 25 
5.3 
Interim analyses .............................................................................................................. 26 
5.4 
Analyses and reporting .................................................................................................... 26 
6 
Sample size determination ................................................................................................... 26 
7 
Analysis sets ........................................................................................................................ 26 
7.1 
Safety analysis set (SAF) ................................................................................................ 26 
7.2 
Full analysis set (FAS) .................................................................................................... 27 
7.3 
PK analysis set (PKAS) .................................................................................................. 27 
7.4 
Immunogenicity analysis set ........................................................................................... 27 
8 
General issues for statistical analysis ................................................................................... 27 
8.1 
Handling of missing data and outliers ............................................................................. 28 
8.2 
Multicenter studies .......................................................................................................... 29 
8.3 
Multiple comparisons and multiplicity ........................................................................... 29 
8.4 
Derived and computed variables ..................................................................................... 29 


 
SOBI003-001 
Confidential 
Page 3 of 67 
Version 1.0, Final 24 Mar 2020 
8.4.1 First and last study treatment ................................................................................... 29 
8.4.2 Study treatment exposure ......................................................................................... 29 
8.4.3 Baseline and change from baseline .......................................................................... 30 
8.4.4 Age ........................................................................................................................... 30 
8.4.5 Adverse event duration ............................................................................................ 30 
8.4.6 Time since study treatment administration for adverse event.................................. 30 
8.4.7 Body mass index (BMI) ........................................................................................... 30 
8.4.8 Dose received ........................................................................................................... 30 
8.4.9 Time since diagnosis ................................................................................................ 31 
9 
Patient disposition ................................................................................................................ 31 
10 
Demographics and baseline characteristics ......................................................................... 31 
10.1 Demographics and baseline characteristics ..................................................................... 31 
10.2 Medical history................................................................................................................ 32 
10.2.1 MPS IIIA diagnosis .................................................................................................. 32 
11 
Prior and concomitant medication ....................................................................................... 32 
12 
Treatment compliance .......................................................................................................... 32 
13 
Efficacy analyses ................................................................................................................. 33 
13.1 Questionnaires and scales ............................................................................................... 33 
13.1.1 VABS-II ................................................................................................................... 33 
13.1.2 BSID-III ................................................................................................................... 34 
13.1.3 KABC-II................................................................................................................... 34 
13.1.4 PedsQL ..................................................................................................................... 35 
13.1.5 CSHQ ....................................................................................................................... 35 
13.2 Secondary efficacy endpoints ......................................................................................... 36 
13.2.1 Neurocognitive developmental age .......................................................................... 36 
13.2.2 Adaptive behavior .................................................................................................... 36 
13.2.3 Magnetic resonance imaging ................................................................................... 36 
13.2.4 Quality of life and caregiver burden ........................................................................ 36 
13.3 Exploratory efficacy endpoints ....................................................................................... 37 
13.3.1 Adaptive behavior composite score ......................................................................... 37 
13.3.2 Neurocognitive composite score .............................................................................. 37 
13.3.3 Language .................................................................................................................. 37 
13.3.4 Motor function ......................................................................................................... 37 
13.3.5 Sleep pattern ............................................................................................................. 37 
13.3.6 Magnetic resonance imaging ................................................................................... 38 
13.4 Subgroup analyses ........................................................................................................... 38 


 
SOBI003-001 
Confidential 
Page 4 of 67 
Version 1.0, Final 24 Mar 2020 
14 
Safety analyses ..................................................................................................................... 38 
14.1 Drug exposure ................................................................................................................. 39 
14.2 Adverse events ................................................................................................................ 39 
14.2.1 Serious adverse events ............................................................................................. 41 
14.2.2 Adverse events leading to withdrawal ..................................................................... 41 
14.2.3 Deaths....................................................................................................................... 41 
14.2.4 Infusion related reaction symptoms ......................................................................... 41 
14.3 Vital signs ....................................................................................................................... 42 
14.4 Laboratory data ............................................................................................................... 42 
14.5 Immunogenicity .............................................................................................................. 43 
14.6 CRIM status .................................................................................................................... 44 
14.7 ECG ................................................................................................................................. 45 
14.8 Other safety assessments ................................................................................................. 45 
14.8.1 Echocardiography .................................................................................................... 45 
14.8.2 Physical examination and anthropometry ................................................................ 45 
14.8.3 Neurological examination ........................................................................................ 46 
15 
Pharmacokinetic analyses .................................................................................................... 46 
15.1 Secondary pharmacokinetic endpoint analyses ............................................................... 46 
15.2 Serum PK sampling schedule.......................................................................................... 47 
15.3 Serum PK endpoints ........................................................................................................ 48 
15.4 CSF PK endpoints ........................................................................................................... 48 
15.5 Presentation of concentration data in serum and CSF .................................................... 49 
15.5.1 Handling of missing data ......................................................................................... 49 
15.5.2 Listing and Presentation of individual PK data ....................................................... 49 
15.5.3 Summary of serum and CSF PK concentrations ...................................................... 50 
15.5.4 PK parameters derivation ......................................................................................... 50 
15.5.5 PK parameters summarization ................................................................................. 51 
15.6 Attainment of steady state for SOBI003 ......................................................................... 52 
15.7 Assessment of Dose Proportionality for SOBI003 ......................................................... 53 
16 
Pharmacodynamic analyses ................................................................................................. 54 
16.1 Secondary pharmacodynamic endpoint analyses ............................................................ 54 
16.2 Presentation of concentration data for HS in serum, urine, and CSF ............................. 55 
16.2.1 Handling of missing data ......................................................................................... 55 
16.2.2 Listing and Presentation of individual PD data ....................................................... 55 
16.2.3 Summary of HS concentrations in serum, urine, and CSF ...................................... 55 
17 
Changes from protocol ......................................................................................................... 57 


 
SOBI003-001 
Confidential 
Page 5 of 67 
Version 1.0, Final 24 Mar 2020 
18 
References ............................................................................................................................ 58 
19 
Data presentation ................................................................................................................. 60 
19.1 Listings Index .................................................................................................................. 60 
19.2 Tables and Figures Index ................................................................................................ 62 
 
 
 


 
SOBI003-001 
Confidential 
Page 6 of 67 
Version 1.0, Final 24 Mar 2020 
1 
Abbreviations and definition of terms 
ADA 
Anti-drug antibody 
AE 
Adverse event 
AEq 
Age-equivalence 
ANOVA 
Analysis of variance 
ATC 
Anatomical therapeutic chemical 
AUC 
Area under curve 
AUC0-168h 
The area under the serum concentration-time curve from time 0 to 
168 after dose 
LLOQ 
Below the assay’s lower limit of quantification 
BMI 
Body mass index 
BSID-III 
Bayley scales of infant and toddler development®, third edition  
CEnd of inf 
The observed serum concentration at the end of infusion of SOBI003 
Cmax 
Maximum observed serum concentration 
CPre-dose 
The observed serum concentration immediately before the start of 
infusion of SOBI003 
CTrough 
The minimum observed serum concentration 
CI 
Confidence interval 
CL 
Clearance 
CNS 
Central nervous system 
CRIM 
Cross reactive immunological material 
CSF 
Cerebrospinal fluid 
CSHQ 
Children´s sleep habits questionnaire 
CSP 
Clinical study protocol 
CSR 
Clinical study report 
CV 
Coefficient of variation 
DMC 
Data monitoring committee 
DQ 
Development quotient 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
ERT 
Enzyme replacement therapy 


 
SOBI003-001 
Confidential 
Page 7 of 67 
Version 1.0, Final 24 Mar 2020 
ET 
Early termination 
FA 
Fractional anisotropy 
FAS 
Full analysis set 
FDA 
Food and drug administration 
FIH 
First time in human 
HS 
Heparan sulfate 
ICF 
Informed consent form 
ICH 
International council for harmonization 
IMP 
Investigational medicinal product 
IRR 
Infusion related reaction 
i.v. 
Intravenous 
KABC-II 
Kaufman assessment battery for children, second edition 
LSM 
Least square means 
λz 
Terminal elimination rate constant 
MAR 
Missing at random 
MD 
Mean diffusivity 
MedDRA 
Medical dictionary for regulatory activities 
MPS IIIA 
Mucopolysaccharidosis type IIIA 
MRI 
Magnetic resonance imaging 
NAb 
Neutralizing antibody 
NCI CTC 
National cancer institute common terminology criteria 
NH 
Natural history 
NVI 
Nonverbal index 
PD 
Pharmacodynamic 
PedsQL 
Pediatric quality of life inventory 
PI 
Principal investigator 
PK 
Pharmacokinetic 
PKAS 
PK analysis set 
PPS 
Per-protocol analysis set 
PT 
Preferred term 


 
SOBI003-001 
Confidential 
Page 8 of 67 
Version 1.0, Final 24 Mar 2020 
Q1 
First quartile 
Q3 
Third quartile 
SAE 
Serious adverse event 
SAF 
Safety analysis set 
SAP 
Statistical analysis plan 
SD 
Standard deviation 
SE 
Standard error of the mean 
Sobi 
Swedish orphan biovitrum 
SOC 
System organ class 
SRC 
Safety review committee 
SWI 
Susceptibility weighting imaging 
t 
Time 
tEnd of inf 
tlast 
The time of the end of the infusion of SOBI003 
The time of the last measurable concentration 
tmax 
The time at which the maximum serum concentration is observed 
t1/2 
Half-life 
TEAE 
Treatment emergent adverse event 
TST 
Total sleep time 
VABS-II 
Vineland adaptive behavior scales, second edition 
WASO 
Wake after sleep onset 
WHO-DD 
World health organization drug dictionary 
 
 
 


 
SOBI003-001 
Confidential 
Page 9 of 67 
Version 1.0, Final 24 Mar 2020 
2 
Introduction 
This statistical analysis plan (SAP) describes the planned analysis and reporting for Swedish 
Orphan Biovitrum (Sobi) AB (publ), Stockholm, Sweden protocol SOBI003-001 (An open, non-
controlled, parallel, ascending multiple-dose, multicenter study to assess the safety, tolerability, 
pharmacokinetics and pharmacodynamics of SOBI003 in pediatric MPS IIIA patients).  
This phase I/II study is being performed to assess the safety and tolerability of SOBI003 for the 
treatment of mucopolysaccharidosis type IIIA (MPS IIIA); Sanfilippo A syndrome in pediatric 
MPS IIIA patients.  
The purpose of this SAP is to outline the planned analyses to be completed to support the clinical 
study report (CSR) for protocol SOBI003-001. The planned analyses identified in this SAP will 
be included in regulatory submissions and/or future manuscripts. Also, exploratory analyses not 
necessarily identified in this SAP may be performed to support the clinical development 
program. Any post-hoc, or unplanned, analyses not identified in this SAP will be clearly 
identified in the respective CSR. 
The structure and content of this SAP provides sufficient detail to meet the requirements 
identified by the food and drug administration (FDA) and the International council for 
harmonization of technical requirements for registration of pharmaceuticals for human use 
(ICH): guidance on statistical principles in clinical trials (1). All work planned and reported for 
this SAP will follow internationally accepted guidelines, published by the American statistical 
association and the Royal statistical society, for statistical practice (2).  
3 
Study objectives and endpoints 
3.1 
Primary objective 
The primary objective is: 
To evaluate the safety and tolerability of SOBI003 at different dose levels. 
3.2 
Secondary objectives 
The secondary objectives are the following: 
1. To characterize the PK properties of SOBI003 following single and repeated 
administration by the use of non-compartmental analysis  
2. To assess the immunogenicity of SOBI003  
3. To assess the PD effect of different dose levels and treatment duration of SOBI003 on HS 
levels in CSF, serum, and urine 
4. To assess the effect of SOBI003 at different dose levels on neurocognition 
5. To assess the effect of SOBI003 at different dose levels on adaptive behavior 
6. To assess the effect of SOBI003 at different dose levels on gray matter volume 


 
SOBI003-001 
Confidential 
Page 10 of 67 
Version 1.0, Final 24 Mar 2020 
7. To assess the effect of SOBI003 at different dose levels on Quality of life. 
3.3 
Exploratory objectives 
The exploratory objectives are to explore the effect of SOBI003 at different dose levels on: 
1. Clinical manifestations of MPS IIIA as assessed by endpoints specified in Section 3.4.3. 
2. To characterize the PK properties of SOBI003 following single and repeated 
administration by the use of population PK analysis. 
3. To evaluate the PK/PD relationship between SOBI003 concentrations in serum and the 
effect of SOBI003 on HS levels in CSF, serum, and urine by the use of population 
modeling analysis. 
As local regulations permit, and provided that additional separate caregiver consent is given, the 
exploratory objectives are also to: 
• 
Collect and store a blood sample for future pharmacogenetic research aimed to explore 
genetic characteristics that may contribute to and/or modify the disease phenotype and /or 
with possible impact on safety, tolerability, immunogenicity, PK and PD related to 
SOBI003 treatment 
• 
Collect and store serum, CSF and urine samples to enable analyses of biomarkers with 
possible relation to safety, tolerability, immunogenicity, PK and PD of SOBI003, as 
identified in future 
The results of exploratory analyses may not be included in the CSR for this study, but reported 
separately when analyzed.  
3.4 
Study endpoints 
3.4.1 
Primary safety endpoint 
The primary endpoint to evaluate the primary objective of the safety and tolerability of SOBI003 
is: 
• 
Treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) 
3.4.2 
Secondary endpoints 
The secondary endpoints to evaluate the primary objective of the safety and tolerability of 
SOBI003 are: 
• 
Vital signs (blood pressure, heart rate, body temperature, respiratory rate and oxygen 
saturation) 
• 
Laboratory safety variables (hematology, coagulation, clinical chemistry and urine 
analysis) 


 
SOBI003-001 
Confidential 
Page 11 of 67 
Version 1.0, Final 24 Mar 2020 
The endpoints relating to the 1st secondary objective are: 
• 
Serum SOBI003 PK parameters at Weeks 1, 2, 3, 4, 5, 8, 12, 13, 16, 20, and 24; tEnd of inf, 
CEnd of inf, Cmax, tmax, CPre-dose, CTrough, CL, AUC0-168h, t1/2 
• 
CSF SOBI003 concentration at Weeks 12 and 24  
The endpoints relating to the 2nd secondary objective are: 
• 
Occurrence of ADAs against SOBI003 in serum (seroconversion rate, time to 
seroconversion, transient/persistent). For patients with confirmed ADA positive serum 
samples, the following additional endpoints apply: ADA titers and IgG subclasses in 
serum and presence of NAb in serum. 
• 
Occurrence of ADAs against SOBI003 in CSF at baseline, Weeks 12 and 24 (conversion 
rate, time to occurrence, transient/persistent). For patients with confirmed ADA positive 
CSF samples, the following additional endpoints apply: ADA titers and presence of NAb 
in CSF. 
The endpoints relating to the 3rd secondary objective are: 
• 
Change from baseline in CSF HS at Weeks 12 and 24 
• 
Change from baseline in serum HS at Weeks 2, 3, 4, 8, 12, 16, 20, and 24 
• 
Change from baseline in urine HS at Weeks 2, 3, 4, 8, 12, 16, 20, and 24 
The endpoints relating to the 4th secondary objective are neurocognitive development quotient 
(DQ) and age-equivalence (AEq) score as assessed by the Bayley scales of infant and toddler 
development®, third edition (BSID-III) cognitive subtest or the Kaufman assessment battery for 
children, second edition (KABC™-II); change from baseline at Week 24. 
The endpoint relating to the 5th secondary objective is adaptive behavior AEq score as assessed 
by Vineland™ adaptive behavior scales, expanded interview form, second edition (VABS-II); 
change from baseline at Week 24. 
The endpoint relating to the 6th secondary objective is gray matter volume as assessed by brain 
volumetric magnetic resonance imaging (MRI); change from baseline at Week 24. 
The endpoint relating to the 7th secondary objective is pediatric quality of life inventory 
(PedsQL™) total score and PedsQL™ family impact module total score; change from baseline at 
Week 24. 
3.4.3 
Exploratory endpoints 
The endpoints related to the 1st exploratory objective are: 
• 
Adaptive behavior composite score as assessed by VABS-II; change from baseline at 
Week 24 
• 
Neurocognitive composite score as assessed by the BSID-III cognitive subtest or the 
KABC-II; change from baseline at Week 24 
• 
Expressive and receptive language as assessed by the BSID-III language subtests, or the 
KABC-II expressive vocabulary subtest, and the VABS-II communication domain; AEq 


 
SOBI003-001 
Confidential 
Page 12 of 67 
Version 1.0, Final 24 Mar 2020 
change from baseline at Week 24Fine and gross motor function as assessed by the BSID-
III motor subtests and the VABS-II; AEq change from baseline at Week 24 
• 
Sleep pattern as determined by children´s sleep habits questionnaire (CSHQ) score; 
change from baseline at Weeks 12 and 24, respectively 
• 
Sleep pattern as determined by actigraphy including total sleep time, total day- and night 
time sleep duration, sleep latency, sleep efficiency, number of nocturnal awakenings, and 
wake after sleep onset; change from baseline at Weeks 12 and 24, respectively 
• 
Compound ventricular volume as assessed by brain volumetric MRI; change from 
baseline at Week 24 
• 
Fractional anisotropy (FA) and mean diffusivity (MD) of corpus callosum as assessed by 
diffusion tensor imaging MRI; change from baseline at Week 24 
• 
FA and MD of cerebral white matter as assessed by diffusion tensor imaging MRI; 
change from baseline at Week 24 
• 
Cerebral white matter as assessed by susceptibility weighting imaging (SWI) MRI; 
change from baseline at Week 24 
• 
Basal ganglia as assessed by SWI MRI; change from baseline at Week 24 
• 
Liver volume as assessed by abdominal MRI; change from baseline at Week 24 
• 
Spleen volume as assessed by abdominal MRI; change from baseline at Week 24 
The endpoints related to the 2nd exploratory objective are: 
• 
Population PK model parameter estimates and associated covariates describing intra- and 
inter-individual variability in respective parameter estimate. 
The endpoints related to the 3rd exploratory objective are: 
• 
Population PK/PD model parameter estimates and associated covariates describing intra- 
and inter-individual variability in respective parameter estimate. The results of these 
analyses will not be included in the CSR for this study, but reported separately. 
4 
Study methods 
4.1 
Overall study design and plan 
This is an open-label, non-controlled, parallel, sequential ascending multiple-dose, multicenter 
study to assess the dose related safety, tolerability, pharmacokinetics (PK), and 
pharmacodynamics (PD) of SOBI003 in pediatric MPS IIIA patients. An overview for the study 
design is presented in Figure 1. 
In February 2020, Sobi decided to discontinue the SOBI003 program. At the time of the 
decision, 3 patients had been included in Cohort 1 and 3 patients in Cohort 2 of the FIH study 
(SOBI003-001). All patients had been enrolled in the Extension study (SOBI00-002) and will 
have the possibility to continue their treatment for a total of two years. Thus, Cohort 3 in the FIH 
study (SOBI003-001) will not be started. Statistical analysis for the FIH study (SOBI003-001) 
CSR will be done for Cohort 1 and 2.  


 
SOBI003-001 
Confidential 
Page 13 of 67 
Version 1.0, Final 24 Mar 2020 
 
Figure 1 Overview for study design for Study SOBI003-001 
 
SOBI003 is administered as weekly intravenous (i.v.) infusions over a period of time of 4 hours. 
The study treatment period comprises 24 weekly infusions. Prior to initiation of each infusion, 
the patients are pre-treated with a single dose of non-sedative antihistamine. If infusion-related 
reactions occur, then the infusion duration may be expanded up to 24 hours and supportive 
medication may be administered, at the discretion of the investigator. 
The study is planned to consist of 3 dose cohorts, each comprising 3 patients, provided that no 
significant safety concern arise. An additional cohort comprising 3 patients may be added, if 
deemed necessary to more accurately characterize the safety, tolerability, PK or PD. 
The screening visit can be performed up to 12 weeks prior to the first SOBI003 infusion. At the 
screening visit, the MPS IIIA diagnosis is verified and the genotype is determined at a central 
laboratory. Patients are assigned to a dose cohort in consecutive order as the eligibility criteria 
have been confirmed, with prioritization of the younger patients.  
Treatment initiations will be staggered within each cohort in order to be able to observe, interpret 
and treat possible adverse reactions and to ensure that such reactions can be dealt with promptly. 
For each cohort, safety review committee (SRC) meetings are scheduled approximately 3 weeks 
after completion of the 3rd patient’s 4th dose administration. Based on the safety, 
immunogenicity, PK and PD data, the SRC will determine what dose to apply in the next cohort. 
A data monitoring committee (DMC), independent from Sobi and the principal investigator PI(s) 
will monitor safety data.  


 
SOBI003-001 
Confidential 
Page 14 of 67 
Version 1.0, Final 24 Mar 2020 
The DMC will review cumulative data from both the FIH study (SOBI003-001) and the 
extension study (SOBI003-002). The first DMC review meeting will be held 6 months following 
first patient visit in the extension study and will occur every 6 months until completion of the 
extension study (SOBI003-002). If requested by Sobi or DMC, additional ad-hoc meetings may 
be held. 
Upon completion of the 24-week treatment period with satisfactory tolerability, the patient is 
offered to receive continued SOBI003 treatment by participation in an extension study 
(SOBI003-002). 
The complete schedule of assessments is shown in Table 1 (Screening to Week 24), Table 2 
(Weeks 1 to 4) and Table 3 (Weeks 12 and 24). 
 
 
 


 
SOBI003-001 
Confidential 
Page 15 of 67 
Version 1.0, Final 24 Mar 2020 
Table 1 Schedule of events – Screening to Week 24 
 
Screeninga 
Baselineb 
 
Treatment period (24 weeks) 
ETc 
Week 
-12 to -7 
-6 to -1  
1 
2 
3 
4 
5 
6 
8 
9 
12 
13 
16 
17 
20 
22 
24/ 
END 
 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demography 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eligibility criteria 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prior & concomitant therapyd  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examinatione  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Neurological examination 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
Height & head circumference 
 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
X 
Weightf 
X 
X 
X 
 
 
 
X 
 
 
X 
X 
 
 
X 
 
 
X 
X 
Vital signsg 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
12-lead ECGh 
X 
 
X 
X 
X 
X 
 
X 
X 
 
X 
 
 
 
 
 
X 
X 
Echocardiography 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
Antihistaminei 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
SOBI003 administrationi 
 
 
 
 
Adverse events 
Xj 
Xj 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xj 
Anesthesia/sedationk for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Venous access port 
 
Xl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CSF sampling (PK, ADA, 
  HS, future researchm) 
 
Xm 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
Xm 
 
  MRI (brain, spleen, liver) 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 


 
SOBI003-001 
Confidential 
Page 16 of 67 
Version 1.0, Final 24 Mar 2020 
 
Screeninga 
Baselineb 
 
Treatment period (24 weeks) 
ETc 
Week 
-12 to -7 
-6 to -1  
1 
2 
3 
4 
5 
6 
8 
9 
12 
13 
16 
17 
20 
22 
24/ 
END 
 
Blood sampling for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Sulfamidase activityn 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  SGSH genotyping 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Safety laboratoryo 
X 
Xp 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
 
X 
X 
X 
X 
  Immunogenicity 
 
X 
 
X 
 
X 
 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
  HS 
 
X 
 
X 
X 
X 
 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
  PKq 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
X 
X 
 
X 
 
X 
X 
  Future researchm 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
X 
Urine collection for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Safety laboratory (Dipstick)o 
X 
 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
 
X 
X 
X 
X 
  HSu 
X 
X 
 
X 
X 
X 
 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
  Future researchm 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
X 
CRIM status (skin fibroblasts) 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Actigraphy (sleep pattern)r 
 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
BSID-III/KABC-II 
(neurocognition, language, 
motor function)s 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Parent/caregiver 
questionnaires: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  VABS-II 
X 
Xt 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
  CSHQr 
 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
  PedsQL, incl. Family Impact 
  Module 
 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
a  Screening assessments do not need to be performed on the same day, but should be completed to allow baseline assessments to be completed within 6 weeks prior 
to first SOBI003 infusion. 


 
SOBI003-001 
Confidential 
Page 17 of 67 
Version 1.0, Final 24 Mar 2020 
b Baseline assessments/procedures are not performed on the same day, but should be completed within 6 weeks prior to first SOBI003 infusion. The venous access 
port should be inserted at least 2 weeks prior to first SOBI003 infusion. 
c In case of early termination (ET) of SOBI003 treatment, the assessments should be completed as soon as possible after decision of treatment withdrawal. When 
possible, all study assessments should continue in accordance with the Schedule of Events until completion of the Week 24 visit. At a minimum, the ET 
assessments should be repeated 30 to 40 days after the last SOBI003 administration. Patients with ADA-positive samples should continue to be followed in 
accordance with clinical study protocol (CSP) Section 7.5.5.3. 
d Prior and concomitant therapy are recorded continuously from screening until completion of the Week 24 visit. 
e General appearance and skin are examined prior to start of each infusion and within 1 hour of completion of each infusion to capture any physical changes during 
infusion. Any new clinically significant finding or worsening of MPS IIIA related symptoms should be reported as an AE. 
f  During the treatment period, weight is assessed at approximately 4-week intervals to determine the actual SOBI003 to be administered. Weight is therefore 
obtained prior to preparation of the SOBI003 infusions solution at Weeks 1, 5, 9, 12, 17, 21 and 24. The weight is obtained either the day prior to the infusion or the 
day of infusion. The dose may be adjusted on the week after the body weight is obtained, at the discretion of the investigator. 
g  Vital signs includes blood pressure, heart rate, body temperature, respiratory rate and oxygen saturation. At each infusion, assessments are done pre-infusion, 
2 hours after start of infusion and within 1 hour after end of infusion. At Weeks 1 to 8, assessments are also done at 1, 3, 6 to 7, and 8 to 12 hours after start of 
infusion, and on Days 2 and 3. In addition, at Weeks 1 and 2 assessments are done on Day 5. At Weeks 12 and 24, assessments are also done on Day 3. Continuous 
pulse oximetry is applied from start of infusion until the completion of each of the 4 first infusions. 
h  ECGs are obtained on Day 1 at pre-infusion and 4-5 hours after start of infusion (i.e., within an hour after completion of the infusion).  
i 
Within 30 to 60 minutes prior to each SOBI003 infusion, a single dose of a non-sedative antihistamine should be administered. SOBI003 is administered as weekly 
infusions; +/- 1-day window is applied after the 4th infusion. 
j  SAE(s) are reported from the time point when the informed consent form (ICF) is signed until 28 days past last SOBI003 infusion. AEs are reported from start of 
first SOBI003 infusion.  
k  Use of general anesthesia or sedation is per local hospital routine and anesthesiologist judgement, as well as selection of anesthetic/sedative agents. If all Baseline 
procedures are not completed in one session, then local hospital routine determines minimum time between consecutive anesthetic/sedation episodes.  
l    The port should be inserted at least 2 weeks prior to first SOBI003 infusion. 
m Only applicable when separate consent has been provided for future research. At Week 22, blood is collected for future genetic research. At Baseline and Week 22, 
blood and urine are collected for future biomarker research. CSF is collected at Baseline and Week 24 for future biomarker research. In case of ET of SOBI003 
treatment, blood and urine is collected for storage for future biomarker and genetic research. 
n  Central laboratory analyses of sulfamidase activity in leucocytes. 
o  Sampling time points;  
Weeks 1 to 3: pre-infusion (Day 1) and Day 3. For patients <15 kg body weight, blood sampling on Day 3 at Week 3 is NOT applicable. 
Weeks 4 to 8: pre-infusion.  
Weeks 10 to 22: biweekly pre-infusion, i.e., Weeks 10, 12, 14 etc.  
Week 24: Day 3.   
p  Blood sampling for only hsCRP, IL-1ra, TNFα, IgE, and tryptase. Baseline sample analyzed only in case acute infusion/anaphylactic reaction occur during 
SOBI003 treatment to facilitate the determination of reaction etiology.  
q  Frequent PK blood sampling is conducted at Weeks 1, 2, 3, 4, 5, 8, 12, 13, 16, 20, and 24. Samples are also collected before start of infusion and at completion of 
the infusion at Weeks 2, 3 and 8 and before start of infusion, completion of infusion and at 168 hours (Day 8) at Week 16 and 20. PK blood sampling will be 


 
SOBI003-001 
Confidential 
Page 18 of 67 
Version 1.0, Final 24 Mar 2020 
adjusted based on the patient´s bodyweight in order not to exceed blood draw volume limits. At Baseline, the PK and immunogenicity samples should be taken on 
the day of CSF sampling for HS analysis. Details on PK blood sampling are given in CSP Table 6.  
r 
Sleep pattern is assessed by actigraph recordings for 7 consecutive days at Baseline and within 2 weeks prior to Week 12 and 24, i.e., Baseline assessment should 
preferably be completed prior to any anesthetic/sedation is applied and prior to PK and HS blood samplings. The aim should be to have the recordings completed 
during normal patient sleeping conditions and prior to the SOBI003 infusions on Day 1 at Weeks 12 and 24. A sleep diary is completed during the days of 
actigraphy. Parents should complete the CSHQ upon completion of each actigraph assessment  
s  In case both BSID-III and KABC-II are to be administered, there should be at least 2 days between the assessments. Attempts should be made to have the 
assessment(s) performed at least 5 days after any anesthesia/sedation. The Baseline assessment should be completed within 2 weeks prior to the first SOBI003 
infusion.  
t 
The Baseline assessment should be completed within 2 weeks prior to the first SOBI003 infusion. 
u Blood samples for immunogenicity and HS and urine sample for HS should be collected pre-infusion. 
 
 


 
SOBI003-001 
Confidential 
Page 19 of 67 
Version 1.0, Final 24 Mar 2020 
Table 2 Detailed schedule of events – Weeks 1 to 4 
 
Weeks 1, 2, 3 and 4 
Day 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
3 
5 
6 
Time 
Pre-inf 
0 
1:00 
2:00 
3:00 
4:00 
4:01 - 5:00 
6:00 – 7:00 
8:00 - 12:00  
 
 
 
 
Medical history 
Xa 
 
 
 
 
 
 
 
 
 
 
 
 
Eligibility criteria 
Xa 
 
 
 
 
 
 
 
 
 
 
 
 
Prior & concomitant medication  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examinationb 
X 
 
X 
X 
X 
 
X 
X 
X 
X 
X 
Xd 
 
Weight 
Xc 
 
 
 
 
 
 
 
 
 
 
 
 
Vital signsl 
X 
 
X 
X 
X 
 
X 
X 
X 
X 
X 
Xd 
 
Continuous pulse-oximetrye 
→ 
→ 
→ 
→ 
→ 
→ 
← 
 
 
 
 
 
 
12-lead ECG 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
Antihistaminef 
X 
 
 
 
 
 
 
 
 
 
 
 
 
SOBI003 administration: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Start of infusion 
 
X 
 
 
 
 
 
 
 
 
 
 
 
  Stop of infusion 
 
 
 
 
 
X 
 
 
 
 
 
 
 
Adverse events 
Xg 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Blood sampling for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Safety laboratory   
X 
 
 
 
 
 
 
 
 
 
Xh 
 
 
  Immunogenicity 
Xi 
 
 
 
 
 
 
 
 
 
 
 
 
  HS 
Xj 
 
 
 
 
 
 
 
 
 
 
 
 
  PK 
Xj 
 
 
 
 
 
X 
Xk 
Xk 
Xk 
Xk 
Xk 
Xk 
Urine collection for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Safety laboratory (Dipstick) 
X 
 
 
 
 
 
 
 
 
 
Xh 
 
 
  HS 
Xj 
 
 
 
 
 
 
 
 
 
 
 
 


 
SOBI003-001 
Confidential 
Page 20 of 67 
Version 1.0, Final 24 Mar 2020 
a  Only applicable at Week 1. Medical conditions present pre-infusion are recorded as medical history. At the time of the 1st infusion, the patient should not have 
evidence of ongoing infection, as judged by the investigator. In such case, the 1st infusion should be postponed until the infection has resolved. 
b  General appearance and skin to capture any physical changes during infusion. Any new clinically significant finding or worsening of MPS IIIA related symptoms 
should be reported as an AE. 
c  Only applicable at Week 1. Weight obtained pre-infusion at Week 1 determines the actual SOBI003 dose to be administered at Weeks 1 to 4. The dose may be 
adjusted in the week after the body weight is obtained, at the discretion of the investigator. 
d  Only applicable at Weeks 1 and 2  
e  Continuous monitoring up to 24 hours after start of infusion  
f  Within 30 to 60 minutes prior to each SOBI003 infusion, a single dose of a non-sedative antihistamine should be administered. 
g  SAE(s) are reported from the time point when ICF is signed until 28 days past last dose of IMP. AEs are reported from start of first SOBI003 infusion. 
h  NOT applicable at Week 4 and blood sampling is not applicable at Week 3 for patients < 15 kg body weight. 
i  Only applicable for Weeks 2 and 4. 
j   NOT applicable for Week 1. 
k Only applicable for Weeks 1 and 4. PK sampling time points are pre-dose, 4 hours (end of infusion), 6, 12, 24, 48, 96, 120 and 168 hours after start of infusion. In 
case SOBI003 infusion is prolonged, applicable adjustments the PK sampling time points are applied (refer to CSP Table 6). 
l   If the infusion time is reduced or extended, hourly vital signs during infusion should be recorded. 
 
 


 
SOBI003-001 
Confidential 
Page 21 of 67 
Version 1.0, Final 24 Mar 2020 
Table 3 Detailed schedule of events – Weeks 12, 16, 20 and 24; PK at Weeks 5, 8, 12, 13, 16, 20, and 24; ADA, Serum HS, and 
Urine HS at Weeks 8, 12, 16, 20, and 24  
 
 
Weeks 12, 16, 20 and 24 
PK: Weeks 5, 8, 12, 13, 16, 20, and 24 
ADA, Serum HS, Urine HS: Weeks 8, 12, 16, 20, and 24 
Week 
12 
Week 
24 END 
Day 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
3 
4 
5 
6 
7 (8a) 
7 (8a) 
Time 
Pre-
inf 
0 
1:00 
2:00 
3:00 
4:00 
4:01 -  
5:00 
6:00 –  
7:00 
8:00 –  
12:00 
 
 
 
 
 
 
 
Prior & concomitant 
medication  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
X 
Physical examination 
Xb 
 
 
 
 
 
Xb 
 
 
 
 
 
 
 
 
X 
Neurological examination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Height & head circumference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
Weight 
Xk 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
Vital signs 
X 
 
 
X 
 
 
Xl 
 
 
 
X 
 
 
 
 
 
12-lead ECG 
Xm 
 
 
 
 
 
Xm 
 
 
 
 
 
 
 
 
Xc 
Echocardiography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Xc 
Antihistamined 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOBI003 administration: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Start of infusion 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Stop of infusion 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
Adverse events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
X 
Anesthesia for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CSF sampling (SOBI003, 
  ADA, HS, future researche) 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
  MRI (brain, spleen, liver) 
 
 
 
 
 
 
 
 
 
Xf 
 
 
 
 
 
 


 
SOBI003-001 
Confidential 
Page 22 of 67 
Version 1.0, Final 24 Mar 2020 
 
 
Weeks 12, 16, 20 and 24 
PK: Weeks 5, 8, 12, 13, 16, 20, and 24 
ADA, Serum HS, Urine HS: Weeks 8, 12, 16, 20, and 24 
Week 
12 
Week 
24 END 
Day 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
3 
4 
5 
6 
7 (8a) 
7 (8a) 
Time 
Pre-
inf 
0 
1:00 
2:00 
3:00 
4:00 
4:01 -  
5:00 
6:00 –  
7:00 
8:00 –  
12:00 
 
 
 
 
 
 
 
Blood sampling for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Safety laboratory  
Xg 
 
 
 
 
 
 
 
 
 
Xf 
 
 
 
 
 
  Immunogenicity 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  HS 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
  PK 
X 
 
 
 
 
 
Xh 
Xh 
Xh 
Xh 
Xh 
Xh 
Xh 
Xh 
Xh 
Xh 
Urine collection for: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Safety laboratory (Dipstick) 
Xg 
 
 
 
 
 
 
 
 
 
Xf 
 
 
 
 
 
  HS 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
Actigraph device collection 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BSID-III and/or KABC-II 
(neurocognition, language, 
motor function)i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Parent/caregiver 
questionnaires: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  VABS-II 
 
 
 
 
 
 
 
 
 
 
Xf 
 
 
 
 
 
  CSHQj 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  PedsQL incl. Family Impact 
  Module 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
a  Only PK sampling applicable on Day 8. All other assessments performed on Day 7. 
b  General appearance and skin at the infusion site are examined prior to start of each infusion and within 1 hour of completion of each infusion to capture any 
physical changes during infusion. Any new clinically significant finding or worsening of MPS IIIA related symptoms should be reported as an AE. 
c  If it is not practically feasible to conduct echocardiography and ECG on Day 7, these can be done during Days 3 to 7. 
d  Within 30 to 60 minutes prior to each SOBI003 infusion, a single dose of a non-sedative antihistamine should be administered. 
e  Only applicable when separate consent has been provided for future research. 


 
SOBI003-001 
Confidential 
Page 23 of 67 
Version 1.0, Final 24 Mar 2020 
f  Only applicable for Week 24  
g Only applicable for Week 12 
h  PK sampling time points are 4 hours (end of infusion), 6, 12, 24, 48, 96, 120 and 168 hours after start of infusion. Samples are also collected at 4 hours (end of 
infusion) and at 168 hours (Day 8) at Week 5, 8, 12, 13, 16, 20 and 24. The 168-hour sample at Week 12, 16, and 20 is thus taken prior to start of infusion on Day 1 
of Week 13, 17, and 21, respectively. The 168-hour sample at Week 24 is thus taken on Day 8 (For patients continuing in the extension study (SOBI003-002), this 
is prior to start of infusion on Day 1 of the extension study).  
i  In case both BSID-III and KABC-II are to be administered, there should be at least 2 days between the assessments (i.e., one should then be administered on Days 4 
or 5 of Week 24 and the other one on Day 7 of Week 24). A +7-day window is applied for the BSID III/KABC-II assessments. 
j  CSHQ is completed any time during the infusion days 
k Weight is obtained prior to preparation of  the SOBI003 infusions solution at Week 12. The weight is obtained either the day prior to the infusion or the day of 
infusion. The dose may be adjusted on the week after the body weight is obtained, at the discretion of the investigator. 
l 
At each infusion, vital sign assessments are done pre-infusion, mid-infusion and within 1 hour after end of infusion. Timing of assessment to be adjusted in 
accordance with infusion time. 
m Only applicable for Week 12 and 24.  
 
 
 
 


 
SOBI003-001 
Confidential 
Page 24 of 67 
Version 1.0, Final 24 Mar 2020 
4.2 
Selection of study population 
4.2.1 
Inclusion criteria 
A patient must fulfill the following criteria in order to be included in the study: 
1. Informed consent obtained from the patient’s legally authorized representative(s) 
2. Patients with MPS IIIA, as confirmed by both: 
• A documented deficiency in sulfamidase enzyme activity in concordance with a 
diagnosis of MPS IIIA*, and 
• Normal enzyme activity level of at least one other sulfatase measured in 
leukocytes 
3.  Chronological age of ≥12 and ≤72 months (i.e., 1 to 6 years) at the time of the first 
SOBI003 infusion and has a developmental age ≥12 months at screening as assessed by 
the VABS-II 
4.  Medically stable patient who is expected to be able to comply with study procedures 
* as determined by the reference ranges applied by the Greenwood Genetic Center 
4.2.2 
Exclusion criteria 
The presence of any of the following will exclude a patient from inclusion in the study: 
1. At least one S298P mutation in the N-sulfoglucosamine sulfohydrolase (SGSH) gene 
2. Contraindications for anesthetic procedures, surgical procedure (venous access port), 
MRI scans and/or lumbar punctures 
3. History of poorly controlled seizures 
4. Patients is currently receiving psychotropic or other medications which in the 
investigator's opinion, would be likely to substantially confound test results 
5. Significant non-MPS IIIA-related central nervous system (CNS) impairment or 
behavioral disturbances, which in the investigator's opinion, would confound the 
scientific integrity or interpretation of study assessments 
6. Prior administration of stem cell or gene therapy, or enzyme replacement therapy (ERT) 
for MPS IIIA 
7. Concurrent or prior (within 30 days of enrolment into this study) participation in a study 
involving invasive procedures 
4.3 
Method of treatment assignment and randomization 
This is a non-randomized, open-label study; no blinding of treatment assignments is required. 
Upon provision of signed informed consent, patients are assigned a site-specific enrolment 
number in consecutive order. Upon completion of the screening assessments and confirmation of 
patient eligibility, patients are allocated to a dose cohort in consecutive order, with prioritization 


 
SOBI003-001 
Confidential 
Page 25 of 67 
Version 1.0, Final 24 Mar 2020 
of the younger patients. There is thus no restriction or requirement regarding the site distribution 
of patients per cohort, i.e., patients within one cohort can be recruited at only one site or at 
multiple sites. 
5 
Sequence of planned analysis 
5.1 
Safety review committee 
Treatment initiations will be staggered within each cohort in order to be able to observe, interpret 
and treat possible adverse reactions and to ensure that such reactions can be dealt with promptly. 
For each cohort, SRC meetings are scheduled approximately 3 weeks after completion of the 3rd 
patient’s 4th dose administration. Based on the safety, immunogenicity, PK and PD data, it is the 
responsibility of the SRC to determine: 
• whether dosage of ongoing cohort(s) can continue  
• if the infusion time and rate of subsequent administrations at ongoing dose level should 
be altered  
• whether it is safe to continue to the next cohort, i.e., to expose new study patients to 
SOBI003 treatment  
• the SOBI003 dose to be administered in the next cohort and to ongoing patients in the 
extension study (SOBI003-002).  
Additional SRC meetings will be scheduled ad hoc as per principal investigator or Sobi SRC 
member requests. The SRC will review cumulative data from both the FIH study (SOBI003-001) 
and the extension study (SOBI003-002). 
An SRC charter will specify the operating procedures including SRC membership, voting 
members, responsibilities, data review meeting details, and lines of communication with the 
study teams at Sobi, Syneos Health, and investigational sites.  
The SRC charter will also specify in detail the data and outputs presented in the SRC summary 
reports, which will be provided to the SRC members for their review. 
5.2 
Data safety monitoring committee 
In addition to the SRC, a DMC is assigned to monitor safety, PK, PD, and immunogenicity data. 
The primary responsibility of the DMC is to provide additional safety oversight of the study 
conduct in order to further protect study participants. 
A DMC charter will specify the operating procedures including DMC membership, 
responsibilities, data review meeting details, and lines of communication with the study teams at 
Sobi and Syneos Health.  
The DMC charter will also specify in detail the data and outputs presented in the open reports, 
which will be provided to the voting members of the DMC for their review. 


 
SOBI003-001 
Confidential 
Page 26 of 67 
Version 1.0, Final 24 Mar 2020 
The DMC will review cumulative data from both the FIH study (SOBI003-001) and the 
extension study (SOBI003-002). The first DMC review meeting will be held 6 months following 
first patient visit in the extension study and will occur every 6 months until completion of the 
extension study. If requested by Sobi or DMC, additional ad-hoc meetings may be held.  
5.3 
Interim analyses 
No interim analysis is planned for this 24-week study. 
5.4 
Analyses and reporting 
All final, planned, analyses identified in the CSP and in this SAP will be performed only after 
the last patient has completed the study. Tables, listings, and figures to be provided for SRC and 
DMC review are specified in separate SRC Listing and SRC Table shell documents. 
Any post-hoc analyses included in the CSR, which were not identified in this SAP, will be 
clearly identified as such in the relevant section of the CSR. 
6 
Sample size determination 
Given that this is a FIH study with no formal hypothesis tests, no sample size calculation has 
been performed. Three sequential dose levels with 3 patients in each cohort was considered 
sufficient to allow assessment of safety and tolerability concerns, as well as characterize a PD 
dose-response relationship in this rare population with a high unmet medical need. 
7 
Analysis sets  
The following analysis sets will be used in the statistical analyses. Analyses will be performed 
by dose cohort; in addition, summary tables will be presented for all patients. 
For PK and PD, analyses will be performed by dose level as described in Section 15 and 16. 
7.1 
Safety analysis set (SAF) 
The SAF is the primary analysis set and will consist of all patients who received at least 1 dose 
of investigational medicinal product (IMP).  
The SAF will be used for the safety analyses. 


 
SOBI003-001 
Confidential 
Page 27 of 67 
Version 1.0, Final 24 Mar 2020 
7.2 
Full analysis set (FAS) 
The FAS will consist of all patients who have a baseline and at least 1 post-baseline assessment 
of any secondary or exploratory assessment.  
The FAS will be used for the secondary and explorative efficacy analyses. 
7.3 
PK analysis set (PKAS) 
The PKAS will consist of all patients where at least 1 SOBI003 dose has been administered 
correctly and where SOBI003 serum or CSF concentration data is available without any protocol 
deviation interfering with these results. 
The PKAS will be used for the analysis of PK secondary endpoints relating to the 1st secondary 
objective. 
7.4 
Immunogenicity analysis set 
The immunogenicity set will consist of those patients in the safety analysis set who have 
sufficient blood samples taken for ADA testing at baseline and at least 1 post-dose time-point. 
The immunogenicity set will be used for the immunogenicity analyses. 
In case any patient has missing baseline, a second immunogenicity analysis set will be formed 
including all patients with sufficient blood samples for ADA testing (i.e. including those with 
missing baseline). All immunogenicity analyses without considering baseline will be performed 
on that second set.  
8 
General issues for statistical analysis 
All statistical tests will be two-sided and performed using a 5 % significance level, if not stated 
otherwise. Results will be presented as the estimated mean value for each treatment group, the 
estimated difference between groups, the associated 95 % two-sided confidence interval and P-
value. P-values from statistical analyses will be presented to three decimal places with values 
below 0.001 displayed as <0.001 and confidence intervals will be presented to one more decimal 
places than the raw data. 
Continuous data will be summarized using descriptive statistics: number of patients (n), mean, 
standard deviation (SD), standard error of the mean (SE), median, minimum and maximum 
values, unless otherwise indicated. Minimum and maximum values will be presented to the same 
number of decimal places as the raw data and mean, SD, SE of the mean and median will be 
presented to one more decimal place than the raw data. Summary tables over all patients will 
include in addition the first quartile (Q1) and the third quartile (Q3), presented to one more 
decimal place than the raw data. 


 
SOBI003-001 
Confidential 
Page 28 of 67 
Version 1.0, Final 24 Mar 2020 
Categorical data will be summarized using frequency counts and percentages. Percentages will 
be suppressed when the count is zero, however the category will still be displayed. The 
denominator for all percentages will be the number of patients within the treatment group for the 
population of interest, unless otherwise indicated. Percentages will be presented to one decimal 
place. 
Data for the FIH SOBI003-001 study (up to Week 24) and extension study SOBI003-002 (Week 
25 to 104) will be collected in a combined database. All analyses specified in this SAP refer to 
FIH study SOBI003-001, i.e. for data up to Week 24. 
Data obtained up to Week 24 will be summarized in tables by dose cohort, visit, and time point, 
if applicable. All data obtained up to Week 24 will be listed in individual patient data listings, 
which will be sorted by dose cohort and patient ID. 
If not specified otherwise for the purpose of tabulations, the unscheduled post-baseline values 
will generally be excluded. 
Statistical analyses will be performed using SAS software Version 9.4 or later (SAS Institute Inc, 
Cary, North Carolina, United States).  
8.1 
Handling of missing data and outliers 
For all questionnaires and scales, (see Section 13.1 for more details) items that are not answered 
by the patient will remain as missing. If applicable, specific rules for the calculation of each 
score are also defined in Section 13.1. 
Complete missing or partial dates will be presented in the listings as reported on the electronic 
case report forms (eCRFs). 
If an AE has a completely missing onset date, then the AE will be considered a TEAE, unless the 
(partial) stop date indicates differently. A medication with a completely missing start date is 
considered a prior medication. A medication with a completely missing stop date is considered a 
concomitant medication. 
If an AE or a medication has a partial missing start or stop date, the rules presented in Table 4 
will be used to impute the date. The imputed date will be used to determine whether it is a TEAE 
for AE, or a prior or concomitant medication. 


 
SOBI003-001 
Confidential 
Page 29 of 67 
Version 1.0, Final 24 Mar 2020 
Table 4 Partial date derivation 
Partial Missing Start or Stop 
Date 
Derived Start Date 
Derived Stop Date 
Missing month and day, and the 
year is present 
 
January 1st of that year or first dose date 
if the year is the same as the year of first 
dose date 
December 31st of that year 
Missing day, but year and month 
are present 
 
First day of that month or first dose date 
if the year and month are the same as the 
year and month of first dose date 
Last day of that month 
Missing month, but year and day 
are present 
Missing month derived as January or 
same as first dose month if the year is 
the same as the year of first dose 
Missing month derived as 
December 
8.2 
Multicenter studies 
The planned study centers are located in the U.S.A., Turkey, the Netherlands, and Germany. The 
study will be conducted at up to 5 study centers in total. Analysis will be performed on the 
combined data from all study centers.   
8.3 
Multiple comparisons and multiplicity 
There will be no adjustments for multiplicity. 
8.4 
Derived and computed variables  
8.4.1 
First and last study treatment 
Day 1, Week 1 is the day of first study treatment, the day prior to 1st study treatment is Day -1. 
The last study treatment will be at the latest at Week 24 of the Treatment period. 
8.4.2 
Study treatment exposure 
For patients who continued study treatment until end of the study SOBI003-001, study treatment 
exposure in weeks will be calculated as ([date of last visit attended – date of 1st infusion of study 
treatment] + 1) / 7, rounded to the nearest decimal.  
For patients who stopped study treatment during the course of the study, study treatment 
exposure in weeks will be calculated as ([date of last infusion + 7 days – date of 1st infusion of 
study treatment] + 1) / 7, rounded to the nearest decimal.  


 
SOBI003-001 
Confidential 
Page 30 of 67 
Version 1.0, Final 24 Mar 2020 
8.4.3 
Baseline and change from baseline 
Baseline is defined as the last available assessment prior to 1st infusion of study treatment.  
Change from baseline = (post-baseline value – baseline value).  
8.4.4 
Age 
Age (months) will be derived as date of 1st infusion – birth date. Since only month and year of 
birth are captured, “15” will be used as day of birth for calculation. 
8.4.5 
Adverse event duration 
If times are available and if the duration is less than 24 hours, the duration will be calculated as 
(end date/time – start date/time) and presented in hh:mm. If at least 1 time is missing or if the 
duration is at least 24 hours it will be calculated as (end date - start date)+1 and presented in 
days.  
In case of partial/missing start or end date duration will not be calculated. 
8.4.6 
Time since study treatment administration for adverse event 
If times are available and if time to onset is less than 24 hours, the time will be calculated as 
(start date/time – first/last administration date/time) and presented in hh:mm. If at least 1 time is 
missing or if the time to onset is at least 24 hours then it will be calculated as (start date – 
first/last administration date) + 1 and presented in days.  
In case of partial/missing AE start date the time since study treatment administration will not be 
calculated. 
8.4.7 
Body mass index (BMI) 
Body mass index (kg/m2) will be derived as weight (kg)/(height(cm)/100)2 and rounded to the 
nearest decimal. 
8.4.8 
Dose received 
At each visit from Week 1 onwards, the actual infusion volume administered, including the 
added SOBI003 volume is reported in the eCRF. Total infusion volume to be administered is 
100 mL for patients with a bodyweight < 25 kg and 250 mL for patients with a body weight 
≥ 25 kg. 
Dose received will be calculated at each visit as (added SOBI003 volume * 20), rounded to the 
nearest decimal and presented in mg. 


 
SOBI003-001 
Confidential 
Page 31 of 67 
Version 1.0, Final 24 Mar 2020 
Dose received will also be calculated at each visit in mg/kg as (added SOBI003 volume * 20 / 
bodyweight, rounded to the nearest decimal. 
8.4.9 
Time since diagnosis 
Time since diagnosis will be calculated as ([date of 1st infusion – date of diagnosis]+1)/30.4373 
and presented in months. In case of partial/missing date of diagnosis, time since diagnosis will 
not be calculated. 
9 
Patient disposition 
An overall summary of patient disposition by dose cohort will be displayed for all screened 
patients with the numbers and percentage of patients screened, screen failures, treated, and 
included in the analysis sets. Additionally, the numbers and percentage of patients who 
completed study and were withdrawn from the study will be summarized, including the reason 
for study withdrawal. All data, including the reasons for screen failure and reasons for exclusion 
from each of the analysis sets, will be listed. 
All protocol deviations identified will be summarized and listed.  
Violated inclusion criteria and fulfilled exclusion criteria will also be listed. 
10 
Demographics and baseline characteristics 
Demographic and other baseline characteristics will be summarized by dose cohort with 
descriptive statistics using the SAF.  
10.1 
Demographics and baseline characteristics 
Date of birth, gestational age at birth, gender, ethnicity, race, country of residence and native 
language will be captured at Screening. In addition, information on the patient’s siblings is 
captured, including age and MPS IIIA diagnostic status (confirmed as nonaffected/ confirmed as 
affected/under current investigation) (3). For sibling(s) with confirmed diagnosis, the sibling’s 
age at diagnosis and genotype are also captured, when known.  
For patient data, the following variables will be summarized: Age at first infusion (derived), 
gestational age at birth, gender, baseline weight, ethnicity, race, country of residence and native 
language. The same variables will be also included in listings, as well as date of birth.  
For patient’s siblings’ data, the following variables will be summarized: Age (derived), MPS 
IIIA diagnostic status, and age at confirmed diagnosis. The same variables will also be included 
in listings, including also the genotype of siblings with confirmed diagnosis. 


 
SOBI003-001 
Confidential 
Page 32 of 67 
Version 1.0, Final 24 Mar 2020 
10.2 
Medical history 
For all medical history data, a frequency table of the number and percentage of patients will be 
provided by system organ class (SOC) and preferred term (PT) for each dose cohort. Tables will 
be sorted alphabetically by SOC and PT. 
All medical history data will be coded using the latest version of the medical dictionary for 
regulatory activities (MedDRA), all data will be listed. 
10.2.1 
MPS IIIA diagnosis 
Information on diagnosis date and prior MPS IIIA diagnostic procedures will be captured in the 
eCRF including assessment date, diagnostic method used and test result. Summary statistics will 
be presented for diagnostic status and time since diagnosis (defined in 9.4.9). All data will be 
listed.  
11 
Prior and concomitant medication 
Prior medications will be defined as any medications taken prior to the date of 1st study 
treatment. Concomitant medications will be defined as medications ongoing or with a start date 
on or after the date of the 1st study treatment or a stop date on or after the date of the 1st study 
treatment. 
All prior and concomitant medication will be coded using the latest version of world health 
organization drug dictionary (WHO-DD). Data will be listed and summary tables will be 
presented by anatomical therapeutic chemical classification [ATC] level 4, and WHO-DD 
preferred term using the SAF.  
Prior to each infusion of SOBI003, a single dose of non-sedative antihistamine will be 
administered. Antihistamine administration including date and time, medication name, dose, unit 
and route will be listed and summarized per visit. 
For patients continuing in the extension study (SOBI003-002), any medications with onset after 
the 1st dose of study drug in the extension study will not be presented in the tables and listings of 
the FIH study (SOBI003-001) but in the tables and listings of the extension study.  
12 
Treatment compliance  
There will be no measurement of, or analysis of, treatment compliance, nor does it affect 
population assignment (patients must be exposed to study drug to qualify for the analysis sets).  


 
SOBI003-001 
Confidential 
Page 33 of 67 
Version 1.0, Final 24 Mar 2020 
13 
Efficacy analyses 
Efficacy data will be summarized descriptively by dose cohort, visit, and time point using the 
FAS. 
13.1 
Questionnaires and scales 
The patient’s chronological age in combination with the patient’s adaptive behavior age 
equivalent score as established by VABS-II, will determine which neurocognitive test(s) to 
apply. The algorithm in Table 5 is applied and the test(s) administered at Baseline should also be 
used at Week 24. 
Table 5 Selection of neurocognitive assessment method  
Chronological age at the 
assessment time point 
VABS-II adaptive behavior age-
equivalence  
Neurocognitive test to apply 
<42 months 
Any age-equivalence 
BSID-III 
≥42 months 
<36 months 
BSID-III 
≥42 months 
36 to 42 months 
BSID-III + KABC-II* 
≥42 months  
>42 months 
KABC-II 
* The BSID-III should be administered first, and there should be at least 2 days until the KABC-
II assessment in order to reduce KABC-II outcome bias of patient tiredness. 
13.1.1 
VABS-II 
For this study, the VABS-II assesses adaptive behavior in 4 competence domains 
(communication, socialization, daily living skills, and motor skills). The domain scores yield an 
adaptive behavior composite of the 4 domains (4). The VABS-II is assessed by parent/caregiver 
interviews performed by child development specialists/ psychologists with prior experience of 
MPS IIIA patients. A series of age-equivalent questions obtains a decreasing score between “4” 
and “0” or “DK” (don’t know) based on how independently the individual is able to perform the 
behavior (i.e., 4 = “performs almost always independently”, 0 = “never performs/never performs 
independently”) is answered. The developmental age at Screening will be determined as the 
mean of the subdomain AEq scores including the communication, socialization, daily living 
skills, and motor skills domains 
The adaptive behavior AEq and composite score will be obtained with the mean of the 
subdomain scores communication, socialization, daily living skills and motor skills for patients 
aged up to 6 years and 11 months. For patients aged 7 years and above, the adaptive behavior 
composite score will be obtained with the 3 subdomain scores communication, socialization, and 
daily living skills. 
The VABS-II will be assessed at Screening, Baseline (within 2 weeks prior to 1st SOBI003 
infusion) and at Week 24 (see Table 1). Each patient’s parent/caregiver should preferably have 
the same interviewer throughout the study in order to reduce potential variability. Completed 


 
SOBI003-001 
Confidential 
Page 34 of 67 
Version 1.0, Final 24 Mar 2020 
assessment forms will be sent to a central reader (NeuroCog Trials), for data quality assurance of 
completed assessment forms, calculation of final scores and determination of AEq scores, and 
data management. 
Changes from baseline (as defined in Section 8.4.3) will be calculated at Week 24.  
13.1.2 
BSID-III 
The BSID-III is a standard series of measurements used primarily to assess the development of 
infants and toddlers. Children are assessed in the 5 key developmental subtests of cognitive, 
language, social-emotional, motor and adaptive behavior (5). For each developmental subtest the 
patient must respond to a series of questions with a score of “1” or “0” based on the successful 
completion (“1”) of a task. Total raw scores for each subtest can be obtained by adding all scores 
of the questions in the subtest.  
The BSID-II will be assessed at Baseline (within 2 weeks prior to 1st SOBI003 infusion) and at 
Week 24, if applicable (see Table 1). Each patient should preferably have the same assessor 
throughout the study in order to reduce potential variability.  
Changes from Baseline (as defined in Section 8.4.3) will be calculated at Week 24.  
13.1.3 
KABC-II 
The KABC™-II is a standardized test that assesses intelligence and achievement in children. The 
test is comprised of four global test scores that include: sequential processing, simultaneous 
processing, achievement and mental processing (6). Each of the global tests contains a number of 
subtests with several questions. For each question, the patient must respond with a categorical 
score (mostly between “2”and “0”, but between “4” and “0” for some subtests), based on the 
difficulty that the patient experiences while answering the question (e.g., a difficult task would 
be scored with “0” and an easy task would be scored with “2” or “4” depending on the subtest).  
A cumulative raw score can be obtained then for each subtest by adding the scores for each 
question in the subtest. Raw scores can be then transformed to adjusted scores and AEq. 
The nonverbal index (NVI) of KABC-II is defined by adding certain subtests and based on the 
age of the patient. For patients between 3-6 years (cognitive age) it includes the subtests: 
conceptual thinking, face recognition, story completion, triangles, pattern reasoning and hand 
movements.  
The KABC-II will be assessed at Baseline (within 2 weeks prior to 1st SOBI003 infusion) and at 
Week 24, if applicable (see Table 1). Each patient’s parent/caregiver should preferably have the 
same assessor throughout the study in order to reduce potential variability.  
To ensure that the KABC-II assessments are performed in accordance with the study 
instructions, completed assessment forms will be sent to a central reader (NeuroCog Trials) for 
data quality assurance, calculation of final scores and determination of AEq and DQ scores. 
Changes from Baseline (as defined in Section 8.4.3) will be calculated at Week 24.  


 
SOBI003-001 
Confidential 
Page 35 of 67 
Version 1.0, Final 24 Mar 2020 
13.1.4 
PedsQL 
The PedsQL™ is a modular approach to measuring health-related quality of life in healthy 
children and adolescents and those with acute and chronic health conditions. PedsQL includes 
the following scales covering 4 domains: physical, emotional, social and school functioning (7). 
Questions and scales vary for the different age categories (13 to 24 months, 2 to 4 years, and 5 to 
7 years). Also, the PedsQL™ Family Impact Module will be completed with the following 8 
domains: physical, emotional, social, and cognitive functioning, as well as communication, 
worry, daily activities, and family relationships. 
For each of the domains, a series of questions will be answered and then rated with a categorical 
score between “4”, “3”, “2”, “1” or “0” based on how much of a problem the patient has in 
solving the task described by the question. A summary score is subsequently obtained for each 
patient so that higher scores indicate better health-related quality of life. 
The total score of the PedsQL (for both the assessment of the child’s quality of life and of 
caregiver burden) will be obtained with the following steps: 
1. Transform score. Items are reversed scored and linearly transformed to a 0-100 scale as 
follows: 0=100, 1=75, 2=50, 3=25, 4=0 
2. Each scale score will be calculated as the sum of the transformed individual score items, 
divided by the number of non-missing items. Note that a scale score is only calculated if 
at least 50% of the associated items are non-missing. 
3. Total score = sum of all the items over the number of items.  
The PedsQL will be assessed at Baseline and at Weeks 12 and 24. Changes from Baseline (as 
defined in Section 8.4.3) will be calculated at Week 12 and 24. The PedsQL will only be listed. 
13.1.5 
CSHQ 
The CSHQ is a psychological questionnaire designed to examine sleep behaviors in children and 
adolescents. The CSHQ includes items related to a number of key sleep domains that represent 
typical sleep complaints in this age group (8). 
The scores for each of the items are assigned corresponding to the number of times per week that 
the sleeping behavior occurs, between “3” (usually, 5 to 7 times), “2” (sometimes, 2 to 4 times), 
or “1” (rarely, 0 to 1 times). A number of items on the questionnaire are reverse-scored, so that 
higher scores consistently indicate problem behaviors. 
Two additional items are added to the original CSHQ questionnaire to further characterize 
common MPS IIIA specific issues with sleep, i.e., disruptive behavior at night and dangerous 
behavior at night. This CSHQ will capture the child’s sleep habits during the past week. 
Items will be combined into 8 subscales. The total sleep disturbance score will be obtained with 
the sum of the score of all items of the 8 subscales. Note that a subscale score will only be 
calculated if at least 50% of the associated items are non-missing and the total sleep disturbance 
score will only be calculated if all subscales have at least 50% non-missing items. For the 
remaining missing values, each item will be imputed with the mean of the subscale.  


 
SOBI003-001 
Confidential 
Page 36 of 67 
Version 1.0, Final 24 Mar 2020 
The CSHQ will be completed at Baseline and prior to the infusions at Weeks 12 and 24. The 
CSHQ will be recorded in the eCRF. Changes from Baseline (as defined in 8.4.3) will be 
calculated at Week 12 and 24. 
13.2 
Secondary efficacy endpoints 
13.2.1 
Neurocognitive developmental age 
The neurocognitive developmental age (months) will be derived on the basis of the BSID-III 
cognitive total score and BSID-III age-normative data. 
The neurocognitive developmental age (months) will be derived from the mean AEq scores on 
the NVI of the KABC-II, where an AEq score is the average score for a particular age. 
The DQ is calculated as the AEq for cognitive development divided by the chronological age for 
the child multiplied by 100, i.e.  
DQ = 100*AEq / age 
For patients completing an assessment of both BSID-III and KABC-II, the BSID-III score will 
be used as a basis for calculating the DQ of neurocognitive development at baseline. A 
calibration of overlapping AEq scores between BDID-III and KABC-II will be done to assess if 
a patient outgrows the BSID-III test during the duration of the study. If confirmed, assessments 
of KABC-II will form the basis for calculating DQ of neurocognitive development for remaining 
study assessments. 
Changes from Baseline (as defined in Section 8.4.3) will be assessed at Week 24.  
13.2.2 
Adaptive behavior 
The endpoint relating to the 5th secondary objective will be obtained with the adaptive behavior 
AEq as assessed by VABS-II (see Section 13.1.2). Change from Baseline (as defined in Section 
8.4.3) will also be assessed at Week 24. 
13.2.3 
Magnetic resonance imaging 
The endpoint relating to the 6th secondary objective will be obtained with the gray matter volume 
assessed by brain volumetric MRI. Changes from Baseline (as defined in Section 8.4.3) will be 
assessed at Week 24. 
13.2.4 
Quality of life and caregiver burden 
The endpoint relating to the 7th secondary objective will be obtained with the parent proxy-report 
format of the PedsQL Version 4.0 used to assess the child’s quality of life, and the family impact 
module of the PedsQL Version 2.0 used to assess the caregiver burden. The PedsQL version (i.e., 


 
SOBI003-001 
Confidential 
Page 37 of 67 
Version 1.0, Final 24 Mar 2020 
infant/toddler/young children) will be selected on the basis of the chronological age of the 
patient. Both questionnaires will be recorded in the eCRF. 
13.3 
Exploratory efficacy endpoints 
13.3.1 
Adaptive behavior composite score 
This endpoint will be obtained with the adaptive behavior composite score of VABS-II.  
Change from Baseline will be assessed at Week 24. 
13.3.2 
Neurocognitive composite score 
This endpoint will be obtained with the cognitive subtest score of BSID-III or the mental 
processing composite score as assessed by KABC-II.  
Change from Baseline will be assessed at Week 24. 
13.3.3 
Language 
Expressive and receptive language is assessed by the BSID-III language subtest score and the 
VABS-II communication domain score, respectively.  
For patients being assessed with the KABC-II for cognition, language development is assessed 
by the subtest “Expressive Vocabulary” of the knowledge test.  
In addition, written language is assessed by the AEq of subdomain “Written” in the 
communication domain of VABS-II. 
Changes from Baseline will be assessed at Week 24. 
13.3.4 
Motor function 
Fine and gross motor skills are assessed by the total scores of the BSID-III corresponding 
subtests of the motor function module, and by the AEq of the VABS-II motor skills domain. 
Changes from Baseline will be assessed at Week 24. 
13.3.5 
Sleep pattern 
The patients’ sleep pattern is evaluated using the CSHQ total score and by use of actigraphy. 
An actigraph (ActiGraph GT9X Link) will be applied to the non-dominant wrist or ankle (9) and 
recordings will be made for 7 consecutive days and nights at Baseline and at Weeks 11 and 23. A 
daily wear time of 20 hours per day will be regarded as a compliant recording. The recording 
will be supported by an actigraph log, recorded in the eCRF.  


 
SOBI003-001 
Confidential 
Page 38 of 67 
Version 1.0, Final 24 Mar 2020 
The following parameters will be determined on the basis of recordings in the actigraph log: 
• 
Bedtime (Clock time child is put to bed) 
• 
Wake time (Clock time of child is taken out of bed) 
• 
Time in bed (Time between Bedtime and Wake time) 
The following variables are derived as obtained from the actigraph software: 
• 
Sleep onset (Clock time for first appearance of a predetermined number of consecutive 
min of sleep) 
• 
Sleep offset (Clock time for last of a predetermined number of consecutive min of sleep) 
• 
Sleep period (Time between sleep onset and sleep offset) 
• 
Total sleep time (TST, Duration of sleep in sleep period) 
• 
Wake after sleep onset (WASO, number of minutes scored as wake during sleep period) 
• 
Sleep efficiency (Percentage sleep: TST/time in bed) 
• 
Night waking frequency (number of night wakings) 
• 
Night waking duration (Sum of minutes scored as night waking) 
• 
24 h sleep duration (amount of sleep in a 24-h period) 
Sleep onset latency is determined as Time between bedtime (as recorded on the actigraph log) 
and sleep onset (as captured by the actigraph software).  
Changes from Baseline will be assessed at Week 12 and 24. 
For more details regarding the methods used by the actigraph software please see the CSP for 
SOB003-001, Section 7.5.4.5. 
13.3.6 
Magnetic resonance imaging 
As listed in Section 3.4.3, the MRI exploratory endpoints refer to compound ventricular volume, 
FA and MD in corpus callosum, FA and MD of cerebral white matter, SWI in cerebral white 
matter, and basal ganglia. Also liver and spleen volume are assessed by abdominal MRI.  
Changes from Baseline (as defined in Section 8.4.3) will be assessed at Week 24. 
13.4 
Subgroup analyses 
No subgroup analyses will be performed for any of the efficacy analyses. 
14 
Safety analyses 
Safety data will be summarized descriptively by dose cohort using the SAF. 


 
SOBI003-001 
Confidential 
Page 39 of 67 
Version 1.0, Final 24 Mar 2020 
14.1 
Drug exposure 
Upon provision of signed informed consent, patients are assigned a patient number and allocated 
to a dose cohort in strict consecutive order. Thus, the first 3 enrolled patients are assigned to 
Cohort 1 and administrations of SOBI003 at 3 mg/kg/week; for Cohorts 2 and 3, dose levels of 
10 mg/kg/week and 20 mg/kg/week are planned. 
At the time of the 1st SOBI003 infusion, the patient should not have any clinically significant 
evidence of an ongoing infection, or an ongoing treatment with antibiotics. In such cases, the 1st 
infusion should be postponed until the infection has resolved. 
SOBI003 is administered as weekly i.v. infusions over a period of time of 4 hours. The study 
treatment period comprises 24 weekly infusions. For each weekly visit, date and time of 
administration will be recorded in the eCRF, as well as reasons for infusion stop (if any), dose 
level, SOBI003 volume, total infusion volume administered, and dosing action taken (e.g., 
“withdrawn”). All data will be listed. 
In addition, actual dose received in mg, actual dose level received in mg/kg (see Section 8.4.8), 
and study treatment exposure in weeks will be calculated (see Section 8.4.2). These data will be 
listed and summarized. 
14.2 
Adverse events 
The primary endpoints are TEAEs and SAEs. 
For the FIH study (SOBI003-001), all AEs (defined in CSP Section 7.5.5.1.1) occurring after the 
patient has received the 1st dose of investigational medicinal product and up to Day 7 of Week 24 
(End of Study) will be recorded on the AE eCRF page.  
For the FIH study, SAEs will be reported from the time the ICF is signed until 28 days past the 
last dose of study drug. 
For patients continuing in the extension study (SOBI003-002), the period for recording AEs, 
including SAEs, on the eCRF begins Day 1 upon signing of the study ICF on Week 25 and ends 
Day 8 of Week 104 (End of Study) (see CSP Section 7.5.4.1.2). This includes all events 
observed/diagnosed or reported since the last visit of the FIH study (Week 24 / End of study).  
For patients continuing in the extension study (SOBI003-002), any AEs and SAEs with onset 
after the 1st dose of study drug in the extension study will not be presented in the tables and 
listings of the FIH study but in the tables and listings of the extension study.  
A TEAE is any AE with onset or worsening reported from the time that the 1st dose of study drug 
is administered until completion of or early termination of the study. In addition to TEAEs, 
SAEs with an onset date equal to or greater than the informed consent date of the FIH study and 
earlier than the start date of 1st dose of study drug (non-treatment emergent) will be collected and 
analyzed. 
AEs with missing onset dates will be considered treatment-emergent, unless the stop date 
indicates otherwise. In the event that only a partial start date (month/year) is available, and 


 
SOBI003-001 
Confidential 
Page 40 of 67 
Version 1.0, Final 24 Mar 2020 
month/year occurs before that of 1st dose of study drug, the AE will be considered as non-
treatment-emergent. If month/year occurs on, or after that of 1st dose of study drug, the AE will 
be considered as treatment emergent. If an AE has a partial missing start or stop date, the rules in 
Section 8.1 will be used to impute the date. 
All AEs will be coded using MedDRA to give a PT and a SOC term for each event. The latest 
version of MedDRA will be used. 
The severity grading is based on the national cancer institute common terminology criteria (NCI 
CTCAE) (version 4.03), see CSP Section 7.5.5.13. 
If the causality assessment (related, not related) of a TEAE is missing, the event will be 
considered as drug-related following the worst case principle. Non-treatment emergent SAEs 
with missing causality assessment are considered not related. 
An Infusion related reaction (IRR) has been defined as any AE occurring during an infusion or 
within 24 hours after end of infusion and which is considered related to SOBI003 treatment as 
judged by the investigator. IRRs may appear as symptoms such as rash, urticaria, erythema,  
emesis, loose stools, fever, alterations in heart rate, and blood pressure, but could also include 
other symptoms considered related to the infusion. Such symptoms (by PT and SOC) will be 
grouped into separate IRRs. There can be one IRR per infusion, in case several IRR symptoms 
are reported for one infusion they will be counted as one single IRR. 
TEAEs will also be classified according to the patients ADA status (positive, negative, boosted, 
unknown) at the time of the AE occurrence. 
All AEs will be summarized by dose cohort. The following analyses will be performed: 
• Overall summary of AEs (overall, non-treatment emergent SAEs, TEAEs, drug-related 
TEAEs, non-serious TEAEs, serious TEAEs, serious drug-related TEAEs, TEAEs 
leading to study and/or treatment withdrawal, drug-related TEAEs leading to study and/or 
treatment withdrawal, serious TEAEs leading to study and/or treatment withdrawal, 
TEAEs leading to death, IRRs) 
• Overall summary of IRRs (overall, serious IRRs, IRRs leading to study and/or treatment 
withdrawal). There can be one IRR per infusion, in case several IRR symptoms are 
reported for one infusion they will be counted as one single IRR. 
• TEAEs by SOC and PT 
• TEAEs by SOC and PT and by maximum CTCAE grade 
• Drug-related TEAEs by SOC and PT 
• Drug-related TEAEs by SOC and PT by maximum CTCAE grade 
• Serious TEAEs by SOC and PT 
• Serious TEAEs by SOC and PT by maximum CTCAE grade 
• Serious drug-related TEAEs by SOC and PT 
• Serious drug-related TEAEs by SOC and PT by maximum CTCAE grade 
• TEAEs leading to study and/or treatment withdrawal by SOC and PT 
• TEAEs leading to study and/or treatment withdrawal by SOC and PT by maximum 
CTCAE grade 


 
SOBI003-001 
Confidential 
Page 41 of 67 
Version 1.0, Final 24 Mar 2020 
• Drug-related TEAEs leading to study and/or treatment withdrawal by SOC and PT 
• Drug-related TEAEs leading to study and/or treatment withdrawal by SOC and PT by 
maximum CTCAE grade 
• TEAEs by SOC and PT and by ADA status 
• IRR symptoms by SOC and PT 
• IRR symptoms by SOC and PT by maximum CTCAE grade 
• Serious IRR symptoms by SOC and PT 
• Serious IRR symptoms by SOC and PT by maximum CTCAE grade 
• IRR symptoms leading to study and/or treatment withdrawal by SOC and PT 
• IRR symptoms leading to study and/or treatment withdrawal by SOC and PT by 
maximum CTCAE grade 
• Frequency of IRR symptoms resolved within 24 hours. 
For each SOC and PT, summaries will be made with respect to the proportion of patients having 
a least one occurrence of that event and the total number of events, with the exception of tables 
by maximum CTCAE grade (which include only the proportion of patients having at least one 
occurrence of that event). Tables will be sorted alphabetically, first by SOC and then by PT. 
14.2.1 
Serious adverse events 
All serious TEAEs will be presented in a summary table by SOC, PT, and maximum CTCAE 
grade (see paragraph above). In addition to the summary tables, a detailed listing of all SAEs will 
be provided in CSR Section 14.3.2. 
14.2.2 
Adverse events leading to withdrawal 
All AEs collected with a study medication action taken as “withdrawn” will be presented in a 
summary table by SOC, PT, and maximum CTCAE grade (see Section 14.2). In addition to the 
summary tables, a detailed listing of all TEAEs leading to study drug discontinuation will be 
provided in CSR Section 14.3.2. 
14.2.3 
Deaths 
All patient deaths during this study will be presented in a data listing, which will be provided in 
CSR Section 14.3.2. Data presented will include date of death, date of last visit, date of 1st dose, 
days from 1st dose until death, date of last dose, number of days from last dose of study drug to 
death, number of AEs (if applicable), cause of death, and relationship of cause of death to study 
drug. 
14.2.4 
Infusion related reaction symptoms 
For the overall summary of AEs as well as the overall summary of IRRs several IRR symptoms 
reported for one infusion will be grouped into one single IRR and counted as one event. 


 
SOBI003-001 
Confidential 
Page 42 of 67 
Version 1.0, Final 24 Mar 2020 
All individual IRR symptoms will be presented in a summary table by SOC, PT, and maximum 
CTCAE grade (see paragraph above). Summary tables by SOC, PT, and maximum CTCAE 
grade will also be provided for all IRR symptoms leading to study and/or treatment withdrawal 
and all serious IRR symptoms. Also, the frequency of IRR symptoms resolved within 24 hours 
will be presented.  
In addition to the summary tables, a detailed listing of all IRR symptoms will be provided in 
CSR Section 14.3.2.  
14.3 
Vital signs 
Vital signs (systolic and diastolic blood pressure, heart rate, body temperature, respiratory rate, 
and oxygen saturation measured with pulse oximetry) are the 1st secondary endpoint related to 
the primary objective of this study and are measured at the screening visit and at each infusion.  
At Weeks 1 to 8, assessments will be performed at pre-infusion, 1 hour (+/- 5 minutes), 2 hours 
(+/- 5 minutes) and 3 hours (+/- 5 minutes) after start of infusion, within 1 hour after end of 
infusion, within 6 to 7 hours after start of infusion, within 8 to 12 hours after start of infusion, 
and on Days 2 and 3. In addition, at Weeks 1 and 2 the assessments are also done on Day 5. 
At Weeks 9 to 24, assessments will be performed at pre-infusion, 2 hours (+/- 5 minutes) after 
start of each infusion and within 1 hour after end of each infusion. At Weeks 12 and 24, the 
assessments are also done on Day 3. 
In case of prolonged SOBI003 infusions (i.e., > 4 hours) and regardless of which Study Week, 
the assessment schedule should be adjusted so that vital signs are assessed every hour during 
infusion and within an hour of completion of the infusion. After completed SOBI003 infusion, 
vital signs are also assessed on Days 2 and 3 (where Day 1 equals the start of the SOBI003 
infusion). Depending on the duration of the infusion, the assessment at 8 to 12 hours after start of 
infusion may also apply. In case of need to prolong infusions (i.e., > 4 hours) at any time during 
the study, pulse oximetry monitoring will be applied, as judged by the investigator. 
Vital signs values will be listed and summarized descriptively by visit and time point including 
changes from Baseline.  
14.4 
Laboratory data 
Laboratory safety variables are the 2nd secondary endpoint related to the primary objective of this 
study. Clinical chemistry, hematology, coagulation and urine analyses are conducted at a central 
laboratory (BARC). The time points for sample collection are described in Table 6, together with 
the analyses performed at each sampling occasion. 
 


 
SOBI003-001 
Confidential 
Page 43 of 67 
Version 1.0, Final 24 Mar 2020 
Table 6 
Safety laboratory assessment time points 
Analyses 
Study visit 
Sampling time point(s) 
Clinical chemistry (1.5 mL blood): 
Aspartate aminotransferase (AST), Alanine 
aminotransferase (ALT), Total bilirubin (if 
>upper limit of normal [ULN] then also 
direct and indirect bilirubin), Creatinine, 
Albumin, Potassium (K), Sodium (Na), 
Calcium (Ca), non-fasting Glucose, and C-
reactive protein (CRP). 
Hematology (0.5 mL blood): Hemoglobin 
(Hb), Erythrocytes, White blood cell count 
(WBC), Differential blood count and 
Platelet count. 
Coagulation (1.7 mL): PT/INR, APTT, 
and Fibrinogen. 
Urinalysis (dip-stick analyses, central 
laboratory): pH, Glucose, Proteins, and 
Blood 
Screening 
 
Weeks 1 to 3 
pre-infusion (Day 1) and Day 3 
Weeks 4 to 8 
 pre-infusion 
Weeks 10, 12, 14, 16, 18, 20, 
and 22 
 pre-infusion 
Week 24 
Day 3 
C-reactive protein (CRP), IL-1ra, TNFα, 
IgE, and tryptase (6.4 mL blood) 
Baseline 
 
In case of 
infusion/anaphylactic reaction 
 
Clinical laboratory values will be listed and summarized descriptively by visit and time point 
including changes from baseline. A separate listing will be provided for abnormal results. Shift 
tables will be used to evaluate categorical changes from Baseline to End of Study visit by 
examining the proportion of patients whose test values are outside the normal ranges. Patient 
plots will illustrate laboratory results for each parameter graphically. 
14.5 
Immunogenicity 
Serum samples are collected at Baseline (same time as the CSF sample is collected) and prior to 
start of SOBI003 infusion at Weeks 2, 4, 8, 12, 16, 20, and 24, and if applicable at Early 
Termination of SOBI003 treatment, CSF samples (0.5 mL) are collected at Baseline and at 
Weeks 12 and 24. 
The analysis of immunogenicity will in general be based on the immunogenicity analysis set. In 
case any patient has missing baseline, all immunogenicity analyses without considering baseline 
will be performed on a second immunogenicity analysis set including all patients with sufficient 
blood samples for ADA testing (i.e. including those with missing baseline).  
The analyses of PK by ADA status at baseline will be based on the PKAS. 
The following definitions will apply as defined in the harmonized terminology for 
immunogenicity (10): 


 
SOBI003-001 
Confidential 
Page 44 of 67 
Version 1.0, Final 24 Mar 2020 
• Evaluable patient: A patients with at least 1 sample taken after study drug administration 
that is appropriate for ADA testing (with reportable result). 
• ADA-positive sample: When ADA is detected in a sample, the sample is considered 
positive. 
• Baseline ADA: Pre-existing antibodies detected at baseline. 
• Treatment induced ADA: de novo development following administration of study drug 
(i.e., formation of ADA any time after the initial study drug administration in a patient 
without preexisting ADA). 
• Treatment boosted ADA: Baseline ADA boosted to higher level following study drug 
administration (i.e., at any time after the initial study drug administration the ADA titer is 
greater than the baseline titer by a factor of four). 
• ADA-positive patient: A patient with at least 1 treatment-induced or treatment-boosted 
ADA-positive sample at any time during the treatment or follow-up observation period. 
• ADA-negative patient: A patient without a treatment induced or treatment-boosted ADA-
positive sample during the treatment or follow-up observation period. 
• Baseline ADA positive patient: A patient with ADA at baseline. Such patient can have 
treatment boosted ADA after dosing. 
Note that the requirement for inclusion in the immunogenicity set of at least 1 post-dose ADA 
assessment means that all patients in the immunogenicity set are “evaluable patients”.  
The immunogenicity data will be listed for each patient and individual patient plots of titer 
measurement over time presented. Titer measurements will be summarized by visit using 
descriptive statistics by dose cohort and overall. Immunogenicity will be evaluated in regards 
antibody prevalence (pre-existing antibodies), antibody incidence, titer and boosting following 
dosing, impact on PK and PD responses. 
A summary of ADA positive patients over time will be presented. For each visit this will 
summarize the number of patients who were ADA positive (treatment induced or treatment 
boosted ADA). A summary of ADA change from baseline immune response will be presented, 
summarizing the overall ADA incidence (number of ADA positive patients) as well as the 
numbers of patients for whom this was treatment induced ADA and treatment boosted ADA, 
together with summaries of titer.  
Figures for each patient will be produced with titer and TEAEs plotted against time with ADA 
status (positive, negative, boosted) will be marked as well. 
14.6 
CRIM status 
At the Baseline visit, a skin biopsy is obtained for isolation of fibroblasts for assessment of cross 
reactive immunological material (CRIM) status at the central laboratory. The biopsy should 
preferably be obtained at least 2 weeks prior to the 1st SOBI003 infusion. 
CRIM status values will be listed and summarized. 


 
SOBI003-001 
Confidential 
Page 45 of 67 
Version 1.0, Final 24 Mar 2020 
14.7 
ECG 
12-lead Electrocardiograms (ECG) are obtained at Screening and at Weeks 1 to 4, 6, 8, 12, and 
24. During the treatment period, ECGs are obtained pre-infusion and within an hour after end of 
infusion, i.e., 4 to 5 hours after start of the infusion.  
ECG values will be listed and number and percentage of patients with normal and abnormal 
results will be summarized by visit and time point.  
14.8 
Other safety assessments 
14.8.1 
Echocardiography 
At screening and Week 24, an echocardiography is performed to determine if there are any 
cardiac safety concerns that would prevent the patient from participating in the study.  
These measurements will be listed and number and percentage of patients with normal and 
abnormal results will be summarized. 
14.8.2 
Physical examination and anthropometry 
The physical examination will be performed at Screening, Baseline and at completion of the 
Week 24 visit. 
At Weeks 1 to 4, general appearance and skin at the infusion site are examined prior to start of 
each infusion, 1 hour (+/- 5 minutes), 2 hours (+/- 5 minutes) and 3 hours (+/- 5 minutes) after 
start of infusion, within 1 hour after end of infusion, and 6 to 7 and 8 to 12 hours after start of 
infusion. At Weeks 1 and 2, the examinations are repeated on Days 2, 3, and 5. At Weeks 3 and 
4, the examinations are repeated on Days 2 and 3. 
At Weeks 5 to 24, general appearance and skin at the infusion site are examined prior to start of 
each infusion and within 1 hour after end of infusion. 
Physical examination data will be listed and number and percentage of patients with normal and 
abnormal results will be summarized by visit and time point. 
Weight is assessed at Screening, Baseline, every 4 weeks during the treatment period in order to 
determine the actual SOBI003 dose to be administered, and at completion of the Week 24 visit. 
Weight is hence obtained prior to start of infusion at Weeks 1, 5, 9, 13, 17, and 21. The body 
weight is obtained either on the day prior to the infusion or the day of infusion, BMI is calculated 
(see Section 8.4.7). 
Height and head circumference are assessed at Baseline, at Week 12 and at completion of the 
Week 24 visit (if applicable, also at ET of SOBI003 treatment). 
Anthropometric measurements will be listed and summarized by visit, including change from 
baseline. 


 
SOBI003-001 
Confidential 
Page 46 of 67 
Version 1.0, Final 24 Mar 2020 
14.8.3 
Neurological examination 
At Screening and at completion of the Week 24 visit (if applicable, also at Early Termination of 
SOBI003 treatment), a pediatric neurologist conducts an applicable age-related neurological 
examination including:  
• Cranial Nerves 
• Cerebellar function 
• Sensory function 
• Reflexes 
• Motor function 
Normal/abnormal status will be captured, and any abnormalities will be specified. Number and 
percentage of patients with normal and abnormal status will be summarized; all data will be 
listed. 
15 
Pharmacokinetic analyses 
15.1 
Secondary pharmacokinetic endpoint analyses 
The PKAS will be used for PK analyses including PK parameter calculations, graphical displays 
of individual and mean data, and the listings and summarization of PK parameters. Patients with 
missing PK parameters due to unreliable or missing data will be flagged and excluded from 
summarization. 
The SAF will be used for listing of PK concentrations for all patients who received any amount 
of IMP. The protocol deviations including the deviations leading to patient’s exclusion from 
PKAS will be shown as flags in the listing. 


 
SOBI003-001 
Confidential 
Page 47 of 67 
Version 1.0, Final 24 Mar 2020 
15.2 
Serum PK sampling schedule  
Table 7 Detailed PK blood sampling schedule 
Week 
Time 
 BW ≥20 kg 
No of samplesa 
BW ≥15 kg 
No of samplesa 
BW ≥10 kg 
No of samplesa 
 
Screening 
1 
1 
1 
 
Baseline 
1 
1 
1 
Week 1 
4h / End of Infusion 
2 
2 
2c 
 
6h  
2 
 
 
 
12h 
2 
 
 
 
24h 
2 
2 
 
 
48h 
1 
 
 
 
72hb 
1 
1 
 
 
96hb 
1 
1 
 
 
120h 
1 
1 
 
Week 1 (2) 
168h/Pre-infusion 
1 
1 
1 
 
4h / End of Infusion 
2 
2 
 
Week 3 
Pre-infusion 
1 
1 
 
 
4h / End of Infusion 
2 
2 
 
Week 4 
Pre-infusion 
1 
1 
1 
 
4h / End of Infusion 
2 
2 
2 
 
6h 
2 
2 
 
 
12h 
2 
2 
 
 
24h 
2 
2 
2 
 
48h 
1 
1 
 
 
72hb 
1 
1 
1 
 
96hb 
1 
1 
1 
 
120h 
1 
1 
 
Week 4 (5) 
168h/ Pre-infusion 
1 
1 
1 
Week 8 
Pre-infusion 
1 
1 
1 
 
4h / End of Infusion 
2 
2 
2 
Week 12  
Pre-infusion 
1 
1 
1 
 
4h / End of Infusion 
2 
2 
2 
 
6h  
2 
2 
 
 
12h 
2 
2 
 
 
24h 
2 
2 
2 
 
48h 
1 
1 
 


 
SOBI003-001 
Confidential 
Page 48 of 67 
Version 1.0, Final 24 Mar 2020 
Week 
Time 
 BW ≥20 kg 
No of samplesa 
BW ≥15 kg 
No of samplesa 
BW ≥10 kg 
No of samplesa 
 
72hb 
1 
1 
1 
 
96hb 
1 
1 
1 
 
120h 
1 
1 
 
 
168h 
1 
1 
1 
Week 16 
Pre-infusion 
1 
1 
1 
 
4h / End of Infusion 
1 
1 
1 
 
168h 
1 
1 
1 
Week 20 
Pre-infusion 
1 
1 
1 
 
4h / End of Infusion 
1 
1 
1 
 
168h 
1 
1 
1 
Week 24 
Pre-infusion 
1 
1 
1 
 
4h / End of Infusion 
2 
2 
2 
 
6h  
2 
2 
 
 
12h 
2 
2 
 
 
24h 
2 
2 
2 
 
48h 
1 
1 
 
 
72hb 
1 
1 
1 
 
96hb 
1 
1 
1 
 
120h 
1 
1 
 
 
168h 
1 
1 
1 
a If Number = 1; PK blood sample is collected from central venous access port. If Number =2; One PK sample 
will be collected from the central venous access port and one PK sample will be collected from a peripheral 
venous line. At the Screening visit 1; from peripheral venous line as no central access port has yet been placed.  
b If infusion is prolonged, PK samples will be collected 2h and 8h after End of infusion. Thereafter PK sampling 
will be conducted according to ordinary PK sampling schedule (refer to CSP Section 7.5.6.1). 
15.3 
Serum PK endpoints 
The following parameters will be derived: 
• Serum SOBI003 PK parameters at Weeks 1, 4, 12, and 24 and as applicable at Weeks 16 
and 20; tend of inf, Cend of inf, Cmax, tmax, Cpre-dose, Ctrough, CL, AUC0-168h, t1/2 
Other parameters may be derived such as accumulation ratios RCmax, RCtrough, RAUC0-168h, 
fluctuation%, etc. 
15.4 
CSF PK endpoints 
• CSF SOBI003 concentration at Baseline, Weeks 12 and 24 


 
SOBI003-001 
Confidential 
Page 49 of 67 
Version 1.0, Final 24 Mar 2020 
• Ratio of SOBI003 CSF concentration/SOBI003 serum concentration Week 12 and 24: 
(SOBI003 concentration CSF / SOBI003 concentration serum)*100 (%)   
15.5 
Presentation of concentration data in serum and CSF 
15.5.1 
Handling of missing data  
Missing concentration data for all patients who are administered scheduled study treatment will 
be considered as non-informative missing and will not be imputed. No concentration estimates 
will be provided for missing sample values. 
For the derivation of the area under the curve (AUC) and for the individual serum concentration 
versus time curves, the following rules will apply: 
• Concentration values below the assay’s lower limit of quantification (LLOQ) in pre-dose 
samples and in samples taken before the time of the 1st quantifiable concentration will be 
treated as zero; except for the log-transformed concentrations for graphs, where 
concentration values below the assay’s LLOQ in pre-dose samples will be set to 
LLOQ/2;  
• The sampling time of pre-dose samples relative to dosing will also be treated as zero; 
• In case a concentration value pre-dose is not available, the concentration value collected 
at screening may be used for derivation of AUC;   
• Post-dose below LLOQ values after the 1st quantifiable time point will be set to missing; 
• Samples taken outside the sampling windows may be excluded from by-time point 
summary statistics; this will be determined prior to database lock. 
For serum concentration summary, the following rules will apply: 
• Serum concentrations below LLOQ in pre-dose samples and in samples taken before the 
time of the 1st quantifiable value will be set to zero; 
• The serum concentrations below LLOQ after quantifiable concentration will set to 
missing.  
For CSF concentration summary, the following rules will apply:  
• CSF concentrations below LLOQ in the pre-dose samples taken before the time of the 1st 
quantifiable value will be set to zero;  
• The CSF concentrations below LLOQ after quantifiable concentration will be 
summarized.  
No further imputation will be applied to any missing values. 
15.5.2 
Listing and Presentation of individual PK data 
PK concentrations in serum and CSF will be listed for SAF. Flags will be used to show 
deviations from protocol with the explanation in the footnote. 


 
SOBI003-001 
Confidential 
Page 50 of 67 
Version 1.0, Final 24 Mar 2020 
The actual sampling time of PK blood or CSF sample collection, in relation to start of 
administration of dose, will be listed for each treatment and will include the deviation in time 
from the protocol scheduled time, if applicable. 
Individual subject serum and CSF concentration data will be listed by subject, time point and 
SOBI003 dose (mg/kg). Individual subject PK parameters will be listed for the PKAS by subject 
and will be summarized by treatment group/cohort. Unreliable PK parameters will be listed but 
flagged and excluded from summary. 
The following figures will be produced for individual data for SOBI003: 
• Individual serum concentration-time profiles will be presented for each dose level with 
all patients in the same figure on linear and log-linear scales vs actual time for Weeks 1, 
4, 12, and 24. Profiles for patients within the same treatment will be combined. 
• Individual trough and end-of-infusion serum concentrations vs dose number for all 
Weeks combined. Profiles for patients within the same cohort will be combined. 
• Scatter plots of CSF concentrations for Weeks 12 and 24 for different treatments. 
15.5.3 
Summary of serum and CSF PK concentrations  
PK results, i.e., SOBI003 concentrations in serum and CSF and PK parameters in serum and 
CSF, will be presented by dose level using descriptive statistics. In addition, results will be 
presented by demographic characteristics, e.g., age-group and bodyweight, as applicable. 
PK serum and CSF concentration data will be summarized by treatment using the following 
descriptive statistics: n, number and % LLOQ, arithmetic mean, SD, CV%, minimum, median 
and maximum. 
Mean serum concentrations will not be presented if 1 or more out of 3 patients of the actual 
values at any one time point in the terminal phase are LLOQ or missing. 
Samples taken outside the allowed time windows may be excluded from summarization. This 
will be determined prior to database lock. 
Mean ± SD serum concentration-time profiles will be presented, combining the curves for all 
dose levels within the same figure, on linear and log-linear scales vs nominal time. 
Mean ± SD trough and CEnd of inf or Cmax serum concentrations and dose number for all cycles 
combined. Profiles for cohorts with different dose levels will be combined. 
15.5.4 
PK parameters derivation 
The PK parameters will be estimated as follows: 
• The apparent Cmax and the corresponding Tmax will be read directly from the 
concentration-time plot (observed data). 
• AUClast is calculated using the log-linear trapezoidal interpolation rule for intravenous 
model. 


 
SOBI003-001 
Confidential 
Page 51 of 67 
Version 1.0, Final 24 Mar 2020 
Terminal elimination parameters, elimination rate constant and t1/2, will be derived as below if 
sufficient data are available. 
The terminal elimination rate constant (λz) will be determined by log linear regression obtained 
on at least the 3 last quantifiable concentrations and will not include Cmax; 
t1/2 is calculated by the program as ln2/λz; 
The AUC0-inf is calculated by the program as: 
AUC0-inf = AUClast + AUCextrap where last is the sampling time point of the last measurable 
concentration (tlast). AUCextrap is calculated by the program as: Clast/λz, where Clast is the observed 
concentration at time tlast and λz is the elimination rate constant during the apparent terminal 
elimination phase; AUC0-inf will only be presented for patients with a reliable λz; 
For single-dose, CL is calculated by program as (dose/AUC0-inf) and for multiple-dose, CL is 
calculated by program as (dose/AUC0-168h); 
V is calculated by the program as (dose/AUC0-inf)/λz; 
Fluctuation % is calculated by the program as 100×((Cmax-Cmin)/Cavg). 
The following PK acceptance criteria will be considered to when the reliability of elimination 
parameters are assessed: 
• Number of points to calculate λz is greater than or equal to 3 excluding Cmax point; 
• Interval for calculation of λz is longer than half-life; 
• The adjusted square of the correlation coefficient (Rsquare adjusted) for the goodness of 
fit of the regression line through the data points must be ≥0.75; 
• AUCextrap ≤30%.  
However, less strict acceptance criteria may be applied, in exceptional cases, since the number of 
PK samples are limited. PK parameters may be calculated and reported even if the strict criteria 
are not fulfilled. When PK parameters are based on less strict criteria, this will be described on 
an individual level. 
Accumulation ratios will be calculated as ratio of PK parameters (Cmax, Cmin, CEnd of inf, 
AUC0-168h) for the last vs 1st dose. 
15.5.5 
PK parameters summarization 
Table 8 SOBI003 PK Summary Statistics 
Variable 
Summarized with: 
AUC0-168h, Cmax, Cend of inf, Cpre-dose, 
Ctrough, CL, RCmax, RCtrough, RAUC0-168h, 
fluctuation% 
n, arithmetic mean, SD, CV%, minimum, median, 
maximum, geometric mean and geometric CV%  
t1/2, and λz  
n, arithmetic mean, SD, CV%, minimum, median, 
maximum 


 
SOBI003-001 
Confidential 
Page 52 of 67 
Version 1.0, Final 24 Mar 2020 
Variable 
Summarized with: 
tmax, tend of inf, tlast (actual time) 
n, minimum,Q1, median, Q3 and maximum 
AUC0-168h = area under the serum concentration-time curve from time 0 to 168 hours after dose; Cend of inf = observed 
serum concentration at the end of infusion of SOBI003; CL = clearance; Cmax = maximum observed serum 
concentration; Cpre-dose = observed serum concentration immediately before the start of infusion of SOBI003; Ctrough = 
minimum observed serum concentration; CV = coefficient of variation; RCmax = Cmax accumulation ratio; RCTrough = 
Ctrough accumulation ratio;  RAUC0-168h =  AUC0-168h accumulation ratio; SD = standard deviation; tend of inf = time of the 
end of the infusion of SOBI003; tlast = time of the last measurable concentration; tmax = time at which the maximum 
serum concentration is observed; t1/2 = half-life; λz = terminal elimination rate constant. 
The following conventions will be used for the presentation of the descriptive statistics of PK 
parameters and of serum concentrations: 
Table 9 PK Reporting Precision 
Statistics 
Degree of Precision 
Minimum, Maximum 
3 significant digits or as needed based on actual 
measured values (for example PK concentrations) 
Mean (arithmetic and geometric), Median 
4 significant digits 
Standard deviation 
5 significant digits 
CV and Geometric CV 
1 decimal point 
CV = coefficient of variation 
15.6 
Attainment of steady state for SOBI003 
Aggregate assessment of trough concentrations by repeated measures analysis of variance 
(ANOVA) may be used to evaluate attainment of steady state and determine the dose number to 
achieve steady state for SOBI003 (11). The approach is based on the comparison of log-
transformed trough concentration values for each dose to the mean of the results for all the 
following doses.  
If data are sufficient to support the analysis, repeated measures analysis will be carried out on 
log-transformed Ctrough (pre-infusion concentrations) for Week 2 through Week 24 for each 
infusion where data available. The following SAS code will be used to conduct the repeated 
measurement analysis: 
PROC MIXED 
CLASS dose patient; 
MODEL logCmin = dose; 
REPEATED / TYPE=UN SUBJECT=patient; 
RUN; 


 
SOBI003-001 
Confidential 
Page 53 of 67 
Version 1.0, Final 24 Mar 2020 
The trough concentrations observed after Week 2 through Week 24 for SOBI003 for each 
infusion will be compared with the average trough levels for the rest of the period to determine 
the time at which steady state was achieved. Contrasts will be tested between a time point and 
the pooled mean over all remaining time points, such as: 
Week 2 pre-infusion value vs. the average of Weeks 2 through 24 
Week 3 pre-infusion value vs. the average of Weeks 4 through 24 
… 
Week 8 pre-infusion value vs. the average of Weeks 12 and 24 
Week 12 pre-infusion value vs. the Week 24 
The first non-significant comparison will be concluded to be the dosing interval at which steady 
state concentrations are attained. The p-value for difference of least square means (LSM), LSM 
ratio, and the 90% confidence interval (CI) for the contrasts will be provided. 
Additionally, steady state will be assessed using a mixed model (12) with repeated measures 
performed on Cmin ss including dosing interval (Week 2 through Week 24 for SOBI003) as a 
covariate and subject as a random effect. A random slope effect for dosing interval will also be 
included. The linear effect of dosing interval on the Cmin ss over time will be used to assess the 
assumption of steady state. 
PROC MIXED data=cminDATASET; 
CLASS subject ; 
MODEL log_Cmin_ss = doseno / ddfm=kr;  
RANDOM intercept doseno  /subject= subject; 
RUN; 
The DDFM = KR (KenwardRoger) option performs the degrees-of-freedom calculations detailed 
by Kenward and Roger (1997) (13). As recommended, the denominator degrees of freedom for 
the fixed effects will be estimated as the most appropriate method in the mixed-model analysis. 
15.7 
Assessment of Dose Proportionality for SOBI003 
Exploratory dose proportionality will be analyzed with the method originally described by 
Gough et al. (1995) (14) and modified as described by Smith et al. (2000) (15) and further 
adapted by Hummel et al. (2009) (16).  
Cend of inf, AUC0-168h will be analysed, and depending on the results other parameters may be 
analysed such as Cmax, Cmin and AUC0-inf may also be analyzed.  The general model log (Cmax, 
Cmin, Cend of inf, AUC0-168h, AUC0-inf for all doses and cycles where available) = µ+ ß log (dose) 
will be used to investigate the null hypothesis (H0: ß=1). Dose-proportionality will be rejected if 
the 90% CI of the estimated slope falls outside the critical interval. Patient’s weight or age may 
be included as covariate. 


 
SOBI003-001 
Confidential 
Page 54 of 67 
Version 1.0, Final 24 Mar 2020 
The critical interval will be calculated as follows:  
First the ratio (r) of the highest dose level to the lowest dose level will be calculated. 
The lower limit of the critical interval will be calculated as: Log (0.5)/log(r) + 1. 
The upper limit of the critical interval will be calculated as: Log (2.0)/log(r) + 1. 
r value is based on the ratio between highest and lower dose levels of SOBI003 and equals to 
20 / 3 mg/kg = 6.667 
Thus, critical interval to declare dose linearity will be 0.63 to 1.37 for 90% CI of the slope 
estimate. 
Additionally, PK parameters Cmax, Cmin, CEnd of inf, AUC0-168h, AUC0-inf with total dose and body 
weight adjusted dose will be investigated using Pearson correlation analysis to estimate which 
type of dosing has an effect on pharmacokinetics of SOBI003.  
The FISHER option in the PROC CORR statement will be used to estimate confidence limits 
and p-values for Pearson correlation coefficients based on Fisher’s z transformation. Alpha value 
and a null hypothesis value will be specified for 95% two-sided CI. 
The formula for sample Pearson product-moment correlation is:  
rxy =
∑(xi −xത)(yi −y)ഥ
i
ඥ∑(xi −xത)2
i
∑(yi −yത)2
i
 
Fisher z transformation is calculated as z = 0.5loge ቀ
1+r
1−rቁ 
CIs in addition to p-value will be calculated to demonstrate the validity of correlation.  
Dose proportionality will also be explored graphically with plots of Cmax, AUClast and AUCinf vs 
body weight adjusted dose (mg/kg) or total dose (mg). 
Dose proportionality plots will be presented for SOBI003 Cmax, Cmin, Cend of inf, AUC0-168h, 
AUC0-inf. Regression/scatter plot in log-log and linear scales of PK parameters vs dose levels 
including body weight normalized and total dose will be presented. 
16 
Pharmacodynamic analyses 
16.1 
Secondary pharmacodynamic endpoint analyses 
Serum and urine sampling for HS quantification will be performed at Baseline, Weeks 2, 3, 4, 8, 
12, 16, 20, and 24 or at ET. CSF sampling for HS concentrations will be performed at Baseline, 
Weeks 12 and 24 or at ET. 


 
SOBI003-001 
Confidential 
Page 55 of 67 
Version 1.0, Final 24 Mar 2020 
16.2 
Presentation of concentration data for HS in serum, urine, and 
CSF 
16.2.1 
Handling of missing data  
Missing concentration data for all patients will be considered as non-informative missing and 
will not be imputed. No concentration estimates will be provided for missing sample values. 
For concentration summary in all matrices, the following rules will apply: 
• LLOQ values for HS concentrations in all matrices will be imputed as 0 for all time 
points where observed.  
No further imputation will be applied to any missing values. 
16.2.2 
Listing and Presentation of individual PD data 
HS concentrations in serum, urine, and CSF will be listed for SAF. The same listings will also 
contain change from baseline values for all time points. Baseline will be defined as HS 
concentration in each matrix before the administration of the 1st dose of SOBI003. Flags will be 
used to show deviations from protocol with the explanation in the footnote. 
The actual sampling time of PD serum, urine or CSF sample collection will be listed for each 
treatment and will include the deviation in time from the protocol scheduled time, if applicable. 
Individual subject serum, urine and CSF concentration data will be listed by subject, age, body 
weight, gender, time point and treatment (in relevant concentration units). The following figures 
will be produced for individual data for SOBI003: 
• Individual serum and urine HS concentration-time profiles will be presented, for each 
treatment with all patients in the same figure on linear scale vs Week number. Profiles for 
patients within the same treatment will be combined. 
• Scatter plots of HS concentrations in CSF for Weeks 12 and 24 for different treatments. 
16.2.3 
Summary of HS concentrations in serum, urine, and CSF 
HS serum, urine, and CSF concentration data will be summarized by treatment using the 
following descriptive statistics: n, number and % of LLOQ, arithmetic mean, SD, CV%, 
minimum, median and maximum, Q1 and Q3. In addition, results will be presented by 
demographic characteristics, e.g., age group and bodyweight, as applicable. 
Samples taken outside the allowed time windows may be excluded from summarization. This 
will be determined prior to database lock. 
Mean ± SD HS concentrations in serum, urine and CSF vs Week number profiles will be 
presented, combining the curves for all dose levels within the same figure. 


 
SOBI003-001 
Confidential 
Page 56 of 67 
Version 1.0, Final 24 Mar 2020 
The HS levels including change from baseline will also be summarized by visit and time point 
using descriptive statistics. The HS change from baseline will also be presented as percentages. 
The conventions presented in Table 9 for PK parameters will also be used for the presentation of 
the descriptive statistics of HS serum concentrations. 
 
 
 


 
SOBI003-001 
Confidential 
Page 57 of 67 
Version 1.0, Final 24 Mar 2020 
17 
Changes from protocol  
• Schedule of events tables Table 1, Table 2, Table 3, and Table 7 have been updated 
according to protocol clarification letters 
• According to the protocol linear mixed models were planned to be used to assess the PD 
effect of different dose levels of SOBI003 on HS levels in CSF, serum, and urine. 
Because of the discontinuation of the program modelling will be not be performed.  
 


 
SOBI003-001 
Confidential 
Page 58 of 67 
Version 1.0, Final 24 Mar 2020 
18 
References 
1 
ICH Topic E9. Statistical principles for clinical trials (CPMP/ICH/363/96). March 1998: 
http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html 
2 
Committee on Professional Ethics of the American Statistical Association. Ethical 
Guidelines for Statistical Practice dated 2016. Available from: 
http://www.amstat.org/ASA/Your-Career/Ethical-Guidelines-for-Statistical-Practice.aspx       
3 
Van de Kamp JJP, Niermeijer MF, von Figura K and Giesberts MAH. Genetic 
heterrogeneity and clinical variability in the Sanfilippo syndrome (types A, B and C). 
Clinical Genetics. 1981; 20: 152-60. 
4 
Community-University Partnership for the Study of Children, Youth, and Families (2011). 
Review of the Vineland Adaptive Behavior Scales-Second Edition (Vineland-II). 
Edmonton, Alberta, Canada. 
5 
NCS Pearson (2006). Bayley Scales of Infant and Toddler Development-Third Edition. 
Green Valley Drive Bloomington, Minnesota, USA. 
6 
NCS Pearson (2004). Kaufman Assessment Battery for Children-Second Edition. Green 
Valley Drive Bloomington, Minnesota, USA. 
7 
Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality 
of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med 
Care. 2001; 39(8):800-12. 
8 
Owens JA, Spirito A, McGuinn M. The Children's Sleep Habits Questionnaire (CSHQ): 
Psychometric properties of a survey instrument for school-aged children. Sleep, 2000;23: 
1043-51. 
9 
Sadeh A, Sharkey KM, Carskadon MA. Activity-based sleep-wake identification: an 
empirical test of methodological issues. Sleep, 1994; 17(3):201-7.  
10 
Shankar et al. Assessment and Reporting of the Clinical Immunogenicity of Therapeutic 
Proteins and Peptides - Harmonized Terminology and Tactical Recommendations. The 
AAPS Journal, 2014; DoI:10.1208/s12248-014-9599-2 
11 
Maganti L, Panebianco DL, Maes AL. Evaluation of Methods for Estimating Time to 
Steady State with Examples from Phase 1 Studies. The AAPS Journal. 2008; 10(1):141-
147. 
12 
Newlands A. Statistics and Pharmacokinetics in Clinical Pharmacology Studies (Paper 
ST03). PhUSE 2006. 
13 
Kenward, M. G. and J. H. Roger Small sample inference for fixed effects from restricted 
maximum likelihood. Biometrics, 1997, 53(3), 983–997. 
14 
Gough K, Hutchinson M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J. Assessment of 
Dose Proportionality: Report from the Statisticians in The Pharmaceutical 
Industry/Pharmacokinetics UK joint working party. Drug Inf J. 1995; 29:1039-1048. 
15 
Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST. 
CI criteria for assessment of dose proportionality, Pharmaceut. Res. 2000; 17: 1278-1283. 


 
SOBI003-001 
Confidential 
Page 59 of 67 
Version 1.0, Final 24 Mar 2020 
16 
Hummel J, McKendrick S, Brindley C and French, R. Exploratory assessment of dose 
proportionality: review of current approaches and proposal for a practical criterion. 
Pharmaceut. Statist. 2009; 8: 38-49. 
 
 


 
SOBI003-001 
Confidential 
Page 60 of 67 
Version 1.0, Final 24 Mar 2020 
19 
Data presentation 
Footnotes will be used to clarify ambiguities (e.g., the denominator used to calculate a 
percentage) and abbreviations. The tables and listings will be presented in A4 landscape, in a 
fixed font (Courier New) with a size as 8.  
19.1 
Listings Index 
The numbering of the listings will be such that they can be easily integrated into the CSR 
following ICH E3, Section 16.2. 
 
16.2  PATIENT DATA LISTINGS  
 
16.2.1 Patient Disposition 
Listing 16.2.1.1  
Patient Disposition (Part 1) – Screened Patients 
Listing 16.2.1.2  
Patient Disposition (Part 2) – Screened Patients 
Listing 16.2.1.3 
Patient Disposition – Screen Failures 
 
16.2.2 Protocol Deviations 
Listing 16.2.2.1  
Protocol Deviations – Safety Analysis Set 
 
16.2.3 Patients Excluded from the Analysis Sets 
Listing 16.2.3.1 
Violated Inclusion Criteria  – Safety Analysis Set 
Listing 16.2.3.2 
Fulfilled Exclusion Criteria  – Safety Analysis Set 
Listing 16.2.3.3 
Exclusion from Analysis Sets – Safety Analysis Set 
 
16.2.4 Demographic Data 
Listing 16.2.4.1 
Demographics  – Safety Analysis Set 
Listing 16.2.4.2 
MPS III History of Siblings – Safety Analysis Set 
Listing 16.2.4.3 
Historical MPS IIIA Diagnostic Procedures  – Safety Analysis Set 
Listing 16.2.4.4 
Central Laboratory Confirmation of MPS IIIA – Safety Analysis Set 
Listing 16.2.4.5 
Central Laboratory Confirmation of MPS IIIA SGSH  – Safety Analysis Set 
Listing 16.2.4.6 
Medical History – Safety Analysis Set 
Listing 16.2.4.7 
Prior and Concomitant Medication – Safety Analysis Set 
Listing 16.2.4.8 
Antihistamine – Safety Analysis Set 
Listing 16.2.4.9 
Anesthesia/Sedation – Safety Analysis Set 
 
16.2.5 Compliance 
Listing 16.2.5.1 
Study Drug (SOBI003) Administration – Safety Analysis Set 
Listing 16.2.5.2 
Study Drug (SOBI003) Administration: Vial Numbers – Safety Analysis Set 
 


 
SOBI003-001 
Confidential 
Page 61 of 67 
Version 1.0, Final 24 Mar 2020 
16.2.6 Individual Efficacy Response Data 
Listing 16.2.6.1 
Vineland adaptive behaviour scales, second edition (VABS)-II – Full Analysis 
Set 
Listing 16.2.6.2 
Bayley Scales of Infant and Toddler Development, third edition (BSID-III) – 
Full Analysis Set 
Listing 16.2.6.3 
Kaufman Assessment Battery for Children (KABC-II) – Full Analysis Set 
Listing 16.2.6.4 
Magnetic Resonance Imaging (MRI) – Full Analysis Set 
Listing 16.2.6.5 
Pediatric Quality of Live Inventory (PedsQL) – Full Analysis Set 
Listing 16.2.6.6 
Children’s Sleep Habits Questionnaire (CSHQ) – Full Analysis Set 
Listing 16.2.6.7 
Actigraphy (sleep pattern) – Full Analysis Set 
 
16.2.7 Adverse Events Listings 
Listing 16.2.7 
All Adverse Events – Safety Analysis Set 
 
16.2.8.1  Listing of individual laboratory measurements by patient 
Listing 16.2.8.1.1 
Laboratory Reference Ranges – Safety Analysis Set 
Listing 16.2.8.1.2 
Clinical Chemistry – Safety Analysis Set 
Listing 16.2.8.1.3 
Hematology – Safety Analysis Set 
Listing 16.2.8.1.4 
Coagulation – Safety Analysis Set 
Listing 16.2.8.1.5 
Urinalysis – Safety Analysis Set 
Listing 16.2.8.1.6 
Other – Safety Analysis Set 
 
16.2.8.2 Other Safety Data  
Listing 16.2.8.2.1 
Vital Signs  – Safety Analysis Set 
Listing 16.2.8.2.2 
Antropometry (Height, Weight, Body Mass Index and Head Circumference)   – 
Safety Analysis Set 
Listing 16.2.8.2.3 
Physical Examination – Safety Analysis Set 
Listing 16.2.8.2.4 
Neurological Examination – Safety Analysis Set 
Listing 16.2.8.2.5 
12-Lead Electrocardiogram (ECG) – Safety Analysis Set 
Listing 16.2.8.2.6 
Echocardiography – Safety Analysis Set 
Listing 16.2.8.2.7 
Immunogenicity in Cerebrospinal Fluid (CSF) – Safety Analysis Set 
Listing 16.2.8.2.8 
Immunogenicity in Serum – Safety Analysis Set 
Listing 16.2.8.2.9 
PK Sampling and Concentration Data – PK Analysis Set 
Listing 16.2.8.2.10 
PK Parameters – PK Analysis Set 
Listing 16.2.8.2.11 
PD assessments Heparan Sulfate (HS) in Cerebrospinal Fluid (CSF) – Safety 
Analysis Set 
Listing 16.2.8.2.12 
PD assessments Heparan Sulfate (HS) in Serum – Safety Analysis Set 
Listing 16.2.8.2.13 
PD assessments Heparan Sulfate (HS) in Urine – Safety Analysis Set 
Listing 16.2.8.2.14 
PD assessments Heparan Sulfate (HS) Sampling and Concentration Data – 
Safety Analysis Set 
Listing 16.2.8.2.15 
Cross Reactive Immunological Material (CRIM) status at Baseline – Safety 
Analysis Set 
 


 
SOBI003-001 
Confidential 
Page 62 of 67 
Version 1.0, Final 24 Mar 2020 
19.2 
Tables and Figures Index 
The numbering of the tables will be such that they can be easily integrated into the CSR 
following ICH Section 14. 
 
14. TABLES, FIGURES AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE 
TEXT  
 
14.1 DEMOGRAPHIC DATA  
14.1.1 Patient Disposition  
Table 14.1.1.1 
Number of Patients Screened and Study Termination – Screened Patients 
 
14.1.2 Protocol Deviations  
Table 14.1.2.1 
Protocol Deviations – Safety Analysis Set 
 
14.1.3.1 Demographics and Baseline Characteristics  
Table 14.1.3.1.1 
Demographics – Safety Analysis Set 
Table 14.1.3.1.2 
MPS III History of Siblings – Safety Analysis Set 
 
14.1.3.2 Baseline Disease Characteristics  
Table 14.1.3.2.1 
Duration of Disease – Safety Analysis Set 
Table 14.1.3.2.2 
MPS IIIA Diagnostic Status – Safety Analysis Set 
Table 14.1.3.2.3 
Central Laboratory Confirmation of MPS IIIA – Safety Analysis Set 
 
14.1.3.3 Medical History  
Table 14.1.3.3.1 
Medical History – Safety Analysis Set 
 
14.1.4 Medications  
Table 14.1.4.1 
Prior Medications – Safety Analysis Set 
Table 14.1.4.2 
Concomitant Medications - Safety Analysis Set 
Table 14.1.4.3 
Antihistamines - Safety Analysis Set 
Table 14.1.4.4 
Anesthesia and Sedation - Safety Analysis Set 
 
14.2 EFFICACY DATA  
14.2.1 Vineland Adaptive Behaviour Scales (VASB-II) 
Table 14.2.1.1 
Vineland Adaptive Behaviour Scales (VASB-II) - Communication: Summary by 
Visit and Change from Baseline – Full Analysis Set 
Table 14.2.1.2 
Vineland Adaptive Behaviour Scales (VASB-II) - Daily Living Skills: Summary 
by Visit and Change from Baseline – Full Analysis Set 
Table 14.2.1.3 
Vineland Adaptive Behaviour Scales (VASB-II) - Socialization: Summary by 
Visit and Change from Baseline – Full Analysis Set 
Table 14.2.1.4 
Vineland Adaptive Behaviour Scales (VASB-II) - Motor Skills: Summary by 
Visit and Change from Baseline – Full Analysis Set 
Table 14.2.1.4 
Vineland Adaptive Behaviour Scales (VASB-II) – Adaptive Behaviour 
Composite Standard Score and Age-equivalent (AEq): Summary by Visit and 
Change from Baseline – Full Analysis Set 


 
SOBI003-001 
Confidential 
Page 63 of 67 
Version 1.0, Final 24 Mar 2020 
 
14.2.2 Bayley Scales of Infant and Toddler Development (BSID-III) 
Table 14.2.2.1 
Bayley Scales of Infant and Toddler Development (BSID-III) - Neurocognitive: 
Summary by Visit and Change from Baseline – Full Analysis Set 
Table 14.2.2.2 
Bayley Scales of Infant and Toddler Development (BSID-III) - Neurocognitive 
Language: Summary by Visit and Change from Baseline – Full Analysis Set 
Table 14.2.2.3 
Bayley Scales of Infant and Toddler Development (BSID-III) - Motor Function: 
Summary by Visit and Change from Baseline  – Full Analysis Set 
 
14.2.3 Kaufman Assessment Battery for Children (KABC-II) 
Table 14.2.3.1 
Kaufman Assessment Battery for Children (KABC-II) - Neurocognitive 
Development Quotient (DQ): Summary by Visit and Change from Baseline – 
Full Analysis Set 
Table 14.2.3.2 
Kaufman Assessment Battery for Children (KABC-II) - Neurocognitive 
Composite Score: Summary by Visit and Change from Baseline – Full Analysis 
Set 
Table 14.2.3.3 
Kaufman Assessment Battery for Children (KABC-II) - Expressive Vocabulary 
Subdomain: Summary by Visit and Change from Baseline – Full Analysis Set  
 
14.2.4 Neurocognitive Development Quotient (BSID-III and KABC-II combined) 
Table 14.2.4.1 
Neurocognitive Development Quotient (DQ): Summary by Visit and Change 
from Baseline – Full Analysis Set 
 
14.2.5 Magnetic Resonance Imaging (MRI) 
Table 14.2.5.1 
Brain Volumeric Magnetic Resonance Imaging (MRI) – Gray Matter Volume: 
Summary by Visit and Change from Baseline – Full Analysis Set 
Table 14.2.5.2 
Brain Volumeric Magnetic Resonance Imaging (MRI) – Compound Ventricular 
Volume: Summary by Visit and Change from Baseline – Full Analysis Set 
Table 14.2.5.3 
Diffusion Tensor Imaging Magnetic Resonance Imaging (MRI) – Fractional 
Anisotropy (FA) and Mean Diffusivity (MD) of Corpus Callosum: Summary by 
Visit and Change from Baseline – Full Analysis Set 
Table 14.2.5.4 
Diffusion Tensor Imaging Magnetic Resonance Imaging (MRI) – Fractional 
anisotropy (FA) and Mean Diffusivity (MD) of Cerebral White Matter: Summary 
by Visit and Change from Baseline – Full Analysis Set 
Table 14.2.5.5 
Susceptibility Weighting Imaging (SWI) Magnetic Resonance Imaging (MRI) – 
Cerebral White Matter: Summary by Visit and Change from Baseline – Full 
Analysis Set 
Table 14.2.5.6 
Susceptibility Weighting Imaging (SWI) Magnetic Resonance Imaging (MRI) – 
Basal Ganglia: Summary by Visit and Change from Baseline – Full Analysis Set 
Table 14.2.5.7 
Abdominal Magnetic Resonance Imaging (MRI) – Liver Volume: Summary by 
Visit and Change from Baseline – Full Analysis Set 
Table 14.2.5.8 
Abdominal Magnetic Resonance Imaging (MRI) – Spleen Volume: Summary by 
Visit and Change from Baseline – Full Analysis Set 
 
 


 
SOBI003-001 
Confidential 
Page 64 of 67 
Version 1.0, Final 24 Mar 2020 
14.2.6 Children’s Sleep Habits Questionnaire (CSHQ) and Actigraphy 
Table 14.2.6.1 
Children’s Sleep Habits Questionnaire (CSHQ) – Sleep Disturbance Score: 
Summary by Visit and Change from Baseline  – Full Analysis Set 
Table 14.2.6.2 
Actigraphy: Summary by Visit and Change from Baseline  – Safety Analysis Set 
 
14.3 SAFETY DATA  
14.3.1 Displays of Adverse Events  
Table 14.3.1.1 
Overall Summary of Adverse Events - Safety Analysis Set 
Table 14.3.1.2 
Treatment Emergent Adverse Events (TEAEs) by System Organ Class and 
Preferred Term – Safety Analysis Set 
Table 14.3.1.3 
Treatment Emergent Adverse Events (TEAEs) by System Organ Class, Preferred 
Term and maximum CTCAE grade - Safety Analysis Set 
Table 14.3.1.4 
Drug-related Treatment Emergent Adverse Events (TEAEs) by System Organ 
Class and Preferred Term – Safety Analysis Set 
Table 14.3.1.5 
Drug-related Treatment Emergent Adverse Events (TEAEs) by System Organ 
Class, Preferred Term and maximum CTCAE grade - Safety Analysis Set 
Table 14.3.1.6 
Serious Treatment Emergent Adverse Events (TEAEs) by System Organ Class 
and Preferred Term – Safety Analysis Set 
Table 14.3.1.7 
Serious Treatment Emergent Adverse Events (TEAEs) by System Organ Class, 
Preferred Term and maximum CTCAE grade - Safety Analysis Set 
Table 14.3.1.8 
Serious drug-related Treatment Emergent Adverse Events (TEAEs) by System 
Organ Class and Preferred Term – Safety Analysis Set 
Table 14.3.1.9 
Serious drug-related Treatment Emergent Adverse Events (TEAEs) by System 
Organ Class, Preferred Term and maximum CTCAE grade - Safety Analysis Set 
Table 14.3.1.10 
Treatment Emergent Adverse Events (TEAEs) leading to Study and/or Treatment 
Withdrawal by System Organ Class and Preferred Term – Safety Analysis Set 
Table 14.3.1.11 
Treatment Emergent Adverse Events (TEAEs) leading to Study and/or Treatment 
Withdrawal by System Organ Class, Preferred Term and maximum CTCAE 
grade - Safety Analysis Set 
Table 14.3.1.12 
Drug-related Treatment Emergent Adverse Events (TEAEs) leading to Study 
and/or Treatment Withdrawal by System Organ Class and Preferred Term – 
Safety Analysis Set 
Table 14.3.1.13 
Drug-related Treatment Emergent Adverse Events (TEAEs) leading to Study 
and/or Treatment Withdrawal by System Organ Class, Preferred Term and 
maximum CTCAE grade - Safety Analysis Set 
Table 14.3.1.14 
Treatment Emergent Adverse Events (TEAEs) by System Organ Class, Preferred 
Term and Anti-Drug Antibody (ADA) status - Safety Analysis Set 
Table 14.3.1.15 
Overall Summary of Infusion Related Reactions (IRRs) - Safety Analysis Set 
Table 14.3.1.16 
Infusion Related Reactions (IRRs) Symptoms by System Organ Class and 
Preferred Term - Safety Analysis Set 
Table 14.3.1.17 
Infusion Related Reactions (IRRs) Symptoms by System Organ Class, Preferred 
Term and maximum CTCAE grade - Safety Analysis Set 
Table 14.3.1.18 
Serious Infusion Related Reaction (IRRs) Symptoms by System Organ Class and 
Preferred Term - Safety Analysis Set 
Table 14.3.1.19 
Serious Infusion Related Reactions (IRRs) Symptoms by System Organ Class, 
Preferred Term and maximum CTCAE grade - Safety Analysis Set 


 
SOBI003-001 
Confidential 
Page 65 of 67 
Version 1.0, Final 24 Mar 2020 
Table 14.3.1.20 
Infusion Related Reaction (IRRs) leading to Study and/or Treatment Withdrawal 
by System Organ Class and Preferred Term - Safety Analysis Set 
Table 14.3.1.21 
Infusion Related Reactions (IRRs) leading to Study and/or Treatment Withdrawal  
by System Organ Class, Preferred Term and maximum CTCAE grade - Safety 
Analysis Set 
Table 14.3.1.22 
Infusion Related Reactions (IRRs) Resolved Within 24 Hours, by System Organ 
Class and Preferred Term - Safety Analysis Set 
 
14.3.2 Listings of Deaths, Other Serious and Significant Adverse Events  
Table 14.3.2.1 
Deaths, Listing – Safety Analysis Set 
Table 14.3.2.2 
Serious Adverse events, Listing – Safety Analysis Set 
Table 14.3.2.3 
Treatment Emergent Adverse Events (TEAEs) leading to permanent 
Discontinuation of Study Drug, Listing – Safety Analysis Set 
Table 14.3.2.4 
Infusion Related Reaction (IRR) Symptoms, Listing – Safety Analysis Set 
 
14.3.4.1 Clinical Laboratory Data  
Table 14.3.4.1.1.1 
Clinical Chemistry: Summary by Visit, Time point, and Change from Baseline 
– Safety Analysis Set 
Table 14.3.4.1.1.2 
Clinical Chemistry: Number (%) of Patients with Values Outside of Normal 
Range by  Visit and Time point  – Safety Analysis Set 
Table 14.3.4.1.1.3 
Clinical Chemistry: Abnormal Results, Listing – Safety Analysis Set 
Table 14.3.4.1.1.4 
Clinical Chemistry: Shift from Baseline to End of Study Visit – Safety Analysis 
Set 
Figure 14.3.4.1.2.1 
Clinical Chemistry: Patient plots over Time by Parameter – Safety Analysis Set 
 
 
Table 14.3.4.1.3.1 
Hematology: Summary by Visit, Time point, and Change from Baseline – 
Safety Analysis Set 
Table 14.3.4.1.3.2 
Hematology: Number (%) of Patients with Values Outside of Normal Range by 
Visit and Time point  – Safety Analysis Set 
Table 14.3.4.1.3.3 
Hematology: Abnormal Results, Listing – Safety Analysis Set 
Table 14.3.4.1.3.4 
Hematology: Shift from Baseline to End of Study Visit – Safety Analysis Set 
Figure 14.3.4.1.4.1 
Hematology: Patient plots over Time by Parameter – Safety Analysis Set 
 
 
Table 14.3.4.1.5.1 
Urinalysis: Number (%) of Patients with Values Outside of Normal Range by 
Visit  and Time point– Safety Analysis Set 
Table 14.3.4.1.5.2 
Urinalysis: Abnormal Results, Listing – Safety Analysis Set 
Table 14.3.4.1.6.1 
Coagulation: Summary by Visit, Time point, and Change from Baseline – 
Safety Analysis Set 
Table 14.3.4.1.6.2 
Coagulation: Number (%) of Patients with Values Outside of Normal Range by 
Visit and Time point  – Safety Analysis Set 
Table 14.3.4.1.6.3 
Coagulation: Abnormal Results, Listing – Safety Analysis Set 
Table 14.3.4.1.6.4 
Coagulation: Shift from Baseline to End of Study Visit– Safety Analysis Set 
Figure 14.3.4.1.7.1 
Coagulation: Patient plots over Time by Parameter – Safety Analysis Set 
 
 
Table 14.3.4.1.8.1 
Other Laboratory Data: Summary by Visit, Time point, and Change from 
Baseline – Safety Analysis Set 


 
SOBI003-001 
Confidential 
Page 66 of 67 
Version 1.0, Final 24 Mar 2020 
Table 14.3.4.1.8.2 
Other Laboratory Data: Number (%) of Patients with Values Outside of Normal 
Range by Visit and Time point – Safety Analysis Set 
Table 14.3.4.1.8.3 
Other Laboratory Data: Abnormal Results, Listing – Safety Analysis Set 
Table 14.3.4.1.8.4 
Other Laboratory Data: Shift from Baseline to End of Study Visit – Safety 
Analysis Set 
 
14.3.4.2 Vital Signs 
Table 14.3.4.2.1 
Vital Signs: Summary by Visit, Time point, and Change from Baseline – Safety 
Analysis Set 
Figure 14.3.4.2.2 
Vital Signs: Patient plots over Time by Parameter – Safety Analysis Set 
 
14.3.4.3 Anthropometry (Height, weight, BMI, and head circumference) 
Table 14.3.4.3.1 
Anthropometry: Summary by Visit and Change from Baseline – Safety Analysis 
Set 
 
14.3.4.4 Physical Examination 
Table 14.3.4.4.1 
Physical Examination: Number (%) of Patients with Normal/Abnormal Results 
by Visit and Time point – Safety Analysis Set 
 
14.3.4.5 Neurological Examination 
Table 14.3.4.5.1 
Neurological Examination: Number (%) of Patients with Normal/Abnormal 
Results by Visit – Safety Analysis Set 
 
14.3.4.6 12-Lead Electrocardiogram (ECG) and Echocardiography 
Table 14.3.4.6.1 
ECG: Number (%) of Patients with Normal/Abnormal Results by Visit and Time 
point – Safety Analysis Set 
Table 14.3.4.6.2 
Echocardiography: Number (%) of Patients with Normal/Abnormal Results by 
Visit – Safety Analysis Set 
 
14.3.4.7 Exposure 
Table 14.3.4.7.1 
Extent of Exposure – Safety Analysis Set 
 
14.3.4.8 Immunogenicity 
Table 14.3.4.8.1 
Number (%) of Patients with Anti-Drug Antibody (ADA) and Neutralizing 
Antibody (NAb) in Serum by Visit – Immunogenicity Analysis Set 
Table 14.3.4.8.2 
Number (%) of Patients with Anti-Drug Antibody (ADA) and Neutralizing 
Antibody (NAb)  in Cerebrospinal Fluid (CSF) by Visit – Immunogenicity 
Analysis Set 
Figure 14.3.4.8.3 
Immunogenicity: Patient plots over Time – Immunogenicity Analysis Set 
 
14.3.4.9 PK 
Table 14.3.4.9.1 
Summary of PK concentrations by Dose, Visit and Time point – PK Analysis Set 
Table 14.3.4.9.2 
SOBI003 PK parameters by Dose, Visit – PK Analysis Set 
Table 14.3.4.9.3 
Attainment of Steady State for SOBI003 using Repeated Measures ANOVA – 
PK Analysis Set 


 
SOBI003-001 
Confidential 
Page 67 of 67 
Version 1.0, Final 24 Mar 2020 
Table 14.3.4.9.4 
Dose Proportionality for SOBI003 PK parameters by Visit using Humel Power 
Analysis – PK Analysis Set 
Table 14.3.4.9.5 
Dose Proportionality for SOBI003 PK parameters by Visit using Pearson 
Correlation Analysis – PK Analysis Set 
Figure 14.3.4.9.6 
Individual Serum PK Concentration-Time Profiles at Week 1, 4, 12, and 24 by 
Dose Level in Linear and Log-Linear Scales  – PK Analysis Set 
Figure 14.3.4.9.7 
Mean (SD) Serum PK Concentration-Time Profiles at Week 1, 4, 12, and 24 by 
Dose Level in Linear and Log-Linear Scales  – PK Analysis Set 
Figure 14.3.4.9.8 
Individual Trough and End of Infusion Serum PK Concentrations by Dose Level 
in Linear and Log-Linear Scale – PK Analysis Set 
Figure 14.3.4.9.9 
Mean (SD) Trough and End of Infusion Serum PK Concentrations by Dose Level 
in Linear and Log-Linear Scale – PK Analysis Set 
Figure 14.3.4.9.10 
Scatter Plots of Cerebrospinal Fluid PK Concentrations at Week 12 and 24 by 
Dose Level – PK Analysis Set 
Figure 14.3.4.9.11 
Regression/Scatter Dose Proportionality for SOBI003 in Log-Log and Linear-
Linear Scales – PK Analysis Set 
Figure 14.3.4.9.12 
Regression/Scatter Dose Proportionality for SOBI003 in Linear-Linear Scales – 
PK Analysis Set 
 
14.3.4.10 PD 
Table 14.3.4.10.1 
Heparan Sulphate (HS): Summary by Visit and Change from Baseline – Safety 
Analysis Set 
Table 14.3.4.10.2 
Summary of Heparan Sulphate (HS) Concentrations by Visit and Time point - 
Safety Analysis Set 
Figure 14.3.4.10.3 
Individual Serum Heparan Sulphate (HS) Concentration-Time Profiles by Dose 
Level in Linear and Log-Linear Scales – Safety Analysis Set 
Figure 14.3.4.10.4 
Individual Urine Heparan Sulphate (HS) Concentration-Time Profiles by Dose 
Level in Linear and Log-Linear Scales – Safety Analysis Set 
Figure 14.3.4.10.5 
Mean (SD) Serum Heparan Sulphate (HS) Concentration-Time Profiles by 
Dose Level in Linear and Log-Linear Scales – Safety Analysis Set 
Figure 14.3.4.10.6 
Mean (SD) Urine Heparan Sulphate (HS) Concentration-Time Profiles by Dose 
Level in Linear and Log-Linear Scales – Safety Analysis Set 
Figure 14.3.4.10.7 
Mean (SD) Cerebrospinal Fluid (CSF) Heparan Sulphate (HS) Concentration-
Time Profiles by Dose Level in Linear and Log-Linear Scales – Safety 
Analysis Set 
Figure 14.3.4.10.8 
Scatter Plots of Cerebrospinal Fluid Heparan Sulphate (HS) Concentrations at 
Week 12 and 24 by Dose Level – Safety Analysis Set 
 
14.3.4.11 Cross Reactive Immunological Material (CRIM) status 
Table 14.3.4.11.1 
CRIM: Number (%) of Patients with Negative/Positive Results by Visit – 
Safety Analysis Set